<PAGE>
                                                                    EXHIBIT 10.1

                                                             EXECUTION VERSION

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.



                       COLLABORATION AND LICENSE AGREEMENT

                                 BY AND BETWEEN

                        MILLENNIUM PHARMACEUTICALS, INC.

                                       AND

                               ABBOTT LABORATORIES



<PAGE>

                                TABLE OF CONTENTS


<TABLE>
<CAPTION>
                                                                                                                PAGE
<S>                                                                                                             <C>

     ARTICLE 1    DEFINITIONS.....................................................................................1

       1.1        "Abbott Diagnostic Platform"....................................................................1

       1.2        "Abbott Released Diagnostic"....................................................................1

       1.3        "Abbott Released Diagnostic Net Sales"..........................................................1

       1.4        "Active"........................................................................................2

       1.5        "Ad Hoc Committee"..............................................................................2

       1.6        "Affiliate".....................................................................................2

       1.7        "Annual Research Plan"..........................................................................2

       1.8        "Antibody"......................................................................................2

       1.9        "Antisense Molecule"............................................................................2

       1.10       "Associated Biotherapeutics"....................................................................2

       1.11       "Associated Chemistry"..........................................................................3

       1.12       "Biotherapeutic Gene"...........................................................................3

       1.13       "Biotherapeutic Product"........................................................................3

       1.14       "Candidate Characterization"....................................................................3

       1.15       "Change of Control".............................................................................3

       1.16       "Commercialization" or "Commercialize"..........................................................3

       1.17       "Commercialization Program".....................................................................3

       1.18       "Confidential Information"......................................................................3

       1.19       "Contract Year".................................................................................4

                                       i
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE
       1.20       "Control" or "Controlled".......................................................................4

       1.21       "Co-Promoted Joint Product".....................................................................4

       1.22       "Co-Promotion Territory"........................................................................4

       1.23       "Covering", "Cover", or "Covered"...............................................................4

       1.24       "DDC Family"....................................................................................4

       1.25       "Development" or "Develop"......................................................................5

       1.26       "Development Expenses"..........................................................................5

       1.27       "Development Program"...........................................................................5

       1.28       "Diagnostic"....................................................................................5

       1.29       "Drug Development Candidate" or "DDC"...........................................................5

       1.30       "Druggable Target"..............................................................................5

       1.31       "Excluded Compounds"............................................................................5

       1.32       "Executive Officers"............................................................................6

       1.33       "FDA"...........................................................................................6

       1.34       "FTE"...........................................................................................6

       1.35       "First Commercial Sale".........................................................................6

       1.36       "Hit"...........................................................................................6

       1.37       "IND"...........................................................................................6

       1.38       "Investment Agreement"..........................................................................6

       1.39       "Joint Commercialization Committee".............................................................6


                                       ii
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       1.40       "Joint Development Committee"...................................................................6

       1.41       "Joint Drug Development Candidate" or "Joint DDC"...............................................6

       1.42       "Joint Executive Committee".....................................................................6

       1.43       "Joint Manufacturing Committee".................................................................7

       1.44       "Joint Product".................................................................................7

       1.45       "Joint Research Committee"......................................................................7

       1.46       "Laws"..........................................................................................7

       1.47       "Lead Compound".................................................................................7

       1.48       "Lead Compound Family"..........................................................................7

       1.49       "Manufacturing" or "Manufacture"................................................................7

       1.50       "Master Research Plan"..........................................................................7

       1.51       "Metabolic Disease Field".......................................................................7

       1.52       "Net Sales".....................................................................................7

       1.53       "Obesity".......................................................................................8

       1.54       "Other Diagnostic Platform".....................................................................9

       1.55       "Other Molecule"................................................................................9

       1.56       "Party" or "Parties"............................................................................9

       1.57       "Patent Rights".................................................................................9

       1.58       "Phase I Study".................................................................................9

       1.59       "Phase IIA Study"...............................................................................9

                                       iii
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE
       1.60       "Phase IIB Study"...............................................................................9

       1.61       "Phase IIIA Study"..............................................................................9

       1.62       "Phase IIIB Study"..............................................................................9

       1.63       "Phase IV Study"................................................................................9

       1.64       Program Biotherapeutic"........................................................................10

       1.65       "Program Compound".............................................................................10

       1.66       "Program Compound Family"......................................................................10

       1.67       "Program Diagnostic"...........................................................................10

       1.68       "Program Diagnostic Net Sales".................................................................10

       1.69       "Program Intellectual Property"................................................................10

       1.70       "Program Material".............................................................................11

       1.71       "Program Patent Rights"........................................................................11

       1.72       "Program Target"...............................................................................11

       1.73       "Program Technology"...........................................................................11

       1.74       "Protein"......................................................................................11

       1.75       "Regulatory Approval"..........................................................................12

       1.76       "Regulatory Authority".........................................................................12

       1.77       "Released Compound"............................................................................12

       1.78       "Required Third Party Payments"................................................................13

       1.79       "Research Plans"...............................................................................13
                                       iv
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE
       1.80       "Research Program".............................................................................13

       1.81       "ROW"..........................................................................................13

       1.82       "Royalty-Bearing Product"......................................................................13

       1.83       "Royalty-Paying Party".........................................................................13

       1.84       "Small Molecule"...............................................................................13

       1.85       "Small Molecule Drug"..........................................................................13

       1.86       "Special Purpose Equipment"....................................................................13

       1.87       "Suspended Drug Development Candidate" or "Suspended DDC"......................................13

       1.88       "Suspended Target".............................................................................14

       1.89       "Territory"....................................................................................14

       1.90       "Therapeutic Antibody Product".................................................................14

       1.91       "Therapeutic Antisense Product"................................................................14

       1.92       "Therapeutic Other Molecular Product"..........................................................14

       1.93       "Therapeutic Protein Product"..................................................................14

       1.94       "Third Party"..................................................................................14

       1.95       "Type 1 Diabetes"..............................................................................14

       1.96       "Type 2 Diabetes"..............................................................................14

       1.97       "Unilateral Diagnostic"........................................................................14

       1.98       "Unilateral Diagnostic Net Sales"..............................................................15

       1.99       "Unilateral Drug Development Candidate" or "Unilateral DDC"....................................15


                                       v

<PAGE>
                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE
       1.100      "Unilateral Product"...........................................................................15

       1.101      "Unilateral Product Net Sales".................................................................15

       1.102      "Unilateral Target"............................................................................15

       1.103      "Valid Claim"..................................................................................15

       1.104      Additional Definitions.........................................................................16

     ARTICLE 2    EXCLUSIVITY; SCOPE OF COLLABORATION............................................................19

       2.1        Exclusivity....................................................................................19

       2.2        In-Licensing of Compounds......................................................................22

     ARTICLE 3    RESEARCH PROGRAM...............................................................................23

       3.1        General........................................................................................23

       3.2        Disclosure of Financial and Other Burdens and Obligations......................................24

       3.3        Joint Research Committee.......................................................................25

       3.4        Conduct of the Research Program................................................................28

       3.5        Annual Research Plan...........................................................................30

       3.6        Procedures for Contributions of Targets, Small Molecules and Biotherapeutics...................31

       3.7        Research Program Material Transfer.............................................................34

       3.8        Unilateral Targets, Associated Chemistry and Associated Biotherapeutics........................34

       3.9        Suspended Targets..............................................................................35

       3.10       Non-Field Targets..............................................................................36

                                       vi


<PAGE>

         Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.


                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       3.11       [**] Research Program [**].....................................................................36

       3.12       Research Program Records.......................................................................36

       3.13       Disclosure of Research Program Results.........................................................37

     ARTICLE 4    DEVELOPMENT PROGRAM............................................................................37

       4.1        Drug Development Candidates....................................................................37

       4.2        Joint Development Committee....................................................................39

       4.3        Development Plans..............................................................................42

       4.4        Development Activities.........................................................................42

       4.5        Regulatory Matters.............................................................................42

       4.6        Development Expenses...........................................................................44

       4.7        Commercial Sale of Joint Products..............................................................45

       4.8        Suspended DDC..................................................................................46

       4.9        Unilateral Development.........................................................................46

       4.10       Right to Audit.................................................................................47

       4.11       Disclosure of Development Program Results......................................................48

       4.12       Development Program Material Transfer..........................................................48

     ARTICLE 5    DIAGNOSTICS....................................................................................49

       5.1        Program Diagnostics............................................................................49

       5.2        Abbott Released Diagnostics....................................................................52

       5.3        Unilateral Diagnostics.........................................................................52

                                      vii
<PAGE>
                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

     ARTICLE 6    MANUFACTURING..................................................................................55

       6.1        Joint Manufacturing Committee..................................................................55

       6.2        Manufacturing Plans............................................................................56

       6.3        Designation of Lead Manufacturing Party........................................................56

       6.4        Standard Cost of Goods Sold....................................................................58

       6.5        Quality Manual.................................................................................58

     ARTICLE 7    COMMERCIALIZATION PROGRAM......................................................................59

       7.1        Joint Commercialization Committee..............................................................59

       7.2        Commercialization Plans........................................................................62

       7.3        Commercialization Activities...................................................................63

       7.4        Sales in the United States.....................................................................65

       7.5        Commercialization Expenses and Budget..........................................................65

       7.6        Co-Promotion of Joint Products.................................................................65

       7.7        Safety Issues and Recalls......................................................................70

       7.8        Unilateral Commercialization...................................................................71

     ARTICLE 8    LICENSES.......................................................................................71

       8.1        Millennium Grants..............................................................................71

       8.2        Abbott Grants..................................................................................74

       8.3        Sublicense Rights..............................................................................76

       8.4        Retained Rights................................................................................76

                                      viii

<PAGE>
                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       8.5        Section 365(n) of the Bankruptcy Code..........................................................76

       8.6        Notice of Third Party Breach...................................................................77

     ARTICLE 9    FINANCIAL PROVISIONS...........................................................................77

       9.1        Operating Margin/Profit........................................................................77

       9.2        Royalties on Unilateral Products...............................................................79

       9.3        Program Diagnostic Operating Margin/Profit.....................................................81

       9.4        Abbott Released Diagnostic Royalties and Unilateral Diagnostic Royalties.......................83

       9.5        Royalty Reports; Payments......................................................................86

       9.6        Audits.........................................................................................86

       9.7        Tax Matters....................................................................................86

       9.8        Currency Exchange..............................................................................87

       9.9        Late Payments..................................................................................87

       9.10       Mode of Payment................................................................................87

       9.11       Effect of Future Changes.......................................................................88

     ARTICLE 10   INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED
                  MATTERS........................................................................................88

       10.1       Ownership......................................................................................88

       10.2       Prosecution and Maintenance of Patent Rights...................................................88

       10.3       Exploitation of Joint Inventions...............................................................89

       10.4       Third Party Infringement.......................................................................90

                                       ix

<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       10.5       Other Intellectual Property Infringement.......................................................91

       10.6       Trademarks.....................................................................................92

       10.7       Patent Term Extensions.........................................................................93

       10.8       Manufacturing Process Inquiries................................................................93

     ARTICLE 11   CONFIDENTIALITY................................................................................94

       11.1       Confidential Information.......................................................................94

       11.2       Employee and Advisor Obligations...............................................................94

       11.3       Term...........................................................................................95

       11.4       Publications...................................................................................95

     ARTICLE 12   TERM AND TERMINATION...........................................................................95

       12.1       Term...........................................................................................95

       12.2       Termination For Material Breach................................................................95

       12.3       Dispute Resolution.............................................................................97

       12.4       Residual Rights................................................................................98

       12.5       Change of Control..............................................................................98

     ARTICLE 13   DISPUTE RESOLUTION.............................................................................98

       13.1       Joint Executive Committee......................................................................98

       13.2       Referral of Unresolved Matters to Joint Executive Committee....................................99

       13.3       Referral of Unresolved Matters to Executive Officers..........................................100

       13.4       Independent Experts...........................................................................100

                                       x
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       13.5       Alternative Dispute Resolution................................................................100

     ARTICLE 14   REPRESENTATIONS, WARRANTIES AND COVENANTS.....................................................100

       14.1       Representation of Authority; Consents.........................................................100

       14.2       No Conflict...................................................................................100

       14.3       Employee and Consultant Obligations...........................................................101

       14.4       Burdened Technology Obligations...............................................................101

       14.5       Intellectual Property.........................................................................101

       14.6       Knowledge of Pending or Threatened Litigation.................................................101

       14.7       Disclaimer of Warranty........................................................................102

     ARTICLE 15   MISCELLANEOUS PROVISIONS......................................................................102

       15.1       Indemnification...............................................................................102

       15.2       Insurance.....................................................................................103

       15.3       Governing Law.................................................................................103

       15.4       Assignment....................................................................................104

       15.5       Amendments....................................................................................104

       15.6       Notices.......................................................................................104

       15.7       Force Majeure.................................................................................105

       15.8       Compliance with Export Regulations............................................................105

       15.9       Public Announcements..........................................................................105

       15.10      Independent Contractors.......................................................................106

                                       xi
<PAGE>

                                TABLE OF CONTENTS

                                  (continued)

                                                                                                                PAGE

       15.11      No Strict Construction........................................................................106

       15.12      Headings......................................................................................106

       15.13      No Implied Waivers; Rights Cumulative.........................................................106

       15.14      Severability..................................................................................107

       15.15      Execution in Counterparts.....................................................................107

       15.16      No Third Party Beneficiaries..................................................................107

       15.17      No Consequential Damages......................................................................107

       15.18      Employees.....................................................................................107

</TABLE>








                                      xii

<PAGE>
         Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.


EXHIBITS

The Exhibits referred to in this Agreement have been attached to this Agreement
and shall have the following titles:

Exhibit A         Excluded Compounds

Exhibit B         Abbott Third Party Agreements

Exhibit C         Millennium Third Party Agreements

Exhibit D         Guidelines

Exhibit E         Development Expense Example

Exhibit F         Program Diagnostic Development Expense Example

Exhibit G         Financial Definitions

Exhibit H         Diagnostic Financial Definitions

Exhibit I         Alternative Dispute Resolution Rules

Exhibit J         Abbott [**]

Exhibit K         Millennium [**]

ANCILLARY DOCUMENTS

The Documents referred to in this Agreement are being simultaneously delivered
with the execution of this Agreement as separate documents and shall have the
following titles:

Document I        Master Research Plan

Document II       Precluded Target

Document III      Abbott Pipeline

Document IV       Millennium Pipeline




                                      xiii

<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                       COLLABORATION AND LICENSE AGREEMENT

         This Collaboration and License Agreement dated the 9th day of March,
2001 (the "Effective Date") is by and between Millennium Pharmaceuticals, Inc.,
a corporation organized and existing under the laws of the State of Delaware and
having its principal office at 75 Sidney Street, Cambridge, Massachusetts 02139
("Millennium"), and Abbott Laboratories, a corporation organized and existing
under the laws of the State of Illinois and having its principal office at 100
Abbott Park Road, Abbott Park, Illinois 60064 ("Abbott").

                                  INTRODUCTION

         WHEREAS, Millennium and Abbott are each in the business of discovering,
developing and commercializing pharmaceutical and diagnostic products.

         WHEREAS, Millennium and Abbott are interested in collaborating in the
validation of targets for, and the discovery, development and commercialization
of, (i) small molecules, antibodies, antisense molecules, proteins and other
therapeutic agents, and (ii) diagnostic products, to aid in the diagnosis,
prognosis, monitoring, prevention and treatment of certain metabolic diseases.

         NOW, THEREFORE, Millennium and Abbott agree as follows:

                                   ARTICLE 1

                                   DEFINITIONS

         When used in this Agreement, each of the following terms shall have the
meanings set forth in this Article 1:

         1.1 "ABBOTT DIAGNOSTIC PLATFORM". Abbott Diagnostic Platform means a
semi or fully automated instrument, other than pre-platform equipment (i.e., off
the shelf equipment), used to detect and/or measure clinically relevant
analyte(s) of test specimens, which instrument is owned or otherwise controlled
by Abbott.

         1.2 "ABBOTT RELEASED DIAGNOSTIC". Abbott Released Diagnostic means a
Diagnostic Product developed by Abbott for use in the Metabolic Disease Field
through the use of a Released Target pursuant to the license grant set forth in
Section 8.1.2(c)(iii).

         1.3 "ABBOTT RELEASED DIAGNOSTIC NET SALES". Abbott Released Diagnostic
Net Sales means Net Sales of an Abbott Released Diagnostic.


<PAGE>


   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.4 "ACTIVE". Active means (a) with respect to a Small Molecule, that
such Small Molecule modulates (or, in the case of a [**] a Program Target [**]
as determined by the Joint Research Committee and (b) with respect to an
Antibody, Antisense Molecule, Protein or Other Molecule, that such Antibody,
Antisense Molecule, Protein or Other Molecule [**] a Program Target [**] to be
determined by the Joint Research Committee.

         1.5 "AD HOC COMMITTEE". Ad Hoc Committee means the committee formed
pursuant to Section 4.1.1 to make recommendations relating to potential Drug
Development Candidates.

         1.6 "AFFILIATE". Affiliate means any corporation, company, partnership,
joint venture and/or firm which controls, is controlled by, or is under common
control with a specified person or entity. For purposes of this Section 1.6,
"control" shall be presumed to exist if one of the following conditions is met:
(a) in the case of corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the stock or shares having the right to vote for the
election of directors, and (b) in the case of non-corporate entities, direct or
indirect ownership of at least fifty percent (50%) of the equity interest with
the power to direct the management and policies of such non-corporate entities.
The Parties acknowledge that in the case of certain entities organized under the
laws of certain countries outside of the United States, the maximum percentage
ownership permitted by law for a foreign investor may be less than fifty percent
(50%), and that in such case such lower percentage shall be substituted in the
preceding sentence, PROVIDED THAT such foreign investor has the power to direct
the management and policies of such entity. For the purpose of this Agreement,
TAP Pharmaceutical Products Inc. and its subsidiaries shall not be deemed
Affiliates of Abbott.

         1.7 "ANNUAL RESEARCH PLAN". Annual Research Plan means the plan to be
developed by the Joint Research Committee for each Contract Year.

         1.8 "ANTIBODY". Antibody means a human or humanized polyclonal or
monoclonal antibody, whether multiple or single chain, recombinant, transgenic
animal derived or naturally occurring, whole or fragment, and any constructs
thereof.

         1.9 "ANTISENSE MOLECULE". Antisense Molecule means a nucleic acid or a
functional analog, derivative or homologue thereof which is complementary to a
segment of DNA of a target gene or such target gene's cognate RNA and which,
upon delivery by any means, alters the transcription, processing, elaboration,
RNA expression or protein production of or by such target gene.

         1.10 "ASSOCIATED BIOTHERAPEUTICS". Associated Biotherapeutics means,
with respect to a Program Target that has been designated [**], as the case may
be, [**] of the Program Biotherapeutics [**].


                                      -2-
<PAGE>


   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.11 "ASSOCIATED CHEMISTRY". Associated Chemistry means (a) with
respect to a Program Target that has been designated [**], as the case may be,
[**] included within such target's Program Compound Family; or (b) with respect
to a Program Target that has been designated [**], as the case may be, [**]
included within the Lead Compound Family(ies) of such target with respect to
which research activities [**].

         1.12 "BIOTHERAPEUTIC GENE". Biotherapeutic Gene means a gene for which
there is reasonable evidence (based upon bioinformatics analysis) to suggest
that such gene encodes a therapeutic Protein.

         1.13 "BIOTHERAPEUTIC PRODUCT". Biotherapeutic Product means (a) a
Therapeutic Antibody Product, (b) a Therapeutic Antisense Product, (c) a
Therapeutic Protein Product, and/or (d) a Therapeutic Other Molecular Product,
as the case may be.

         1.14 "CANDIDATE CHARACTERIZATION". Candidate Characterization means any
and all of the activities relating to the qualification of a Small Molecule,
Antibody, Antisense Molecule, Protein or Other Molecule as a Drug Development
Candidate in the Metabolic Disease Field, including, but not limited to,
chemical optimization and pre-clinical activities, as further provided in the
Research Plans. As the context may require, Candidate Characterization shall
also apply to any and all of the activities relating to [**].

         1.15 "CHANGE OF CONTROL". Change of Control means, with respect to a
Party, (a) a merger or consolidation of such Party with a Third Party which
results in the voting securities of such Party outstanding immediately prior
thereto ceasing to represent at least [**]of the combined voting power of the
surviving entity immediately after such merger or consolidation, or (b) a Third
Party, together with its Affiliates, becoming the beneficial owner of [**] or
more of the combined voting power of the outstanding securities of such Party,
or (c) the sale or other transfer to a Third Party of all or substantially all
of such Party's assets which relate to this Agreement.

         1.16 "COMMERCIALIZATION" or "COMMERCIALIZE". Commercialization or
Commercialize means any and all activities directed to marketing, promoting,
distributing, importing and selling a product. The conduct of Phase IV Studies
shall constitute Commercialization.

         1.17 "COMMERCIALIZATION PROGRAM". Commercialization Program means the
Commercialization of all Joint Products.

         1.18 "CONFIDENTIAL INFORMATION". Confidential Information means all
proprietary materials, know-how or other information (whether or not patentable)
regarding a Party's technology, products, business information or objectives,
which is designated as confidential in writing by the disclosing Party, whether
by letter or by the use of an appropriate stamp or legend, prior to or at the
time any such material, know-how or other information is disclosed by the
disclosing Party to the other Party, subject to the provisions of Section 11.1.
Notwithstanding the foregoing, materials, know-how or other information which is
orally, electronically or visually disclosed by a Party, or is disclosed in
writing without an appropriate letter, stamp or

                                      -3-
<PAGE>

legend, shall constitute Confidential Information of a Party (a) if the
disclosing Party, within thirty (30) days after such disclosure, delivers to the
other Party a written document describing the materials, know-how or other
information and referencing the place and date of such oral, visual, electronic
or written disclosure and the names of the persons to whom such disclosure was
made, or (b) such information is of the type that is customarily considered to
be confidential information by persons engaged in activities that are
substantially similar to the activities being engaged in by the Parties.
Notwithstanding the foregoing, any technical or financial information of a Party
disclosed at a meeting of the Joint Research Committee, the Joint Development
Committee, the Joint Manufacturing Committee, the Ad Hoc Committee, the Joint
Commercialization Committee or the Joint Executive Committee (or any
subcommittees or project teams of the foregoing) shall constitute Confidential
Information of a Party unless otherwise specified.

         1.19 "CONTRACT YEAR". Contract Year means (a) with respect to the first
Contract Year, the period beginning on the Effective Date and ending on December
31, 2001 (the "First Contract Year"), and (b) with respect to each subsequent
Contract Year, the twelve (12) month period beginning on the day following the
end of the First Contract Year and each succeeding twelve (12) month period
thereafter during the Research Program Term (except that the last Contract Year
shall end on the fifth (5th) anniversary of the Effective Date). Each Contract
Year (other than the First and last Contract Year) shall be divided into four
(4) "Contract Quarters" comprised of successive three (3) month periods. In the
First Contract Year, the first Contract Quarter shall end on the first day
following the Effective Date that is the last day of a calendar quarter, and in
the last Contract Year, the last Contract Quarter shall end on the fifth (5th)
anniversary of the Effective Date.

         1.20 "CONTROL" or "CONTROLLED". Control or Controlled means with
respect to any (a) material, know-how or other information, or (b) intellectual
property right, the possession (whether by license, other than pursuant to this
Agreement, or ownership) by a Party or its Affiliates of the ability to grant to
the other Party access and/or a license as provided herein without violating the
terms of any agreement or other arrangement with any Third Party existing before
or after the Effective Date.

         1.21 "CO-PROMOTED JOINT PRODUCT". Co-Promoted Joint Product means a
Joint Product as to which Millennium has exercised its co-promotion right
pursuant to Section 7.6.

         1.22 "CO-PROMOTION TERRITORY". Co-Promotion Territory means France,
Germany, Italy, Spain and the United Kingdom.

         1.23 "COVERING", "COVER", or "COVERED". Covering, Cover or Covered
means, with respect to a Patent Right, that, but for a license granted to a
party under a Valid Claim included in such Patent Right, the practice by such
party of an invention claimed in such Patent Right would infringe such Valid
Claim or in the case of a Patent Right that is a patent application, would
infringe a Valid Claim in such patent application if it were to issue as a
patent.

         1.24 "DDC FAMILY". DDC Family means, with respect to a Drug Development
Candidate, such Drug Development Candidate and all Program Compounds and/or
Program

                                      -4-
<PAGE>

Biotherapeutics, as the case may be, designated by the Joint Research Committee
as back-up Drug Development Candidates for such Drug Development Candidate.

         1.25 "DEVELOPMENT" or "DEVELOP". Development or Develop means, with
respect to a Drug Development Candidate, preclinical and clinical drug
development activities, including, among other activities: test method
development and stability testing, toxicology, formulation, quality
assurance/quality control development, statistical analysis and report writing,
clinical studies and regulatory affairs, product approval and registration. As
the context may require, Development or Develop shall also apply to a compound
that has achieved status equivalent to a Drug Development Candidate (such as a
Unilateral DDC).

         1.26 "DEVELOPMENT EXPENSES". Development Expenses means, with respect
to a Drug Development Candidate, all FTE expenses and out-of-pocket expenses
(including clinical supply costs) incurred in connection with the Development of
such Drug Development Candidate, based upon the applicable Development Plan. For
purposes of calculating FTE expenses, the number of FTEs dedicated to the
Development of such Drug Development Candidate shall be multiplied by the
average of the FTE rates of each Party (e.g., if the average Abbott FTE rate is
$200,000 and the average Millennium FTE rate is $220,000, the average FTE rate
would be $210,000).

         1.27 "DEVELOPMENT PROGRAM". Development Program means the Development
undertaken jointly by the Parties with respect to all Joint DDCs.

         1.28 "DIAGNOSTIC". Diagnostic means a product or process that (a)
identifies, through qualitative or quantitative measures, patients having a
particular disease or having a predisposition to a particular disease, (b)
defines, through qualitative or quantitative measures, the prognosis or monitors
the progress of a disease in a patient, or (c) measures the safety, efficacy or
amount of a therapeutic compound for treatment of a patient. The term Diagnostic
shall include, without limitation, analyte specific reagents and in vitro
diagnostic products (as those terms are defined in the FDA regulations),
diagnostic products that have received Regulatory Approval and diagnostic
services.

         1.29 "DRUG DEVELOPMENT CANDIDATE" OR "DDC". Drug Development Candidate
or DDC means a Program Compound or a Program Biotherapeutic that has qualified
for Development as a Small Molecule Drug or a Biotherapeutic Product, as the
case may be, for use in the Metabolic Disease Field, based upon the conduct of
Candidate Characterization activities in accordance with the criteria specified
in the Research Plans, and as determined by the Joint Executive Committee based
upon the recommendation of the Ad Hoc Committee.

         1.30 "DRUGGABLE TARGET". Druggable Target means a target (e.g., a
nucleic acid sequence and/or the Protein that it encodes), for which there is
reasonable evidence (based upon bioinformatics analysis) to suggest that such
target is of a class that is capable of being (a) modulated by a compound and
(b) configured into an assay for high throughput screening, used for
structure-based drug design or used in a method to isolate a compound.

         1.31 "EXCLUDED COMPOUNDS". Excluded Compounds means the compounds set
forth on EXHIBIT A.

                                      -5-
<PAGE>

         1.32 "EXECUTIVE OFFICERS". Executive Officers means the Chief Executive
Officer of Abbott (or an executive of Abbott designated by such Chief Executive
Officer) and the Chief Executive Officer of Millennium (or an executive of
Millennium designated by such Chief Executive Officer).

         1.33 "FDA". FDA means the United States Food and Drug Administration,
or a successor agency thereto.

         1.34 "FTE". FTE means a full time equivalent person year (consisting of
a total of 1,880 hours per year) of scientific, technical or managerial work on
or directly related to the Research Program, the Development Program and/or the
Commercialization Program, subject to the qualifications set forth in the
Research Plans, Development Plans and Commercialization Plans.

         1.35 "FIRST COMMERCIAL SALE". First Commercial Sale means (a) with
respect to a Unilateral Product, on a country-by-country basis, the first bona
fide sale of such Unilateral Product to a Third Party by a Party, its Affiliates
or sublicensees in a country in the Territory after Regulatory Approval has been
achieved for such Unilateral Product in such country, and (b) with respect to an
Abbott Released Diagnostic or a Unilateral Diagnostic, on a country-by-country
basis, the first bona fide sale of such Diagnostic to a Third Party by a Party,
its Affiliates or sublicensees in a country in the Territory. Sales for test
marketing, sampling and promotional uses, clinical trial purposes or
compassionate or similar use shall not be considered to constitute a First
Commercial Sale.

         1.36 "HIT". Hit means a Small Molecule that is confirmed to be Active
against a Program Target.

         1.37 "IND". IND means an application submitted to a Regulatory
Authority to initiate human clinical trials, including (a) (i) a United States
Investigational New Drug Application, or any successor application, and (ii) any
foreign counterpart of a United States Investigational New Drug Application, and
(b) all supplements and amendments that may be filed with respect to the
foregoing.

         1.38 "INVESTMENT AGREEMENT". Investment Agreement means the Investment
Agreement between the Parties dated as of the Effective Date.

         1.39 "JOINT COMMERCIALIZATION COMMITTEE". Joint Commercialization
Committee means the committee formed to oversee the Commercialization Program
pursuant to Section 7.1.

         1.40 "JOINT DEVELOPMENT COMMITTEE". Joint Development Committee means
the committee formed to oversee the Development Program pursuant to Section 4.2.

         1.41 "JOINT DRUG DEVELOPMENT CANDIDATE" or "JOINT DDC". Joint Drug
Development Candidate or Joint DDC means a Drug Development Candidate that the
Parties jointly Develop in accordance with Article 4, together with its DDC
Family.

         1.42 "JOINT EXECUTIVE COMMITTEE". Joint Executive Committee means the
committee formed to oversee the activities contemplated by this Agreement
pursuant to Section 13.1.

                                      -6-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.43 "JOINT MANUFACTURING COMMITTEE". Joint Manufacturing Committee
means the committee formed to oversee the Manufacturing of all Joint DDCs and
Joint Products pursuant to Section 6.1.

         1.44 "JOINT PRODUCT". Joint Product means a therapeutic or prophylactic
product that (a) contains a Joint DDC as an active ingredient, either alone or
with other active ingredients, and (b) has been approved for marketing and sale
in a country by a Regulatory Authority.

         1.45 "JOINT RESEARCH COMMITTEE". Joint Research Committee means the
committee formed to oversee the Research Program pursuant to Section 3.3.

         1.46 "LAWS". Laws means all laws, statutes, rules, regulations,
ordinances and other pronouncements having the effect of law of any federal,
national, multinational, state, provincial, county, city or other political
subdivision, domestic or foreign.

         1.47 "LEAD COMPOUND". Lead Compound means a Program Compound that has
been selected as a lead by the Joint Research Committee based on lead selection
criteria set forth in the Research Plans.

         1.48 "LEAD COMPOUND FAMILY". Lead Compound Family means, with respect
to a Lead Compound, such Lead Compound and all Program Compounds that are [**]
of such Lead Compound in the conduct of the Research Program.

         1.49 "MANUFACTURING" or "MANUFACTURE". Manufacturing or Manufacture
means all activities associated with the production, manufacture, processing,
filling, finishing and packaging of Joint DDCs and/or Joint Products, including
process development, manufacturing scale-up, post-Drug Development Candidate
pre-clinical manufacture, clinical and commercial manufacture and quality
assurance/quality control. As the context may require, Manufacturing or
Manufacture shall also apply to Unilateral DDCs and/or Unilateral Products.

         1.50 "MASTER RESEARCH PLAN". Master Research Plan means the general
research plan covering the activities to be undertaken by the Parties during the
Research Program Term, including the goals for the numbers of Drug Development
Candidates to be generated during each Contract Year. DOCUMENT I sets forth the
Master Research Plan.

         1.51 "METABOLIC DISEASE FIELD". Metabolic Disease Field means (a)
Obesity, (b) Type 1 Diabetes and (c) Type 2 Diabetes. The Metabolic Disease
Field specifically [**].

         1.52 "NET SALES". Net Sales means the gross amount invoiced by the
Royalty-Paying Party and its Affiliates and sublicensees on account of sales of
a Royalty-Bearing Product to Third Parties (including, without limitation, Third
Party distributors and wholesalers), less the total of:

              (a) trade, cash and/or quantity discounts not already reflected in
the amount invoiced;

                                      -7-
<PAGE>

              (b) all excise, sales and other consumption taxes (including VAT)
and custom duties, whether or not specifically identified as such in the invoice
to the Third Party;

              (c) freight, distribution, insurance and other transportation
charges, whether or not specifically identified as such in the invoice to the
Third Party;

              (d) amounts repaid or credited by reason of rejections, defects or
returns or because of chargebacks, retroactive price reductions, refunds or
billing errors;

              (e) compulsory payments and rebates directly related to the sale
of Royalty-Bearing Products, accrued, paid or deducted pursuant to agreements
(including, but not limited to, managed care agreements) or governmental
regulations;

              (f) management fees paid to group purchasing organizations and
relating specifically to the sale of Royalty-Bearing Products to their members;
and

              (g) Required Third Party Payments.

         Use of Royalty-Bearing Products for sampling purposes and for use in
clinical trials shall not be considered in determining Net Sales. In the case of
any sale of a Royalty-Bearing Product between or among the Royalty-Paying Party
and its Affiliates or sublicensees for resale, Net Sales shall be calculated
only on the value charged or invoiced on the first arm's length sale thereafter
to a Third Party. In the case of any other sale for value, such as barter or
counter-trade, of any Royalty-Bearing Product, Net Sales shall be calculated as
above on the value of the consideration received.

         In the event a Royalty-Bearing Product is sold as part of a Combination
Product (as defined below), the Net Sales from the Combination Product, for the
purposes of determining royalty payments, shall be determined by multiplying the
Net Sales of the Combination Product (as defined in the standard Net Sales
definition), during the applicable royalty reporting period, by the fraction,
A/(A+B), where A is the weighted average sale price of the Royalty-Bearing
Product when sold separately in finished form in the country in which the
Combination Product is sold and B is the weighted average sale price of the
other product(s) included in the Combination Product when sold separately in
finished form in the country in which the Combination Product is sold, in each
case during the applicable royalty reporting period or, if sales of both the
Royalty-Bearing Product and the other product(s) did not occur in such period,
then in the most recent royalty reporting period in which sales of both
occurred. In the event that such average sale price cannot be determined for
both the Royalty-Bearing Product and all other product(s) included in the
Combination Product, Net Sales for the purpose of determining royalty payments
shall be mutually agreed by the Parties in good faith based on the relative
value contributed by each component. As used above, the term "Combination
Product" means any product which comprises the Royalty-Bearing Product and other
active compounds and/or active ingredients which are not themselves
Royalty-Bearing Products.

         1.53 "OBESITY". Obesity means the condition of excess body fat (adipose
tissue), in accordance with the National Institutes of Health Federal Obesity
Clinical Guidelines for adults, whereby body mass index calculated by dividing
body mass in kilograms by height in meters squared is equal to or greater than
twenty-five (25) (for purposes of this definition, Obesity shall

                                      -8-
<PAGE>

include an overweight condition in accordance with the above guidelines and
comparable obesity and overweight condition in children).

         1.54 "OTHER DIAGNOSTIC PLATFORM". Other Diagnostic Platform means a
semi or fully automated instrument, other than pre-platform equipment (i.e., off
the shelf equipment), used to detect and/or measure clinically relevant
analyte(s) of test specimens that is not an Abbott Diagnostics Platform.

         1.55 "OTHER MOLECULE". Other Molecule means any molecule that is not a
Small Molecule, Antibody, Antisense Molecule or Protein.

         1.56 "PARTY" or "PARTIES". Party means Abbott or Millennium; "Parties"
means Abbott and Millennium.

         1.57 "PATENT RIGHTS". Patent Rights means rights under all existing
patents and patent applications and all patent applications hereafter filed,
including any continuations, continuations-in-part (but, in the case of Program
Patent Rights, solely to the extent of claims directed to inventions included in
Program Materials or Program Technology), divisions, provisional or any
substitute applications, any patent issued with respect to any such patent
applications, any reissue, reexamination, renewal or extension (including any
supplemental patent certificate) of any such patent, and any confirmation patent
or registration patent or patent of addition based on any such patent, and all
foreign counterparts of any of the foregoing.

         1.58 "PHASE I STUDY". Phase I Study means a clinical study in subjects
to evaluate the pharmacokinetic and pharmacodynamic properties, maximum
tolerated dose, dosing interval, and absorption, distribution, metabolism and
excretion of a Joint DDC. Phase I Studies may include special population
pharmacokinetic and drug interaction studies.

         1.59 "PHASE IIA STUDY". Phase IIA Study means a dose exploration, dose
response, duration of effect, kinetic/dynamic relationship and preliminary
efficacy and safety study of a Joint DDC in the target patient population.

         1.60 "PHASE IIB STUDY". Phase IIB Study means a controlled dose ranging
clinical trial to evaluate further the efficacy and safety of a Joint DDC in the
target patient population and to define the optimal dosing regimen.

         1.61 "PHASE IIIA STUDY". Phase IIIA Study means a controlled clinical
trial to confirm with statistical significance the efficacy and safety of a
Joint DDC in larger target patient populations, performed to obtain Regulatory
Approval of a product application.

         1.62 "PHASE IIIB STUDY". Phase IIIB Study means a clinical trial
intended to enhance the profile of a Joint DDC for a non-approved indication and
not required or pivotal for the original Regulatory Approval of a product
application.

         1.63 "PHASE IV STUDY". Phase IV Study means a study initiated in a
country after receipt of Regulatory Approval for a Joint Product in such
country, usually within and/or in support of the approved product labeling.

                                      -9-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.64 PROGRAM BIOTHERAPEUTIC". Program Biotherapeutic means an Antibody,
Antisense Molecule, Protein or Other Molecule, as the case may be, other than an
Excluded Compound, that (a) (i) is selected by the Joint Research Committee for
Candidate Characterization in the conduct of the Research Program, (ii) is in a
Party's or any of its Affiliates' possession as of the Effective Date, or is
first identified or acquired by either or both Parties or any of their
respective Affiliates during the Research Program Term, [**], (iii) (A) is [**]
a Program Target or (B) is [**] a Program Target, or is [**], and (iv) [**] in
the Metabolic Disease Field [**], or (b) is otherwise designated a Program
Biotherapeutic by the Joint Research Committee.

         1.65 "PROGRAM COMPOUND". Program Compound means a Small Molecule other
than an Excluded Compound, that (a) (i) is selected by the Joint Research
Committee for Candidate Characterization in the conduct of the Research Program,
(ii) is in a Party's or any of its Affiliates' possession as of the Effective
Date, or [**] by either or both Parties or any of their respective Affiliates
during the Research Program Term [**] of the Research Program, and (iii) is [**]
a Program Target, or (b) is [**] of the Research Program, or (c) is otherwise
designated a Program Compound by the Joint Research Committee; PROVIDED HOWEVER
in no event shall [**] a Program Compound unless such designation is
affirmatively agreed to by the Joint Research Committee.

         1.66 "PROGRAM COMPOUND FAMILY". Program Compound Family means, with
respect to all Program Compounds associated with a Program Target, such Program
Compounds [**] that are [**] of such Program Compounds in the conduct of the
Research Program.

         1.67 "PROGRAM DIAGNOSTIC". Program Diagnostic means a Diagnostic for
use in the Metabolic Disease Field that (a) (i) contains a [**] or, [**], or
(ii) detects or measures the presence or concentration of a [**] or, [**],
and (b) is necessary or useful in obtaining the Regulatory Approval of a
Joint DDC or in facilitating the market expansion or market penetration of a
Joint Product, as determined by the Joint Executive Committee based upon the
recommendation of the Joint Development Committee, as further provided in
Section 5.1.1.

         1.68 "PROGRAM DIAGNOSTIC NET SALES". Program Diagnostic Net Sales means
Net Sales of a Program Diagnostic.

         1.69 "PROGRAM INTELLECTUAL PROPERTY". Program Intellectual Property
means Program Patent Rights, as well as any other proprietary rights in Program
Material and Program Technology.

                                      -10-

<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.70 "PROGRAM MATERIAL". Program Material means any [**] and any
material first identified or discovered in the conduct of the Research
Program, the Development Program, in the course of Manufacturing Joint DDCs
and/or Joint Products or in the course of the development of a [**] (but will
not include the Abbott Diagnostic Platform), including, without limitation,
biological materials or chemical compounds Controlled by a Party or jointly
by the Parties.

         1.71 "PROGRAM PATENT RIGHTS". Program Patent Rights means any Patent
Rights that are Controlled by a Party and that Cover any Program Materials or
Program Technology.

         1.72 "PROGRAM TARGET". Program Target means [**] or [**] for which (a)
the Joint Research Committee determines that [**] such target or gene for the
identification of Small Molecules, Antibodies, Antisense Molecules, Proteins or
Other Molecules intended for use as Small Molecule Drugs or Biotherapeutic
Products, as the case may be, in the Metabolic Disease Field, based on
information from each of the following methodologies: [**]; and (b) activities
in the Research Program have been initiated that relate to (i) in the case of a
Druggable Target, (A) the validation of such target in the Metabolic Disease
Field through [**] of such target (e.g., through [**]) and/or (B) drug discovery
(e.g., [**] drug discovery [**] using such target, or (ii) in the case of a
Biotherapeutic Gene, the validation of such target in the Metabolic Disease
Field [**], it being understood that activities in the Research Program may also
have been initiated that relate to [**] such target (e.g., [**]).

         1.73 "PROGRAM TECHNOLOGY". Program Technology means any invention,
information, methods, know-how, trade secrets, data, or copyright that (a) is
Controlled by a Party or jointly by the Parties, and (b) (i) relates to the
Metabolic Disease Field, (ii) is utilized in the Research Program (but only to
the extent so utilized), and (iii) either (A) is in a Party's or any of its
Affiliates' possession as of the Effective Date, or is discovered or acquired by
a Party and/or any of its Affiliates during the Research Program Term [**] or
(B) is first invented or discovered in the conduct of the Research Program, in
the course of the Development, Manufacturing or Commercialization of any Joint
DDC and/or Joint Product or in the course of the development or
Commercialization of a Program Diagnostic ([**]). For clarity, Program
Technology excludes Program Materials.

         1.74 "PROTEIN". Protein means a high molecular weight (i.e. weighing
greater than [**]) polymer compound comprised of a variety of amino acids joined
by peptide linkages, including allelic variants thereof, post-translationally
modified variants thereof and chemically modified versions thereof. The term
"Protein" shall not include an Antibody.

                                      -11-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.75 "REGULATORY APPROVAL". Regulatory Approval means any and all
approvals (including any applicable governmental price and reimbursement
approvals), licenses, registrations, or authorizations of any Regulatory
Authority necessary for the manufacture, use, storage, import, transport,
promotion, marketing and sale of a product in a country, including, but not
limited to approvals of biologics license applications, new drug applications
and product license applications (and their respective foreign counterparts).

         1.76 "REGULATORY AUTHORITY". Regulatory Authority means any federal,
national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority or jurisdiction
over the testing, manufacture, use, storage, import, transport, promotion,
marketing and sale of a therapeutic product in a country, including, but not
limited to, the FDA.

         1.77 "RELEASED COMPOUND". Released Compound shall mean:

              (a) in the case of a Program Target with respect to which research
           activities have been discontinued prior to designation of a DDC, [**]
           Program Target's Program Compound Family;

              (b) in the case of a Program Target with respect to which research
           activities have not been discontinued and a DDC has not yet been
           designated, [**] Program Target's Lead Compound Families with respect
           to which research activities have been discontinued;

              (c) in the case of a Program Target with respect to which research
           activities have not been discontinued and a DDC has not yet been
           designated, [**] Program Target's Lead Compound Families with respect
           to which research activities have not been discontinued but where it
           is determined that, on the basis of a review by the Joint Research
           Committee undertaken at [**] intervals, such [**] such Program Target
           and (ii), unless otherwise specifically determined by the Joint
           Research Committee, Covered by Program Patent Rights; or

              (d) in the case of a Program Target with respect to which a DDC
           has been designated, [**] in such Program Target's Program Compound
           Family that are not included in such DDC's DDC Family and have not
           been previously released pursuant to subsections (b) or (c);

in each case as determined by the Joint Research Committee. "Abbott Released
Compound" means a Released Compound Controlled by Abbott and "Millennium
Released Compound" means a Released Compound Controlled by Millennium.


                                      -12-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         1.78 "REQUIRED THIRD PARTY PAYMENTS". Required Third Party Payment
means (a) payments to a Third Party to license patents Covering such Third
Party's technology if, in the absence of such license, the sale of
Royalty-Bearing Products would or is likely to, in the reasonable judgment of
the Royalty-Paying Party, infringe such patents or (b) payments to a Third Party
made pursuant to Burdened Technology Obligations.

         1.79 "RESEARCH PLANS". Research Plans means the Master Research Plan
and the Annual Research Plans.

         1.80 "RESEARCH PROGRAM". Research Program means the collaborative
research program to be conducted by the Parties in accordance with the Research
Plans and this Agreement. Activities conducted pursuant to Section 3.8 with
respect to Unilateral Targets shall not be part of the Research Program.

         1.81 "ROW". ROW means all the countries in the Territory excluding the
United States.

         1.82 "ROYALTY-BEARING PRODUCT". Royalty-Bearing Product means a
Royalty-Bearing Abbott Released Diagnostic, Royalty-Bearing Unilateral
Diagnostic and Unilateral Product.

         1.83 "ROYALTY-PAYING PARTY". Royalty-Paying Party means, with respect
to a Royalty-Bearing Product, the Party obligated to pay royalties to the other
Party under the provisions of Section 9.2 and Section 9.4.

         1.84 "SMALL MOLECULE". Small Molecule means a compound that has a
molecular weight that is no greater than [**].

         1.85 "SMALL MOLECULE DRUG". Small Molecule Drug means a therapeutic or
prophylactic product in which the active ingredient is a Small Molecule.

         1.86 "SPECIAL PURPOSE EQUIPMENT". Special Purpose Equipment means
equipment which (a) the Joint Manufacturing Committee determines to be necessary
for the Manufacture of a Joint DDC and/or Joint Product, (b) is specialized
equipment that the Lead Manufacturing Party does not own or otherwise have
available as of the date of its designation as the Lead Manufacturing Party, and
(c) once used for the Manufacture of such Joint DDC and/or Joint Product, is not
readily reusable by the Lead Manufacturing Party for any other purpose.

         1.87 "SUSPENDED DRUG DEVELOPMENT CANDIDATE" or "SUSPENDED DDC".
Suspended Drug Development Candidate or Suspended DDC means (a) a Drug
Development Candidate that neither Party initially elects to Develop, as further
provided in Section 4.1.5, or (b) a Drug Development Candidate that was under
Development pursuant to the Development Program as a Joint DDC but is no longer
the subject of Development activities, as further provided in Section 4.7.3, or
(c) a Drug Development Candidate that was under Development as a Unilateral DDC
but is no longer the subject of Development activities, as further provided in
Section 4.7.3.

                                      -13-
<PAGE>

         1.88 "SUSPENDED TARGET". Suspended Target means (a) a Program Target
that was under investigation pursuant to the Research Program as a Program
Target but is no longer the subject of validation and drug discovery activities,
as further provided in Section 3.9, or (b) a target that was under investigation
as a Unilateral Target but is no longer the subject of validation and drug
discovery activities, as further provided in Section 3.9.

         1.89 "TERRITORY". Territory means all the countries of the world.

         1.90 "THERAPEUTIC ANTIBODY PRODUCT". Therapeutic Antibody Product means
a therapeutic or prophylactic product in which the active ingredient is an
Antibody.

         1.91 "THERAPEUTIC ANTISENSE PRODUCT". Therapeutic Antisense Product
means a therapeutic or prophylactic product in which the active ingredient is an
Antisense Molecule.

         1.92 "THERAPEUTIC OTHER MOLECULAR PRODUCT". Therapeutic Other Molecular
Product means a therapeutic or prophylactic product in which the active
ingredient is an Other Molecule.

         1.93 "THERAPEUTIC PROTEIN PRODUCT". Therapeutic Protein Product means a
therapeutic or prophylactic product in which the active ingredient is a Protein.

         1.94 "THIRD PARTY". Third Party means any person or entity other than a
Party or any of its Affiliates.

         1.95 "TYPE 1 DIABETES". Type 1 Diabetes means insulin-dependent
diabetes mellitus as diagnosed according to criteria published in the Report of
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
(DIABETES CARE, Vol. 24, Supp. 1, January 2001) whereby fasting plasma glucose
level is greater than or equal to 126 milligrams per deciliter and for which the
primary cause is beta-cell destruction.

         1.96 "TYPE 2 DIABETES". Type 2 Diabetes means non-insulin-dependent
diabetes mellitus as diagnosed according to criteria published in the Report of
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
(DIABETES CARE, Vol. 24, Supp. 1, January 2001) whereby fasting plasma glucose
level is greater than or equal to 126 milligrams per deciliter.

         1.97 "UNILATERAL DIAGNOSTIC". Unilateral Diagnostic means a Diagnostic
for use in the Metabolic Disease Field, other than a Program Diagnostic or an
Abbott Released Diagnostic, that is being developed and Commercialized by a
Party pursuant to Section 5.3, and that:

              (a) (i)(A) contains (1) a Unilateral Target, (2) a Small Molecule,
Antibody, Antisense Molecule, Protein or Other Molecule that is included in a
Unilateral Target's Associated Chemistry or Associated Biotherapeutics, (3) a
Unilateral DDC or (4) a derivative of a compound included in (a)(i)(A)(1),
(a)(i)(A)(2) or (a)(i)(A)(3), OR (B) detects or measures the presence or
concentration of (1) a Unilateral Target, (2) a Small Molecule, Antibody,
Antisense Molecule, Protein or Other Molecule that is included in a Unilateral
Target's Associated Chemistry or Associated Biotherapeutics, (3) a Unilateral
DDC or (4) a metabolite of a compound included in (a)(ii)(B)(1), (a)(ii)(B)(2)
or (a)(ii)(B)(3), AND

                                      -14-
<PAGE>

                  (ii) is necessary or useful in obtaining the Regulatory
Approval of, or in facilitating the market expansion or market penetration of, a
Unilateral Product, OR

              (b) is a Diagnostic that had previously been designated a Program
Diagnostic and has subsequently been deemed a Unilateral Diagnostic (and no
longer a Program Diagnostic) pursuant to the provisions of Section 5.3.

"Abbott Unilateral Diagnostic" means a Unilateral Diagnostic that is being
developed and Commercialized by Abbott pursuant to Section 5.3.1 and "Millennium
Unilateral Diagnostic" means a Unilateral Diagnostic that is being developed and
Commercialized by Millennium pursuant to Section 5.3.2.

         1.98 "UNILATERAL DIAGNOSTIC NET SALES". Unilateral Diagnostic Net Sales
means Net Sales of a Unilateral Diagnostic.

         1.99 "UNILATERAL DRUG DEVELOPMENT CANDIDATE" or "UNILATERAL DDC".
Unilateral Drug Development Candidate or Unilateral DDC means a Drug Development
Candidate that one Party Develops in accordance with Section 4.9, together with
the other Drug Development Candidates included in its DDC Family. "Abbott
Unilateral DDC" means a Unilateral DDC for which Abbott is the Developing Party,
and "Millennium Unilateral DDC" means a Unilateral DDC for which Millennium is
the Developing Party.

         1.100 "UNILATERAL PRODUCT". Unilateral Product means a therapeutic or
prophylactic product that is being Commercialized by a Party pursuant to Section
7.8, and that (a) contains as an active ingredient (i) a Small Molecule,
Antibody, Antisense Molecule, Protein or Other Molecule that is first
identified, evaluated or optimized by a Party through the use of a Unilateral
Target, (ii) a Small Molecule, Antibody, Antisense Molecule, Protein or Other
Molecule that is first identified, evaluated or optimized in the Research
Program through the use of a Program Target prior to such target's designation
as a Unilateral Target and is included in such target's Associated Chemistry or
Associated Biotherapeutics, or (iii) a Unilateral DDC and (b) has been approved
for marketing and sale in a country by a Regulatory Authority. "Abbott
Unilateral Product" means a Unilateral Product that is being Commercialized by
Abbott pursuant to Section 7.8, and "Millennium Unilateral Product" means a
Unilateral Product that is being Commercialized by Millennium pursuant to
Section 7.8.

         1.101 "UNILATERAL PRODUCT NET SALES". Unilateral Product Net Sales
means Net Sales of a Unilateral Product.

         1.102 "UNILATERAL TARGET". Unilateral Target means a former Program
Target that is the subject of validation and/or drug discovery activities by
only one of the Parties outside of the Research Program in accordance with
Section 3.8. "Abbott Unilateral Target" means a Unilateral Target for which
Abbott is the Researching Party and "Millennium Unilateral Target" means a
Unilateral Target for which Millennium is the Researching Party.

         1.103 "VALID CLAIM". Valid Claim means a claim (a) of any issued,
unexpired patent which has not been revoked or held unenforceable or invalid by
a decision of a court or governmental agency of competent jurisdiction from
which no appeal can be taken, or with respect to which an appeal is not taken
within the time allowed for appeal, and which has not

                                      -15-
<PAGE>

been disclaimed, denied or admitted to be invalid or unenforceable through
reissue, disclaimer or otherwise, or (b) of any patent application which shall
neither have been cancelled, withdrawn or abandoned, nor have been pending for
more than seven (7) years from the earliest priority date claimed for such
application.

         1.104 ADDITIONAL DEFINITIONS. Each of the following definitions is set
forth in the section of this Agreement indicated below:

<TABLE>
<CAPTION>

         DEFINITION                                                                                    SECTION
         ----------                                                                                    -------
         <S>                                                                                          <C>

         Abbott                                                                                       Preamble
         Abbott Indemnified Parties                                                                    15.1.2
         Abbott Unilateral DDC                                                                          1.99
         Abbott Unilateral Diagnostic                                                                   1.97
         Abbott Unilateral Product                                                                      1.100
         Abbott Unilateral Target                                                                       1.102
         Acting Party                                                                                  10.4.5
         ADD                                                                                          5.1.1(a)
         ADR                                                                                            13.5
         ADR Notice                                                                                   EXHIBIT I
         Breach Notice                                                                                 12.2.1
         Breaching Party                                                                               12.2.1
         Burdened Technology                                                                            3.2.1
         Burdened Technology Obligations                                                                3.2.1
         Capital Recovery Period                                                                      6.1.3(h)
         Change of Control Election                                                                     12.5
         Change of Control Party                                                                        12.5
         Close Competitor                                                                               9.2.5
         Combination Product                                                                            1.52
         Commercialization Expenses                                                                   EXHIBIT G
         Commercialization Plans                                                                        7.2.1
         Commercialization Product Team                                                                 7.2.1
         Competitor Product                                                                             9.2.5
         Contract Quarter                                                                               1.19
         Co-Promotion Guidelines                                                                        7.6.5
         CPR                                                                                          EXHIBIT I
         Data Package                                                                                   4.1.1
         Decision Milestone                                                                             7.6.1
         Developing Party                                                                               4.9.1
         Development Plans                                                                               4.3
         Diagnostic Development Expenses                                                              EXHIBIT H
         Disqualifying Commitments                                                                    3.6.2(b)
         Distribution Expenses                                                                        EXHIBIT G
         Distribution Margin/Profit                                                                   EXHIBIT G
         Early Termination                                                                            3.1.2(b)
         Effective Date                                                                               Preamble
         Excess Recovery                                                                               10.4.4

                                      -16-
<PAGE>

         DEFINITION                                                                                    SECTION
         ----------                                                                                    -------

         Final Detail Plan                                                                            7.6.7(a)
         First Contract Year                                                                            1.19
         First Joint DDC                                                                                7.6.1
         First Joint Product                                                                            7.6.1
         Global Commercialization Framework                                                             7.2.1
         Global Development Plan                                                                         4.3
         Global Manufacturing Plan                                                                       6.2
         Global New Product Pre-Launch Team                                                           7.1.3(b)
         Initial Commercialization Plan                                                                 7.2.1
         Initial Development Plan                                                                        4.3
         Initial Manufacturing Plan                                                                      6.2
         Intellectual Property                                                                         14.5(a)
         Joint Development Project Team                                                               4.2.3(c)
         Joint Product Net Sales                                                                      EXHIBIT G
         Joint Program Diagnostic                                                                     5.1.1(b)
         Joint Research Project Team                                                                    3.3.1
         Lead Manufacturing Party                                                                       6.3.1
         Lead Regulatory Party                                                                        4.5.1(a)
         Manufacturing Commencement Date                                                                6.3.3
         Manufacturing Plans                                                                             6.2
         Market Competitive Supplier                                                                    6.3.3
         Marks                                                                                         10.6.1
         Millennium                                                                                   Preamble
         Millennium Indemnified Parties                                                                15.1.1
         Millennium Unilateral DDC                                                                      1.99
         Millennium Unilateral Diagnostic                                                               1.97
         Millennium Unilateral Product                                                                  1.100
         Millennium Unilateral Target                                                                   1.102
         Net Units of Joint Product Sold                                                              EXHIBIT G
         Net Units of Program Diagnostic Sold                                                         EXHIBIT H
         Neutral                                                                                      EXHIBIT I
         Non-Breaching Party                                                                           12.2.1
         Non-Field Target                                                                               3.10
         Non-Program Compounds                                                                          3.6.4
         Non-Researching Party                                                                         3.8(c)
         Non-Selling Party                                                                             10.4.4
         Notice of Discontinuance                                                                       4.7.1
         Operating Margin/Profit                                                                      EXHIBIT G
         Opt-Out Phase                                                                                  9.2.2
         Owning Party                                                                                 10.4.2(b)
         Party-Burdened Field                                                                           3.6.4
         Party-Burdened Target                                                                          3.6.4
         Patent Prosecution                                                                            10.2.1
         Probation Period                                                                             7.6.7(e)
         Product-Specific Patent Rights                                                               10.4.2(a)

                                      -17-

<PAGE>

         DEFINITION                                                                                    SECTION
         ----------                                                                                    -------
         Program Diagnostic Budget                                                                    5.1.1(a)
         Program Diagnostic Commercialization Expenses                                                EXHIBIT H
         Program Diagnostic Distribution Margin/Profit                                                EXHIBIT H
         Program Diagnostic Distribution Expenses                                                     EXHIBIT H
         Program Diagnostic Net Sales                                                                 EXHIBIT H
         Program Diagnostic Operating Margin/Profit                                                   EXHIBIT H
         Program Diagnostic Plan                                                                      5.1.1(a)
         Program Diagnostic ROW Territory Operating Margin/Profit                                     EXHIBIT H
         Program Diagnostic Standard Cost of Goods Sold                                               EXHIBIT H
         Program Diagnostic U.S. Territory Operating Margin/Profit                                    EXHIBIT H
         Proposing Party                                                                              3.6.1(b)
         Released Target                                                                                5.2.1
         Research Program Term                                                                        3.1.2(a)
         Researching Party                                                                             3.8(a)
         ROW Commercialization Activities                                                             7.3.2(b)
         ROW Commercialization Budget                                                                 7.1.5(b)
         ROW Commercialization Plan                                                                     7.2.1
         ROW Commercialization Product Team                                                           7.1.3(e)
         ROW Minus the Co-Promotion Territory                                                         EXHIBIT G
         ROW Minus the Co-Promotion Territory Operating Margin/Profit                                 EXHIBIT G
         ROW Territory                                                                           EXHIBIT G/EXHIBIT H
         ROW Territory Operating Margin/Profit                                                        EXHIBIT G
         Royalty-Bearing Abbott Released Diagnostic                                                     9.4.1
         Royalty-Bearing Unilateral Diagnostic                                                          9.4.2
         Second Joint DDC                                                                               7.6.1
         Second Joint Product                                                                           7.6.1
         Selection Pool                                                                                3.11(b)
         Selling Party                                                                                 10.4.4
         Senior Project Manager                                                                       7.3.3(b)
         Standard Cost of Goods Sold                                                                  EXHIBIT G
         Target Family                                                                                10.1.2(a)
         Third Party Program Diagnostic                                                               5.1.1(c)
         Trademark-Owning Party                                                                        10.6.1
         U.S. Commercialization Activities                                                            7.3.2(a)
         U.S. Commercialization Budget                                                                7.1.4(b)
         U.S. Commercialization Plan                                                                    7.2.1
         U.S. Commercialization Product Team                                                          7.1.3(d)
         U.S./ROW Joint Commercialization Activities                                                  7.3.2(c)
         U.S. Territory                                                                          EXHIBIT G/EXHIBIT H
         U.S. Territory Operating Margin/Profit                                                       EXHIBIT G

</TABLE>

                                      -18-

<PAGE>


   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                   ARTICLE 2

                       EXCLUSIVITY; SCOPE OF COLLABORATION

         2.1 Exclusivity.

              2.1.1 GENERAL. During the Research Program Term, and subject to
the exceptions set forth in Section 2.1.2, neither Party nor its Affiliates
shall, either alone or in collaboration with a Third Party, engage in any
activity (other than the research, Development and Commercialization of Joint
DDCs and Joint Products pursuant to this Agreement), the focus of which is

                  (a) the validation of targets for the discovery of Small
Molecules, Antibodies, Antisense Molecules, Proteins or Other Molecules intended
primarily for use as Small Molecule Drugs or Biotherapeutic Products, as the
case may be, in the Metabolic Disease Field; or

                  (b) the discovery, Development and/or Commercialization of
Small Molecule Drugs or Biotherapeutic Products intended primarily for use in
the Metabolic Disease Field.

              2.1.2 EXCEPTIONS. The prohibitions set forth in Section 2.1.1 do
not apply to any of the following:

                  (a) the [**];

                  (b) activities undertaken in fulfillment of rights and
obligations of a Party existing as of the Effective Date pursuant to an
agreement that is set forth in EXHIBIT B or EXHIBIT C;

                  (c) the Development and Commercialization of [**] in the
Metabolic Disease Field where (i) [**] in the Metabolic Disease Field [**] the
Metabolic Disease Field and (ii) such Party is [**] by this Agreement [**] with
respect to the [**];

                  (d) activities undertaken [**];

                  (e) where a Party's involvement in such activity results from
such Party's acquisition of a commercial Third Party (by merger or otherwise),
which Third Party, prior to such acquisition or merger, was already engaged in
such activity; PROVIDED THAT (i) the acquiring Party [**] previously conducted
by the acquired Third Party in the Metabolic Disease Field, (ii) the acquiring
Party's activities with respect to the acquired Third Party [**] under this
Agreement, and (iii) [**] are used for the benefit of any such activities unless
(x) the acquiring Party acquires a product directed to the [**] under
development by the acquiring Party and (y) the [**] with the program [**] in a
manner which provides for the payment of royalties to the other Party in
accordance with Section 9.2. The exception set forth in this subsection (e)
shall not apply, however, to the acquisition of a commercial Third Party in the
case where all or substantially all of the activities of the commercial Third
Party fall within the scope of Section 2.1.1(a) and/or 2.1.1(b), it being
understood, however, that either Party may initiate a discussion with the other
Party concerning the joint acquisition of such a Third Party and/or seek the
other

                                      -19-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Party's consent (which shall not be unreasonably withheld) to the acquisition by
such Party of such Third Party;

                  (f) activities undertaken by the [**] to the extent otherwise
permitted by the provisions of this Agreement;

                  (g) activities undertaken by a Party with respect to [**] to
the extent otherwise permitted by the provisions of [**] this Agreement; or

                  (h) activities undertaken by Abbott with respect to the target
set forth in DOCUMENT II, it being acknowledged by the Parties that Millennium,
as of the Effective Date, is precluded from including such target in the
Research Program as the result of an agreement with a Third Party. However, if
at any time during the period commencing upon the Effective Date and ending on
the [**]anniversary thereof, Millennium has eliminated such commitments to such
Third Party with respect to such target, then Millennium shall have the right to
include such target in the Research Program by providing written notice to
Abbott of the exercise of such right and reimbursing Abbott for [**] percent
([**]%) of the research and, if applicable, development expenses incurred by
Abbott from the Effective Date to the date of such election with respect to the
research, and if applicable, development expenses with respect to such target in
the Metabolic Disease Field. Upon such foregoing reimbursement by Millennium,
such target shall become a Program Target, subject to Burdened Technology
Obligations, all related materials Controlled by either Party shall become
Program Materials, all related technology Controlled by either Party shall
become Program Technology and all related patent rights Controlled by either
Party shall become Program Patent Rights.

              2.1.3 POST-RESEARCH PROGRAM EXCLUSIVITY.

                  (a) During the [**]year period following expiration of the
Research Program Term, neither the Parties nor any of their respective
Affiliates shall, either alone or in collaboration with a Third Party, engage,
other than pursuant to this Agreement, in the discovery, Development or
Commercialization of Small Molecule Drugs or Biotherapeutic Products [**] the
same Program Target as a Joint DDC, or Joint Product for use in the Metabolic
Disease Field.

                  (b) With respect to a Millennium Unilateral Target, during the
longer of (i) the [**]year period following expiration of the Research Program
Term, or (ii) with respect to any Program Target that has become a Millennium
Unilateral Target during the Research Program Term, [**] years from the date
that such Program Target became a Millennium Unilateral Target, neither Abbott
nor any of its Affiliates shall, either alone or in collaboration with a Third
Party, engage in the discovery, Development and Commercialization of Small
Molecule Drugs or Biotherapeutic Products for use in the Metabolic Disease Field
[**], such Millennium Unilateral Target.

                                      -20-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) With respect to an Abbott Unilateral Target, during the
longer of (i) the [**]year period following expiration of the Research Program
Term, or (ii) with respect to any Program Target that has become an Abbott
Unilateral Target during the Research Program Term, [**] years from the date
that such Program Target became an Abbott Unilateral Target, neither Millennium
nor any of its Affiliates shall, either alone or in collaboration with a Third
Party, engage in the discovery, Development and Commercialization of Small
Molecule Drugs or Biotherapeutic Products for use in the Metabolic Disease Field
[**], such Abbott Unilateral Target.

              2.1.4 PROGRAM DIAGNOSTIC EXCLUSIVITY. During the Research Program
Term and the [**] year period following expiration of the Research Program Term,
neither the Parties nor any of their respective Affiliates shall, either alone
or in collaboration with a Third Party, engage in the development or
Commercialization of a Diagnostic [**] the same Program Target as a Joint
Program Diagnostic or a Third Party Program Diagnostic for use in the Metabolic
Disease Field.

              2.1.5 UNILATERAL DIAGNOSTIC EXCLUSIVITY.

                  (a) With respect to a Millennium Unilateral Target, until the
sooner to occur of (A) the [**] anniversary of the First Commercial Sale of a
Millennium Unilateral Product based upon such target or (B), with respect to any
Program Target that has become a Millennium Unilateral Target during the
Research Program Term, the [**] anniversary of the date that such Program
Target became a Millennium Unilateral Target, neither Abbott nor any of its
Affiliates shall, either alone or in collaboration with a Third Party, engage in
the discovery, development or Commercialization of a Diagnostic for use in the
Metabolic Disease Field that (a) contains such Millennium Unilateral Target,
[**], or (b) detects or measures the presence or concentration of (i) such
Millennium Unilateral Target, [**], or (ii) a Small Molecule, Antibody,
Antisense Molecule, Protein or Other Molecule directed to such Millennium
Unilateral Target, [**]. Notwithstanding the foregoing, this prohibition shall
not apply to a Diagnostic developed by Abbott that is based upon a Millennium
Unilateral Target and that is necessary or useful in obtaining the Regulatory
Approval of, or in facilitating the market expansion or market penetration of,
[**] that is being developed or Commercialized by Abbott or any of its
Affiliates and was developed through the use of such Millennium Unilateral
Target pursuant to Abbott's non-exclusive retained rights set forth in Section
8.2.2(b)(i). For purposes of clarity, nothing in this Section 2.1.5(a) is
intended to diminish the exclusive license granted to Millennium with respect to
certain Millennium Unilateral Diagnostics as set forth in Section 8.2.2(c)(ii)

                  (b) With respect to an Abbott Unilateral Target, until the
sooner to occur of (A) the [**] anniversary of the First Commercial Sale of an
Abbott Unilateral Product based upon such target or (B), with respect to any
Program Target that has become an Abbott Unilateral Target during the Research
Program Term, the [**] anniversary of the date that such Program Target became
an Abbott Unilateral Target, neither Millennium nor any of its Affiliates shall,
either alone or in collaboration with a Third Party, engage in the discovery,
development or Commercialization of a Diagnostic for use in the Metabolic
Disease Field that (a) contains such

                                      -21-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Abbott Unilateral Target, [**], or (b) detects or measures the presence or
concentration of (i) such Abbott Unilateral Target, [**], or (ii) a Small
Molecule, Antibody, Antisense Molecule, Protein or Other Molecule directed to
such Abbott Unilateral Target, [**]. Notwithstanding the foregoing, this
prohibition shall not apply to a Diagnostic developed by Millennium that is
based upon an Abbott Unilateral Target and that is necessary or useful in
obtaining the Regulatory Approval of, or in facilitating the market expansion or
market penetration of, [**] that is being developed or Commercialized by
Millennium or any of its Affiliates and was developed through the use of such
Abbott Unilateral Target pursuant to Millennium's non-exclusive retained rights
set forth in Section 8.1.2(b)(i). For purposes of clarity, nothing in this
Section 2.1.5(b) is intended to diminish the exclusive license granted to Abbott
with respect to certain Abbott Unilateral Diagnostics as set forth in Section
8.1.2(c)(ii).

              2.1.6 RELEASED TARGET EXCLUSIVITY. With respect to a Released
Target, during the longer of (a) the period that commences on the Effective Date
and ends on the [**]anniversary of the expiration of the Research Program Term
or (b) with respect to any Program Target that has become a Released Target
during the Research Program Term, the period that commences on the Effective
Date and ends on the [**] anniversary of the date that such Program Target
became a Released Target, neither Millennium nor any of its Affiliates shall,
either alone or in collaboration with a Third Party, engage in the development
of a Diagnostic for use in the Metabolic Disease Field through the use of such
Released Target.

              2.1.7 RELEASED COMPOUND EXCLUSIVITY. During the Research Program
Term and the [**] year period following expiration of the Research Program Term,
neither the Parties nor any of their respective Affiliates shall, either alone
or in collaboration with a Third Party, engage in the discovery, Development or
Commercialization of Released Compounds directed to a Program Target [**].

              2.1.8 OTHER PERMITTED ACTIVITIES. Except as set forth in Section
2.1.7, either Party may, [**] (including activities involving [**] such Party
and [**] such Party.)

         2.2 IN-LICENSING OF COMPOUNDS. The Parties agree that in-licensing of
compounds may significantly accelerate the objectives of the Parties.
Accordingly, during the Research Program Term, the Parties shall collaborate to
identify and in-license compounds for research, Development and
Commercialization of Joint Products within the Metabolic Disease Field. If,
during the Research Program Term, either Party learns of and wishes to pursue an
in-licensing opportunity, it shall bring such opportunity to the attention of
the Joint Executive Committee as the forum for discussion between the Parties.
If the Joint Executive Committee approves the proposed in-licensing of a
compound, (i) the Joint Executive Committee shall designate one Party as the
lead negotiating Party, which lead negotiating Party shall operate within the
parameters prescribed by the Joint Executive Committee; (ii) the Joint Executive
Committee shall approve any such in-licensing agreement; (iii) all up-front
licensing costs associated with any successfully in-licensed compound shall be
shared equally by the Parties; and (iv) all Development Expenses and U.S.
Territory Operating Margin/Profit and ROW Territory Operating Margin/Profit
associated with any in-licensed compound shall be shared in accordance

                                      -22-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

with the terms of this Agreement. If the Joint Executive Committee approves a
proposed in-licensing opportunity but the Parties are unable to complete an
in-licensing arrangement, then neither Party may pursue on its own such
in-licensing opportunity. If the Joint Executive Committee rejects a proposed
in-licensing of a compound, then the proposing Party may pursue such opportunity
independently only if such opportunity [**]

                                   ARTICLE 3

                                RESEARCH PROGRAM

         3.1 GENERAL.

              3.1.1 OBJECTIVE.

                  (a) The Parties shall collaborate in carrying out the Research
Program with the objective of [**]. It is intended that the Research Program
will be conducted as a unified collaborative effort with activities by the
Parties carried out primarily at each Party's respective facilities, and this
intent shall be reflected in the Research Plans.

                  (b) Subject to existing commitments to Third Parties
(including Burdened Technology Obligations), Disqualifying Commitments and the
provisions of Section 3.6.4, in accordance with the procedures set forth in
Section 3.6, each Party will make available to the Research Program its existing
pipeline of targets, screens, Small Molecules, Antibodies, Antisense Molecules,
Proteins and Other Molecules for which there is a reasonable scientific
rationale for utility in the discovery, Development and/or Commercialization of
Small Molecule Drugs or Biotherapeutic Products in the Metabolic Disease Field,
as further described in DOCUMENT III with respect to Abbott and DOCUMENT IV with
respect to Millennium. In addition to conducting work on the pipelines of the
Parties made available to the Research Program, the Parties will conduct
research for the validation and screening of additional targets and the
discovery and optimization of additional Small Molecules, Antibodies, Antisense
Molecules, Proteins and Other Molecules for use in the discovery, Development
and/or Commercialization of Small Molecule Drugs and Biotherapeutic Products in
the Metabolic Disease Field.

                  (c) It is anticipated that during the initial years of the
Research Program, [**], and during the later years of the Research Program,
[**]

                  (d) Although Millennium will take the leadership position in
[**], both Parties will participate in the range of drug discovery activities
to be conducted in the Research Program, including without limitation [**]

                  (e) The activities conducted by the Parties under the
Research Program shall be [**] as the case may be, within the Metabolic
Disease Field and the determination of whether such [**]. Once a [**] or [**]
has been designated a [**], subject to any applicable Burdened Technology
Obligations and limitations relating to Party-Burdened Targets, the Parties
may Develop and Commercialize such [**].

                                      -23-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (f) Notwithstanding the foregoing provisions of this Section
3.1.1, the Parties agree and acknowledge that the primary focus of the Research
Program [**], and that such focus shall be reflected in the Research Plans.

              3.1.2 TERM.

                  (a) The term of the Research Program (the "Research Program
Term") shall commence on the Effective Date and end on the fifth (5th)
anniversary of the Effective Date, unless (i) earlier terminated pursuant to the
provisions of subsection (b) of this Section 3.1.2 or Article 12 or (ii)
extended pursuant to the provisions of subsection (c) of this Section 3.1.2.

                  (b) At least[**] prior to the [**] anniversary of the
Effective Date, the Joint Executive Committee, together with members senior
management of the Parties, shall assess whether the Research Program is meeting
the mutual expectations of the Parties. Such assessment shall be made by
reference to the guidelines set forth in EXHIBIT D to this Agreement. In the
event that the guidelines have not been achieved and the Parties mutually agree
to an early termination of the Research Program, the Research Program Term shall
end on the [**] anniversary of the Effective Date (an "Early Termination"). Upon
any such Early Termination, the rights of the Parties with respect to Program
Targets, Associated Chemistry, Associated Biotherapeutics and Drug Development
Candidates shall be as provided in Section 3.11.

                  (c) The Parties acknowledge that they may find it to be
mutually beneficial to continue the Research Program after the end of the
Research Program Term in order to progress Program Compounds or Program
Biotherapeutics in the Research Program at such time to the status of a Drug
Development Candidate. Consequently, the Parties hereby agree to negotiate in
good faith, prior to six (6) months before the end of the Research Program Term,
whether to extend the Research Program Term on terms and conditions that are
mutually acceptable to the Parties. Should the Parties choose to extend the
Research Program, they may choose to limit such extension to ongoing
collaboration with respect to particular targets, compounds or products, or
otherwise.

         3.2 DISCLOSURE OF FINANCIAL AND OTHER BURDENS AND OBLIGATIONS.

              3.2.1 BURDENED TECHNOLOGY. The Parties acknowledge that [**]
("Burdened Technology"), and that the use of such Burdened Technology as [**]
or [**] in the Research Program and the Development and Commercialization of
products resulting from the use of such Burdened Technology, [**] or [**] for
research, Development and/or Commercialization purposes under this Agreement,
[**] with the activities contemplated by this Agreement or [**] under this
Agreement [**] (collectively, the "Burdened Technology Obligations").

                                      -24-
<PAGE>


   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              3.2.2 DISCLOSURE OF BURDENED TECHNOLOGY OBLIGATIONS. Each Party
acknowledges its obligation to inform the other Party of Burdened Technology
Obligations relating to any target, Small Molecule, Antibody, Antisense
Molecule, Protein or Other Molecule which it proposes to provide to the
Research Program. With respect to any proposed [**] or [**], all Burdened
Technology Obligations related thereto shall be identified and described in
reasonable detail in writing by the Party that Controls such target, Small
Molecule, Antibody, Antisense Molecule, Protein or Other Molecule to the
Joint Research Committee at such time as such target, Small Molecule,
Antibody, Antisense Molecule, Protein or Other Molecule is proposed for
inclusion in the Research Program as a [**] or [**], as the case may be. The
Joint Research Committee shall evaluate the nature and scope of all Burdened
Technology Obligations and shall have the right to reject any proposed [**]
or [**], as the case may be, on the basis of the Burdened Technology
Obligations. Either Party shall have the right to initiate a discussion at
the Joint Research Committee concerning the possibility of amending or
modifying any Burdened Technology Obligations associated with Burdened
Technology under consideration for inclusion in the Research Program.

              3.2.3 [**] by the Joint Research Committee, [**] with respect
to such [**] or [**], as the case may be, [**] the Joint Research Committee.

         3.3 JOINT RESEARCH COMMITTEE.

              3.3.1 FORMATION AND MEMBERSHIP. As soon as practicable after the
Effective Date, Abbott and Millennium shall establish a Joint Research Committee
comprised of an equal number of representatives of Abbott and Millennium, each
of whom shall have experience and seniority sufficient to enable him or her to
make decisions on behalf of the Party he or she represents. From time to time
during the Research Program Term, the Joint Research Committee may, in its
discretion, establish one or more joint research project teams (each a "Joint
Research Project Team") to implement various aspects of the Research Plans. Such
Joint Research Project Teams shall be governed in the same manner and subject to
the relevant requirements as set forth herein for the Joint Research Committee.

              3.3.2 ADMINISTRATIVE MATTERS. The Joint Research Committee shall
appoint a chairperson from among its members, which shall rotate annually
between the representatives from Millennium and the representatives from Abbott.
The chairperson shall be responsible for calling meetings of the Joint Research
Committee and for leading the meetings. A Joint Research Committee member of the
Party hosting a meeting of the Joint Research Committee shall serve as secretary
of that meeting. The secretary of the meeting shall prepare and distribute to
all members of the Joint Research Committee minutes of the meeting within thirty
(30) days following the meeting to allow adequate review and comment. Such
minutes shall provide a description in reasonable detail of the discussions held
at the meeting and a list of any actions, decisions or determinations approved
by the Joint Research Committee. Minutes of each Joint

                                      -25-
<PAGE>

Research Committee meeting shall be approved or disapproved, and revised as
necessary, at the next meeting. Final minutes of each meeting shall be
distributed to the members of the Joint Research Committee by the chairperson.

              3.3.3 DECISION MAKING. Each Party shall have one vote on the Joint
Research Committee. Both Parties must vote in the affirmative to allow the Joint
Research Committee to take any action that requires the vote of the Joint
Research Committee. Action on any matter may be taken at a meeting, by
teleconference or videoconference or by written agreement. If the Joint Research
Committee is unable to reach unanimous agreement, such issue shall be resolved
in accordance with the provisions of Article 13.

              3.3.4 MEETINGS.

                  (a) The Joint Research Committee shall meet at least once
during each Contract Quarter. Such meetings shall be held at such times as are
mutually agreed upon by the Joint Research Committee, shall alternate between
the facilities of the Parties, and shall be conducted in person. By approval of
the chairperson, where such approval may not unreasonably be withheld,
representatives may participate in any meeting of the Joint Research Committee
by means of conference telephone or similar communications equipment by means of
which all persons participating in the meeting can hear each other.

                  (b) Each Party shall use reasonable efforts to cause its
representatives to attend the meetings of the Joint Research Committee in
person. If a Party's representative is unable to attend a meeting, such Party
may designate an alternate representative to attend such meeting in place of the
absent representative. In addition, each Party may, at its discretion, invite
additional employees, and, with the consent of the other Party, consultants or
scientific advisors, to attend the meetings of the Joint Research Committee.

                  (c) Either Party may also request that a special meeting of
the Joint Research Committee be convened for the purpose of resolving disputes
in connection with, or for the purpose of reviewing or making a decision
pertaining to, the implementation of the Research Plans by providing written
notice to the other Party. Such meeting shall be convened at such time as may be
mutually agreed upon by the Parties, but in any event shall be held within
thirty (30) days after the date of such notice.

              3.3.5 RESPONSIBILITIES. The Joint Research Committee shall be
responsible for, among other things:

                  (a) overseeing the Research Program;

                  (b) preparing the Annual Research Plan for each Contract Year
and making recommendations for and preparing any amendments to such Research
Plans, subject in each case to review and approval by the Joint Executive
Committee;

                  (c) monitoring the Parties' compliance with their respective
obligations under the Research Plans, including the accomplishment of key
objectives and the devotion of an appropriate number of FTEs to the Research
Program, and monitoring the out-of-pocket expenditures made by the Parties;

                                      -26-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (d) appointing one or more Joint Research Project Teams, as
may be appropriate, to implement the Research Plans, and reviewing
recommendations from and advising any Joint Research Project Teams;

                  (e) evaluating any Burdened Technology Obligations and
deciding whether to accept Burdened Technology into the Research Program and
evaluating whether to accept additional Burdened Technology Obligations;

                  (f) determining which (i) targets should be designated as
[**], (ii) Small Molecules should be designated as [**]; and (iii)
Antibodies, Antisense Molecules, Proteins or Other Molecules should be
designated as [**];

                  (g) recommending to the Joint Executive Committee which
[**] and [**] should be designated as [**];

                  (h) determining which research projects (e.g., targets,
screens, hits, leads, Program Compounds or Program Biotherapeutics) will be
pursued in the Research Program and which will be discontinued, as well as which
Small Molecules shall be Released Compounds after assessing what impact the
release of such proposed Released Compounds may have on the patentability of the
applicable Program Compound Family and/or Lead Compound Family(ies);

                  (i) determining whether, and on what terms, the Parties should
in-license targets for use in the Research Program (other than targets
in-licensed pursuant to academic collaborations under Section 3.4.4), PROVIDED
THAT all costs associated with the in-licensing of any such target shall be
shared equally by the Parties, and the approval of the Joint Executive Committee
shall be required for the in-licensing of a target if the license and milestone
fees exceed [**] Dollars ($[**]);

                  (j) monitoring reports submitted by the Parties pursuant to
the Research Plans;

                  (k) scheduling and preparing agendas for the Ad Hoc Committee;

                  (l) reviewing and commenting upon (but not approving) the
patent filing strategies of the Parties as provided in Article 10; and

                  (m) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

                                      -27-

<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         3.4 CONDUCT OF THE RESEARCH PROGRAM.

              3.4.1 EFFORTS. Each Party shall use reasonable efforts to conduct
the activities of the Research Program which are assigned to it in the Research
Plan, and each shall devote sufficient resources to carry out such respective
activities. While the Parties acknowledge and agree that neither Party
guarantees the success of the Research Program or any individual task undertaken
thereunder, each Party agrees that it will perform the activities assigned to it
under the Research Program in a professional manner in accordance with the
highest industry standards.

              3.4.2 RESOURCES. Over the course of the Research Program, tasks
under the Research Program will be allocated between the Parties with the goal
that each Party's participation in the Research Program (based on FTE
utilization and out-of-pocket expenditures) will be substantially equal.
Particular tasks and responsibilities shall be assigned in a manner consistent
with each Party's respective capabilities, capacity and expertise. For purposes
of this Agreement, "out-of-pocket expenditures" includes, but is not limited to
the cost of consultants, subcontractors, academic collaborations and reagent
licensing related to the Research Program, but specifically excludes the cost of
laboratory supplies, laboratory space and capital equipment.

              3.4.3 FTE LEVELS. The Parties anticipate that the combined total
personnel the Parties will commit to the Research Program will start at an
average of [**] FTEs for the First Contract Year and will escalate to an average
of [**] FTEs for the Second Contract Year and to an average of [**] FTEs for the
Third Contract Year and thereafter. Each Party agrees in good faith to expedite
the hiring and utility of such FTEs as early in the applicable Contract Year as
possible. In the event that the Research Program generates more projects that
qualify for lead optimization than are contemplated by the foregoing resource
commitment, the Parties agree to discuss in good faith a possible increase in
the number of FTEs devoted to the Research Program, PROVIDED THAT any such
increase is subject to the mutual agreement of the Parties. In the Master
Research Plan, the Parties shall set forth specific goals for the number of FTEs
assigned to specific activities during each year of the Research Program Term.
The Annual Research Plans shall set forth specific FTE levels for each Contract
Year to be assigned to specific activities.

              3.4.4 ACADEMIC COLLABORATIONS; SUBCONTRACTORS. In accordance with
Section 3.4.2, the Parties will endeavor to optimize the allocation of their
resources for the conduct of the Research Program. As necessary and in
furtherance of the Research Program, however, either Party may enter into
research-related agreements or subcontracts in accordance with this Section
3.4.4. The Joint Research Committee shall decide whether the cost of such
agreement shall be shared equally between the Parties or if the cost is to be
borne by one Party and whether it can be allocated to offset obligations with
respect to FTE levels as set forth in Section 3.4.3 of this Agreement.

                                      -28-

<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (a) In carrying out its respective responsibilities under the
Research Program, either Party may enter into one or more agreements with
academic, research or other non-commercial institutions in connection with the
conduct of activities contemplated in a given Research Plan, PROVIDED THAT such
Party shall obtain a license (or an option to obtain a license), with the right
to grant sublicenses to the other Party, to any inventions relevant to the
Research Program. The Joint Research Committee and/or a Joint Research Project
Team, as applicable, will endeavor to identify in a Research Plan all such
agreements that are anticipated to include a financial commitment for a Party in
excess of [**] Dollars ($[**]). Approval of the Research Plans by the Joint
Research Committee shall constitute approval of such expenditure for purposes of
the Research Program. Subsequent to approval of a Research Plan, if a Party
determines that an agreement with an academic, research or other non-commercial
institution will be useful for that Party to carry out its responsibilities in
connection with that Research Plan, such Party may enter into such agreement
without prior consultation with or approval by the other Party, PROVIDED THAT
such Party shall obtain a license (or an option to obtain a license), with the
right to grant sublicenses to the other Party, to any inventions relevant to the
Research Program. Notwithstanding the foregoing, the expenditure of funds under
any agreement to be entered into by a Party pursuant to this subsection
involving a financial commitment in excess of [**] Dollars ($[**]) shall first
be approved by the Joint Research Committee.

                  (b) In carrying out its respective responsibilities under the
Research Program, either Party may enter into one or more agreements with
subcontractors (e.g., a Third Party providing pharmacology services or services
for knockout models or other validation services) in connection with the conduct
of activities contemplated in a given Research Plan, PROVIDED THAT none of the
rights of the other Party hereunder are diminished or otherwise adversely
affected as a result of such subcontracting.

              3.4.5 REPORTS. Each Party shall submit monthly reports to the
Joint Research Committee, as may be required by the Research Plans, detailing
(a) its activities under the Research Program, and (b) any agreements entered
into, or expected to be entered into, pursuant to Section 3.4.4(a) and (b). The
Joint Research Committee shall use such monthly reports to monitor the Parties'
respective contributions to the Research Program. The Joint Research Committee
may amend the Annual Research Plan as necessary to maintain substantial equality
in resources devoted and participation by the Parties over the course of the
Research Program.

              3.4.6 ADJUSTMENTS. If either Party believes that [**], the
Research Program, such Party may submit the matter to the Joint Research
Committee in writing, providing a reasonably detailed description of its reasons
for such belief. Taking into account historical and prospective participation
and resource devotion of the Parties during the current Contract Quarter and the
immediately following Contract Quarter, the Joint Research Committee shall take
such steps as may be reasonably necessary to ensure substantial equality in
resources devoted and participation by the Parties in the Research Program
including, with respect to any out-of-pocket expenditures, a reimbursement by
one Party to the other Party. At the request of a Party, the other Party shall
permit an independent, certified accountant appointed by the requesting Party,
at reasonable times and upon reasonable notice but no more than once per year,
to examine, at

                                      -29-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

the sole cost of the requesting Party, the records of the other Party to verify
the accuracy of any reports submitted by the other Party to the Joint Research
Committee regarding the level of resources devoted to the Research Program by
such Party.

              3.4.7 PROGRAM DIRECTORS. Each Party shall appoint one of its
designees on the Joint Research Committee to serve as a program director with
responsibility for overseeing the day-to-day activities of the Parties with
respect to the Research Program and for being the primary point of contact
between the Parties with respect to the Research Program. It is anticipated
that, unless otherwise approved by the Joint Research Committee, each program
director shall devote at least [**] percent ([**]%) of his or her working time
to the Research Program.

         3.5 ANNUAL RESEARCH PLAN.

              3.5.1 ANNUAL RESEARCH PLAN PREPARATION. The Joint Research
Committee shall prepare the Annual Research Plan for the First Contract Year
within [**] days of the Effective Date. The Joint Research Committee shall
prepare the Annual Research Plan for each subsequent Contract Year at least [**]
days prior to the commencement of such Contract Year. Each such Annual Research
Plan shall be subject to review and approval by the Joint Executive Committee.

              3.5.2 UPDATES AND AMENDMENTS. The Joint Research Committee shall
propose updates and amendments, as appropriate, to the current Annual Research
Plan, subject to review and approval by the Joint Executive Committee.

              3.5.3 CONTENT. Each Annual Research Plan shall be consistent
with the other terms and conditions of this Agreement. Each Annual Research
Plan shall specify, among other things, (a) specific research objectives, (b)
specific activities to be performed, (c) the Party responsible for
performance of an activity, (d) the types of FTEs to be assigned to specific
activities, (e) timelines for performance, (f) specific deliverables, (g) to
the extent known in advance, the academic collaborations and subcontractor
arrangements anticipated for the applicable Contract Year, and (h) the
anticipated budget for academic collaborations, subcontractor arrangements
and other out-of-pocket expenditures. In addition, each Annual Research Plan
shall identify criteria to be used to determine whether a specific [**] or
[**] qualifies as a [**] (which generally shall be based upon whether a [**]
or [**] has applicability to the Metabolic Disease Field and is ready to
proceed to GLP toxicology studies) and whether a specific [**] or [**]
qualifies as a part of a [**].

                                      -30-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              3.5.4 FAILURE TO APPROVE ANNUAL RESEARCH PLAN. In the event that
the Parties, acting through the Joint Research Committee and the Joint Executive
Committee, are unable to reach agreement on the Annual Research Plan for any
Contract Year, the Master Research Plan shall govern the activities and
obligations of the Parties during such Contract Year until such time as the
Annual Research Plan for such Contract Year is determined in accordance with the
dispute resolution mechanisms of Article 13.

         3.6 PROCEDURES FOR CONTRIBUTIONS OF TARGETS, SMALL MOLECULES AND
BIOTHERAPEUTICS.

              3.6.1 TARGETS.

                  (a) During the Research Program Term, each Party shall use
reasonable efforts to [**] under the Research Plans.

                  (b) During the Research Program Term, each Party (the
"Proposing Party") shall, subject to any applicable Burdened Technology
Obligations and limitations relating to Party-Burdened Targets, present to the
Joint Research Committee for consideration for inclusion in the Research Program
any target that it Controls that, in such Party's reasonable estimation, meets
the criteria set forth in the Annual Research Plan for a Program Target, in
accordance with the following procedures. In no event shall either Party be
obligated to disclose to the other Party the [**] of any target unless and until
such target is designated as a Program Target. Rather, the Proposing Party shall
provide, in confidence, the [**] on the proposed target to a patent attorney
designated by the other Party to determine if the other Party has any prior
commitments to Third Parties relating to the proposed target, including any
Burdened Technology Obligations. If such analysis reveals a prior commitment
which forecloses inclusion of the target in the Research Program, such target
shall not be included in the Research Program. If such analysis does not reveal
such a prior commitment, a patent attorney from one of the Parties (as
designated by the Joint Research Committee) shall undertake, in confidence, a
preliminary patent analysis of the proposed target, the general results of which
shall be made available to the Joint Research Committee.

                  (c) At each meeting of the Joint Research Committee, the Joint
Research Committee shall select Program Targets based on its review of the
criteria set forth in the Research Plans and this Agreement, any Burdened
Technology Obligations and the preliminary patent analysis set forth in
subsection (b) above. If the Joint Research Committee wishes to include a target
that meets such criteria in the Research Program and is willing to commit
resources to the activities set forth in subsection (b) of Section 1.72, then
the Joint Research Committee shall designate such target as a Program Target and
the Joint Research Committee will prepare and approve an amendment to the Annual
Research Plan to reflect the activities to be undertaken by the Parties with
respect to such Program Target. Upon designation as a Program Target, a target
shall be deemed to be included in the Research Program.


                                      -31-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              3.6.2 SMALL MOLECULES.

                  (a) During the Research Program Term, the Parties shall
collaborate in making available for the Research Program Small Molecule chemical
libraries with the objective of [**].

                  (b) Each Party shall disclose to the other Party [**]
performed during the Research Program. The Parties acknowledge that such Small
Molecule chemical libraries may contain specific Small Molecules that are
subject to a Party's ongoing programs outside of the Metabolic Disease Field
and/or prior commitments to one or more Third Parties that individually or in
the aggregate would prevent such compound from inclusion in the Research Program
(collectively, "Disqualifying Commitments"). A Party shall have the right to
withdraw from further consideration as a Program Compound any [**] is subject to
a Disqualifying Commitment. In such event, such Party shall not be obligated to
disclose to the other Party [**].

                  (c) A Party that does not withdraw a [**] from
consideration as a Program Compound shall [**] to the other Party to permit
such other Party to determine if undertaking activities with respect to such
[**] and/or prior commitments to one or more Third Parties. In the event of
any such conflict or prior commitment, such other Party shall have the right
to terminate further consideration of such [**] as a Program Compound.

                  (d) From the pool of [**] that have not been withdrawn from
consideration pursuant to subsections (b) and (c) above, the Joint Research
Committee shall select Program Compounds based upon its review of the
criteria set forth in the Research Plans and any Burdened Technology
Obligations associated therewith. If the Joint Research Committee wishes to
so use a [**] that meets such criteria for use in the Metabolic Disease Field,
then the Joint Research Committee shall designate such [**] as a Program
Compound and the Joint Research Committee shall prepare and approve an
amendment to the Annual Research Plan to reflect the activities to be
undertaken by the Parties with respect to such Program Compound. Upon
designation as a Program Compound, a [**] shall be deemed to be included in
the Research Program.

              3.6.3 BIOTHERAPEUTICS.

                  (a) With respect to any biotherapeutic that a Party Controls
on the Effective Date or comes to Control through means other than the conduct
of the Research Program (as permitted under this Agreement), such Party shall,
subject to any applicable Burdened Technology Obligations and limitations
relating to Party-Burdened Targets, present to the Joint Research Committee for
consideration for inclusion in the Research Program any such biotherapeutic
that, in such Party's reasonable estimation, meets the criteria set forth in the
Annual Research Plan for a Program Biotherapeutic in accordance with the
following procedures. In no event shall either Party be obligated to disclose to
the other Party [**] unless and until such biotherapeutic is designated as a
Program Biotherapeutic. Rather, the Party proposing such biotherapeutic shall
provide, in confidence, [**] to a patent attorney designated

                                      -32-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

by the other Party to determine if the other Party has any prior commitments to
Third Parties relating to the proposed biotherapeutic, including any Burdened
Technology Obligations. If such analysis reveals a prior commitment which
forecloses inclusion of the biotherapeutic in the Research Plan, such
biotherapeutic shall not be included in the Research Program. If such analysis
does not reveal such a prior commitment, a patent attorney from one of the
Parties (as designated by the Joint Research Committee) shall undertake, in
confidence, a preliminary patent analysis of the proposed biotherapeutic, the
general results of which shall be made available to the Joint Research
Committee.

                  (b) At each meeting of the Joint Research Committee, the Joint
Research Committee shall select Program Biotherapeutics based on its review of
the criteria set forth in the Research Plans and this Agreement, and Burdened
Technology Obligations and the preliminary patent analysis set forth in
subsection (a) above. If the Joint Research Committee wishes to include a
biotherapeutic that meets such criteria in the Research Program, then the Joint
Research Committee shall designate such target as a Program Biotherapeutic and
the Joint Research Committee will prepare and approve an amendment to the Annual
Research Plan to reflect the activities to be undertaken by the Parties with
respect to such Program Biotherapeutic. Upon designation as a Program
Biotherapeutic, a biotherapeutic shall be deemed to be included in the Research
Program.

              3.6.4 PARTY-BURDENED TARGETS. Where (a) a Party (i) is conducting
a research and development program [**] ("Party-Burdened Field") and (ii) in
such research and development program has [**] in the Party-Burdened Field, and
(b) such Party believes that the target has a reasonable scientific rationale
for utility in the discovery, Development and/or Commercialization of Small
Molecule Drugs or Biotherapeutic Products in the Metabolic Disease Field, then,
subject to existing commitments to Third Parties (including Burdened Technology
Obligations) and Disqualifying Commitments, the Party Controlling such target
("Party-Burdened Target") shall contribute such Party-Burdened Target to the
Research Program [**]) developed in such program, so long as such Party is
actively pursuing the research, Development or Commercialization of such
Party-Burdened Target and Non-Program Compounds in the Party-Burdened Field. At
the time the Party-Burdened Target is contributed to the Research Program, the
contributing Party shall notify the other Party of the Party-Burdened Field, and
the Joint Research Committee, at such point and thereafter, shall review the
activities undertaken by the contributing Party in the Research Program to
prevent conflicts with respect thereto. [**] relating to such Party-Burdened
Target has been designated by the Parties, subject to any Burdened Technology
Obligations, the Parties may Develop and Commercialize [**] to Develop and
Commercialize [**] are granted to the non-contributing Party in the
Party-Burdened Field and all such rights are reserved by the contributing Party;
PROVIDED THAT, if the contributing Party ceases to conduct such research and
development program based upon such Party-Burdened Target in the Party-Burdened
Field, [**] in the Party-Burdened Field shall terminate.

                                      -33-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         3.7 RESEARCH PROGRAM MATERIAL TRANSFER. In order to facilitate the
Research Program, each Party shall provide [**] and [**] to the other Party
to the extent required to enable the other Party to carry out its assigned
responsibilities under the Research Plans. Either Party may also provide to
the other Party certain additional Program Materials Controlled by the
supplying Party for limited use by the other Party in furtherance of the
Research Program. Except as otherwise provided under this Agreement, all such
[**] and [**] delivered to the other Party shall remain the sole property of
the supplying Party, shall be used only in furtherance of the Research
Program and solely under the control of the other Party and its Affiliates,
shall not be used or delivered to or for the benefit of any Third Party
without the prior written consent of the supplying Party, [**] The [**] and
[**] supplied under this Section 3.7 must be used with prudence and
appropriate caution in any experimental work, since not all of their
characteristics may be known. THE MATERIALS ARE PROVIDED "AS IS" AND WITHOUT
ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY
PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

         3.8 UNILATERAL TARGETS, ASSOCIATED CHEMISTRY AND ASSOCIATED
BIOTHERAPEUTICS.

                  (a) If at any time during the Research Program Term (i) (A) a
Party desires not to participate in further validation or drug discovery
activities with respect to a Program Target and so notifies the other Party, or
(B) a Party has not provided notice under subsection (A) and fails to exercise
reasonable efforts in undertaking the research activities with respect to a
Program Target pursuant to the Research Plans (as may be modified by the Joint
Research Committee pursuant to Section 3.5.2), and does not commence the
exercise of such reasonable efforts within [**] days following written notice of
such failure from the other Party, and (ii) the other Party provides written
notice to the Joint Research Committee that it wishes to continue to participate
in further validation or drug discovery activities with respect to such Program
Target within [**] days of receipt of the notice from the discontinuing Party or
the expiration of such [**] day period, then such Program Target shall be
designated a Unilateral Target (and such target shall no longer constitute a
Program Target) and the other Party shall [**] (such Party being referred to
herein as the "Researching Party").

                  (b) The Researching Party shall have access to all Program
Technology relating to the Unilateral Target and all Program Materials (other
than tissue samples) including those Small Molecules included in the Associated
Chemistry, if any, for such Unilateral Target, and those Antibodies, Antisense
Molecules, Proteins and/or Other Molecules included in the Associated
Biotherapeutics, if any, for such Unilateral Target, but excluding all other
Program Compounds and Program Biotherapeutics.

                                      -34-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) As soon as reasonably practicable after the designation of
a target as a Unilateral Target by the Joint Research Committee, the Party that
is not the Researching Party (the "Non-Researching Party") shall provide the
Researching Party with any Program Materials and all Program Technology as may
be specified in subsection (b) in its Control.

                  (d) The Researching Party shall have the right to:

                      (i) research and [**] identified through the use of a
[**], using such [**] in such research and Development, as necessary;

                      (ii) Commercialize any resulting [**] subject to the
royalty obligation set forth in Section 9.2; and

                      (iii) With respect to any [**] that achieves a status
equivalent to that of a [**], Develop and Commercialize any such [**], using
such [**] in such Development, as necessary.

                  (e) The Researching Party shall provide the Joint Executive
Committee with brief annual reports regarding the general status of its
research, Development and Commercialization activities relating to each[**]

         3.9 SUSPENDED TARGETS.

                  (a) If at any point during the Research Program Term (i)
neither Party desires to continue validation and drug discovery activities with
respect to a Program Target or (ii) the Joint Research Committee decides to
discontinue validation and drug discovery activities with respect to a Program
Target, then such Program Target shall thereafter also be deemed a Suspended
Target.

                  (b) Either Party shall thereafter, during the Research Program
Term, [**], PROVIDED THAT such Party first gives written notice of its desire to
the other Party, [**]and not already provided to the other Party. If the other
Party does not give notice [**] shall thereafter be a [**] and the Researching
Party's rights and obligations with respect to such [**] shall be as set forth
in Section 2.1.3 and Section 3.8.

                  (c) If the other Party gives notice of its desire to
participate in such research and/or drug discovery activities with respect to a
target covered by Section 3.9(b) within such [**] day period, such target shall
thereafter be a [**], and the Annual Research Plan shall be appropriately
amended to include such activities in the Research Program.

                  (d) If at any point during the Research Program Term, (i) a
Party desires not to continue further validation or drug discovery activities
with respect to a [**]for which it is the Researching Party and so notifies the
Joint Research Committee, or (ii) a Party fails to exercise reasonable efforts
in undertaking the research activities with respect to a [**], and does not
commence the exercise of such reasonable efforts within [**] days following
receipt of written notice from the other Party of such failure, then, such [**].


                                      -35-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         3.10 NON-FIELD TARGETS. If the Parties mutually agree that (a) a
Program Target has failed to demonstrate therapeutic effect in the Metabolic
Disease Field ( e.g., [**]), and (b) such Program Target should no longer be a
part of the Research Program, such target shall cease to be a Program Target,
shall thereafter be dropped from the Research Program, shall be deemed a
"Non-Field Target", and rights to the use of such Non-Field Target shall revert
to the Party that Controls such Non-Field Target.

         3.11 [**] RESEARCH PROGRAM [**]. [**] the Research Program, [**] the
Research Program pursuant to [**] shall be as follows:

                  (a) [**], in the conduct of the Research Program, (i) [**]
(ii) [**] and (iii) a Party has [**].

                  (b) [**] during the conduct of the Research Program, [**] the
Parties shall [**] with respect to [**] In the event that the Parties [**] with
respect to [**] pursuant to terms and conditions of this Agreement and/or such
other terms and conditions upon which the Parties shall mutually agree. In the
event that (x) the Parties [**] or (y) [**]regarding [**] with respect to any
such [**] within [**] days [**] the Research Program, then such [**] from which
the Parties shall [**] for further [**] the Parties [**], as necessary to have
[**] which Party [**] shall be deemed to be [**] as the case may be, [**].

                  (c) With respect to each [**] that has been designated [**]
shall continue to be governed by the terms and conditions of this Agreement
pertaining to Development and Commercialization.

         3.12 RESEARCH PROGRAM RECORDS.

              3.12.1 INSPECTION. All work conducted by either Party in the
course of the Research Program shall be completely and accurately recorded, in
sufficient detail and in good scientific manner, in separate laboratory
notebooks. On reasonable notice, and at reasonable intervals, each Party shall
have the right to inspect and copy all such records of the other Party
reflecting Program Technology or work done under the Research Program, to the
extent reasonably required to carry out its respective obligations and to
exercise its respective rights hereunder.

              3.12.2 DEVELOPMENT INFORMATION POLICY. In order to protect the
Parties' Patent Rights under United States law in any inventions conceived or
reduced to practice during or as a result of the Research Program, each Party
agrees to maintain a policy which requires its employees to record and maintain
all data and information developed during the Research Program in such a manner
as to enable the Parties to use such records to establish the earliest date of
invention and/or diligence to reduction to practice. At a minimum, the policy
shall require such individuals to record all inventions generated by them in
standard laboratory notebooks which are dated and corroborated by non-inventors
on a regular, contemporaneous basis.

                                      -36-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         3.13 DISCLOSURE OF RESEARCH PROGRAM RESULTS. Except as provided below,
each Party will disclose to the other all Program Technology discovered,
invented, or made by such Party during the course of the Research Program and
that is useful in or relates to the Research Program, including, without
limitation, information regarding [**] identified in the Research Program
through the use of Program Targets, [**]. Such Program Technology will be
promptly disclosed to the other Party, with meaningful discoveries or advances
being communicated as promptly as practicable after such information is obtained
or its significance is appreciated. The disclosure obligations set forth in the
preceding two sentences shall be subject to a Party's confidentiality
obligations to any Third Party, PROVIDED THAT each Party will use reasonable
efforts to obtain consent from such Third Party to the disclosures contemplated
by this Section 3.13. Each Party will provide the other with copies of the raw
data generated in the course of the Research Program, if reasonably necessary to
the other Party's work under the Research Program. Any information disclosed
pursuant to this Section 3.13 shall be used by the other Party solely for the
purposes of the Research Program or as otherwise expressly permitted in this
Agreement. For clarity, nothing in this Section 3.13 shall be deemed to require
a Party to disclose to the other Party (a) [**] in the Research Program [**] is
designated by the Joint Research Committee [**] or (b) [**] the Joint Research
Committee [**], as the case may be.

                                   ARTICLE 4

                               DEVELOPMENT PROGRAM

         4.1 DRUG DEVELOPMENT CANDIDATES.

              4.1.1 AD HOC COMMITTEE. At such times as the Joint Research
Committee determines to recommend that a [**] or [**] be designated as a Drug
Development Candidate, it shall convene a meeting of the members of the Ad
Hoc Committee, comprised of the Joint Research Committee, the Joint
Development Committee and designated representatives of Millennium and
Abbott. Abbott and Millennium shall each have one vote on the Ad Hoc
Committee. No later than [**] days prior to such meeting, the Joint Research
Committee shall provide to the Ad Hoc Committee all relevant scientific and
technical data relating to such Program Compound or Program Biotherapeutic
available to the Joint Research Committee, as well as a preliminary global
development plan and commercial assessment of the global market for the
proposed Drug Development Candidate and its DDC Family (the "Data Package"),
containing such elements as shall be specified in the Master Research Plan.
The purpose of such meetings shall be to approve or disapprove the Data
Package and make a recommendation to the Joint Executive Committee concerning
the designation of the related Program Compound or Program Biotherapeutic as
a Drug Development Candidate. If the Ad Hoc Committee believes that the Data
Package is (a) complete, it shall make a recommendation to the Joint
Executive Committee concerning whether or not such [**] or [**] should be
designated as a Drug Development Candidate; or (b) insufficient to make a
determination whether to designate such [**] or [**] as a Drug Development
Candidate, it shall promptly notify the Joint Research Committee and
specifically identify any additional data,

                                      -37-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

information, results or materials which should be provided, as well as the steps
to be taken by the Joint Research Committee to obtain such additional data,
information, results or materials.

              4.1.2 JOINT RESEARCH COMMITTEE NOTIFICATION. The Joint Research
Committee shall notify the Joint Executive Committee of the approval by the
Ad Hoc Committee of the Data Package for a [**] or [**] and its
recommendation concerning whether or not such [**] or [**] should be
designated as a Drug Development Candidate. Such notification shall (a)
identify the potential Drug Development Candidate, with specificity, (b)
identify the related Program Target, and (c) identify its DDC Family. The
Joint Research Committee shall also forward to a designated representative of
each of the Parties the Data Package for such Drug Development Candidate and
such additional information relating thereto as may be requested by the Joint
Executive Committee.

              4.1.3 JOINT EXECUTIVE COMMITTEE DETERMINATION. Within [**] days
after the Joint Research Committee provides notice to the Joint Executive
Committee pursuant to Section 4.1.2 with respect to a potential DDC, the
Joint Executive Committee shall convene a meeting (either in person or via
telephone conference call or videoconference) for the purpose of making a
good faith determination as to whether or not such [**] or [**] should be
designated as a Drug Development Candidate.

                  (a) If the Joint Executive Committee elects to designate
such [**] or [**] as a Drug Development Candidate, it shall provide notice to
the Parties of such designation. The Parties shall enter into discussions
concerning the Development of such Drug Development Candidate as a Joint DDC.
Each Party shall indicate its preliminary intention concerning whether it
would elect to Develop the Drug Development Candidate as a Unilateral DDC if
the Parties did not undertake Development of such Drug Development Candidate
as a Joint DDC.

                  (b) If the Joint Executive Committee does not elect to
designate the [**] or [**] as a Drug Development Candidate, it shall provide
written notification to the Joint Research Committee concerning the rationale
for such determination, and the specific additional information, if any, that
is required in order to justify the designation of such [**] or [**] as a
Drug Development Candidate.

              4.1.4 NOTIFICATION OF INTEREST. Each Party shall, as soon as
possible, but in all cases within [**] days after the Joint Executive
Committee has approved the designation of a [**] or [**] as a Drug
Development Candidate, provide written notification to the highest-titled
representative of the other Party on the Joint Executive Committee concerning
its interest in Developing such Drug Development Candidate and its DDC
Family. Failure by a Party to provide written notification within such 30-day
period shall be deemed to constitute an indication that such Party is not
interested in Developing such Drug Development Candidate and its DDC Family.

                                      -38-
<PAGE>

              4.1.5 DESIGNATION OF JOINT DDCS, UNILATERAL DDCS AND SUSPENDED
DDCS. Once the Parties have provided notification of their respective interests
in Developing such Drug Development Candidate and its DDC Family, the
characterization of such Drug Development Candidate (i.e., Joint DDC, Unilateral
DDC or Suspended DDC) for the purposes of this Agreement shall be determined
based on the interests expressed in the Parties' written notifications.

                  (a) If both Parties have notified the Joint Executive
Committee of their interest in Developing the Drug Development Candidate and its
DDC Family, then such compound shall be Developed jointly by the Parties as a
Joint DDC, subject to the terms of this Agreement. The decision to Develop a
Drug Development Candidate and its DDC Family shall constitute an agreement to
make joint decisions concerning the Development and Commercialization of such
Joint DDC and related Joint Products, subject to the terms of this Agreement.

                  (b) If only one Party has notified the Joint Executive
Committee of its interest in Developing the Drug Development Candidate and its
DDC Family, then, subject to the provisions of Section 4.9, such compound may be
Developed and Commercialized unilaterally by such Party as a Unilateral DDC,
subject to the terms of this Agreement. Upon the designation of such DDC as a
Unilateral DDC, such DDC's related target shall be designated a Unilateral
Target (and such target shall no longer constitute a Program Target).

                  (c) If neither Party has notified the Joint Executive
Committee of its interest in Developing the Drug Development Candidate and its
DDC Family, then such Drug Development Candidate and its DDC Family shall be
deemed a Suspended DDC, subject to the terms of this Agreement.

         4.2 JOINT DEVELOPMENT COMMITTEE.

              4.2.1 FORMATION AND MEMBERSHIP; ADMINISTRATIVE MATTERS. As soon as
practicable after the formation of the Joint Research Committee, the Parties
shall establish a Joint Development Committee. The Joint Development Committee
shall be comprised of an equal number of representatives designated by each of
Abbott and Millennium, each of whom shall have experience and seniority
sufficient to enable him or her to make Development decisions on behalf of the
Party he or she represents. The Joint Development Committee shall include at
least one Commercialization representative from each Party. In addition, the
Joint Development Committee shall follow the organizational and meeting
procedures set forth in Sections 3.3.2 and 3.3.4 with respect to the Joint
Research Committee.

              4.2.2 DECISION MAKING. Each Party shall have one vote on the Joint
Development Committee. Both Parties must vote in the affirmative to allow the
Joint Development Committee to take any action that requires the vote of the
Joint Development Committee. Action on any matter may be taken at a meeting, by
teleconference or videoconference or by written agreement. If the Joint
Development Committee is unable to reach unanimous agreement, such issue shall
be resolved in accordance with the provisions of Article 13.

                                      -39-
<PAGE>

              4.2.3 JOINT DEVELOPMENT COMMITTEE RESPONSIBILITIES. The Joint
Development Committee shall be responsible for the following with respect to all
Joint DDCs:

                  (a) overseeing the Development of all Joint DDCs, including
project scheduling, project expenses and resource utilization;

                  (b) overseeing the preparation and implementation of, and
amendments and adjustments to, the Development Plans for all Joint DDCs subject
to review and approval by the Joint Executive Committee;

                  (c) appointing a joint development project team (each a "Joint
Development Project Team") to implement the Development Plan for each Joint DDC,
and reviewing recommendations from and advising all Joint Development Project
Teams;

                  (d) monitoring the Parties' compliance with their respective
obligations under all Development Plans, including the accomplishment of key
objectives and the devotion of an appropriate number of FTEs to the
implementation of such Development Plans, and monitoring the expenditure of
out-of-pocket expenses by the Parties;

                  (e) monitoring reports submitted by the Parties pursuant to
the Development Plans;

                  (f) overseeing the preparation of, and approving, protocols
for, and otherwise overseeing and monitoring, pre-clinical studies, Phase I
Studies, Phase IIA Studies, Phase IIB Studies, Phase IIIA Studies and Phase IIIB
Studies under the Development Program;

                  (g) approving a product profile for each Joint DDC, including
indications for which such Joint DDC will be Commercialized, key labeling claims
and dosing required for commercial success of such Joint DDC given the
competitive environment, and any other key product features and benefits which
will be used to develop or support a promotional message for such Joint DDC;

                  (h) determining what types of documents and correspondence are
material for purposes of Section 4.5.4 (e.g., INDs, NDAs, proposed labeling and
such other documentation as the Joint Development Committee determines is
significant with respect to Regulatory Approvals);

                  (i) developing recommendations with the Joint Manufacturing
Committee regarding the manufacturability of a Joint DDC and other aspects of
the pre-clinical and clinical manufacture of a Joint DDC, including, without
limitation, which Party (or a Third Party) shall be responsible for such supply;

                  (j) developing recommendations with the Joint Executive
Committee with respect to any appropriate actions to be taken concerning adverse
event information under any Development Plan;

                  (k) performing duties with respect to Diagnostics pursuant to
Article 5; and

                                      -40-
<PAGE>

                  (l) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

              4.2.4 JOINT DEVELOPMENT PROJECT TEAM. Each Joint Development
Project Team appointed pursuant to Section 4.2.3(c) shall operate under
guidelines established by the Joint Development Committee and shall be
responsible for the following with respect to each Joint DDC for which it has
been established:

                  (a) oversight concerning the completion of all activities
necessary to Develop such Joint DDC into a commercially viable product on a
global basis;

                  (b) preparing and implementing the Development Plan for a
Joint DDC with review and approval by the Joint Development Committee;

                  (c) making recommendations at least quarterly to the Joint
Development Committee concerning any amendments to a Development Plan, including
whether the Development of such Joint DDC should be continued or terminated, the
level of resources that should be devoted to such Development, and appropriate
adjustments to budgets in accordance with Section 4.6 for approval by the Joint
Development Committee;

                  (d) monitoring the Parties' compliance with their respective
obligations under the applicable Development Plan, including the accomplishment
of key objectives and the devotion of an appropriate number of FTEs for the
implementation of such Development Plan, and monitoring the expenditure of
out-of-pocket expenditures by the Parties under such Development Plan;

                  (e) preparing and submitting reports required by a Development
Plan to the Joint Development Committee;

                  (f) reviewing and commenting on (but not approving) the patent
filing strategies of the Parties as provided in Article 10 with respect to a
Development Plan;

                  (g) preparing and recommending protocols for, and otherwise
overseeing and monitoring, pre-clinical studies, Phase I Studies, Phase IIA
Studies, Phase IIB Studies, Phase IIIA Studies and Phase IIIB Studies relevant
to a Development Plan;

                  (h) facilitating the exchange of all data, information,
material or results relating to the Development of a Joint DDC;

                  (i) recommending a product profile for a Joint DDC to the
Joint Development Committee for approval, including indications for which such
Joint DDC will be Commercialized, key labeling claims and dosing required for
commercial success of such Joint DDC given the competitive environment, and any
other key product features and benefits which will be used to develop or support
a promotional message for such Joint DDC;

                  (j) establishing procedures for the collection, sharing and
reporting of adverse event information related to a Joint DDC; and

                                      -41-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (k) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

         4.3 DEVELOPMENT PLANS. The Joint Development Project Team shall prepare
a global product development plan for the applicable Joint DDC (a "Global
Development Plan") and a detailed development plan for the initial [**] of such
development (an "Initial Development Plan"), each for review and approval by the
Joint Development Committee and the Joint Executive Committee. A development
plan for each subsequent [**] period will be prepared by the Joint Development
Project Team for review and approval by the Joint Development Committee and the
Joint Executive Committee prior to the beginning of such [**] period. The Global
Development Plan, the Initial Development Plan and the subsequent Development
Plans approved by the Joint Development Committee and the Joint Executive
Committee shall be referred to as "Development Plans". The Development Plans
shall detail the Development of each Joint DDC, and shall include a description
of staffing requirements and an expense budget.

         4.4 DEVELOPMENT ACTIVITIES.

              4.4.1 GENERAL. The Development of each Joint DDC shall be
conducted in accordance with criteria established by the applicable Joint
Development Project Team and set forth in the applicable Development Plans. Each
Party shall use reasonable efforts to conduct the Development activities
assigned to it in the Development Plans and will devote sufficient resources to
carry out such responsibilities. Furthermore, each Party agrees to conduct such
Development activities in compliance with all Laws that are applicable to the
Development of the Joint DDC, including without limitation, GLPs, GCPs and GMPs.

              4.4.2 ASSIGNMENT AND RESPONSIBILITY FOR DEVELOPMENT ACTIVITIES.
Each Party shall participate in the range of activities to be conducted under
the Development Program. The Development Plans shall specify the allocation and
assignment of Development activities between the Parties. Tasks and
responsibilities to be conducted under the Development Plans will be allocated
between the Parties with the goal that each Party's participation in the
Development Program shall be substantially equal on an ongoing basis.
[**]


              4.4.3 PROJECT DIRECTORS. Each Party shall appoint one of its
designees on the Joint Development Committee to serve as project director
with responsibility for overseeing the day-to-day activities of the Parties
with respect to the Development of each Joint DDC and for being the primary
point of contact between the Parties with respect to such Development.

         4.5 REGULATORY MATTERS.

              4.5.1 OWNERSHIP.


                  (a) LEAD REGULATORY PARTY. The Joint Executive Committee shall
identify the Party which shall own the INDs for each Joint DDC and the
Regulatory Approvals for each Joint Product (the "Lead Regulatory Party") in the
United States. Abbott shall be the Lead Regulatory Party for the ROW. The Lead
Regulatory Party shall license, transfer, provide a letter of reference with
respect to, or take other action necessary to make available such INDs or

                                      -42-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Regulatory Approvals to the other Party as may be reasonably necessary to enable
such other Party to fulfill its obligations under the Development Plans with
respect to the Development of such Joint DDC and under the Commercialization
Plans with respect to the Commercialization of such Joint Product.

                  (b) REGULATORY APPROVALS. It is the intention of the Parties
that ownership of Regulatory Approvals relating to Joint Products in the United
States shall, on a product-by-product basis, be allocated between the Parties on
a basis consistent with Section 4.4.2, taking into account Regulatory Approvals
that are then owned by each of the Parties with respect to Joint Products, as
well as additional Regulatory Approvals relating to Joint Products to be
allocated to the Parties.

              4.5.2 REGULATORY COORDINATION. The Lead Regulatory Party shall
oversee, monitor and coordinate all regulatory actions, communications and
filings with and submissions, including filings and submissions of supplements
and amendments thereto, to Regulatory Authorities with respect to the relevant
Joint DDC or Joint Product.

              4.5.3 REGULATORY MEETINGS AND CORRESPONDENCE. The Lead Regulatory
Party shall be responsible for interfacing, corresponding and meeting with
Regulatory Authorities with respect to the relevant Joint DDC or Joint Product.
The other Party shall have the right to have a representative participate in all
material meetings and telephone discussions between representatives of the Lead
Regulatory Party and Regulatory Authorities with respect to such Joint DDC or
Joint Product.

              4.5.4 REVIEW OF CORRESPONDENCE. The Lead Regulatory Party shall
provide the other Party with drafts of any material documents or other material
correspondence (as generally determined by the Joint Development Committee
pursuant to Section 4.2.3(h)) to be submitted to Regulatory Authorities
pertaining to the relevant Joint DDC or Joint Product, including without
limitation all proposed labeling, sufficiently in advance of submission so that
the other Party may review and approve such documents and other correspondence
and have a reasonable opportunity to influence the substance of such
submissions. The Lead Regulatory Party shall promptly provide to the other Party
copies of any material documents or other material correspondence (in local
language), including without limitation all proposed labeling, received from
Regulatory Authorities pertaining to the relevant Joint DDC or Joint Product.
The Lead Regulatory Party shall promptly provide the other Party with copies of
all other documents and correspondence (in local language) after they have been
submitted to, or received from, Regulatory Authorities. Both Parties shall agree
on the final labeling for any Joint Product.

              4.5.5 ADVERSE EVENT REPORTING. With respect to each Joint DDC, the
Joint Development Committee, together with (a) the Venture Medical
Representative and the Medical Director of Postmarketing and IND Safety of
Abbott, and (b) their counterparts at Millennium, shall determine a procedure
for the exchange of adverse event information arising in the course of clinical
trials for such Joint DDC. Such determination shall be made at least [**]days
prior to the initiation of such clinical trials.

                                      -43-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         4.6 DEVELOPMENT EXPENSES.

              4.6.1 GENERAL. All Development Expenses for each Joint DDC shall
be provided for in a budget to be included in the Development Plans for such
Joint DDC, and Millennium and Abbott shall [**] of such Development Expenses.
Development Expenses shall be shared as provided above only to the extent made
or incurred in connection with an approved budget line item in the applicable
Development budget or as otherwise may be approved by the Joint Development
Committee.

              4.6.2 QUARTERLY REPORTING AND RECONCILIATION.

                  (a) Within [**] days after the end of each calendar quarter,
each Party shall submit a written report to the other Party setting forth in
reasonable detail, separately with respect to each Joint DDC, all Development
Expenses incurred by or on behalf of the reporting Party during such calendar
quarter (or, in the case of Development Expenses incurred in ROW, the
corresponding reporting quarter (it being understood that there is a one-month
lag behind calendar quarters in ROW reporting - e.g., the fourth reporting
quarter in ROW covers September, October and November)). Such report shall
provide supporting detail for each of the categories of expenses included within
Development Expenses, as determined by the Joint Development Committee.

                  (b) Within [**] days following the end of each calendar
quarter, Abbott shall submit to Millennium a written report setting forth in
reasonable detail the calculation of any net amount owed by Abbott to Millennium
or by Millennium to Abbott, as the case may be, in order to ensure the sharing
of Development Expenses as provided in Section 4.6.1. An example of the sharing
of Development Expenses is set forth as EXHIBIT E to this Agreement. (An example
of the sharing of Diagnostic Development Expenses for Program Diagnostics is set
forth as EXHIBIT F to this Agreement.) The net amount payable shall be paid by
Millennium or Abbott, as the case may be, within [**] days after receipt of such
written report; PROVIDED THAT in the event of a dispute as to the amounts under
this subsection 4.6.2(b), the disputing Party shall pay the amount not in
dispute and shall provide written notice within such [**]day period after
receipt of the written report in question, specifying in detail such dispute.
The Parties shall promptly thereafter meet and negotiate in good faith a
resolution to such dispute. In the event that the Parties are unable to resolve
such dispute within [**] days after notice by the disputing Party, the matter
shall be resolved in a manner consistent with the procedures set forth in
Article 13 (PROVIDED THAT, in the case that the matter has not been resolved by
the Executive Officers, rather than invoking ADR under Section 13.5, the Parties
shall (i) use reasonable efforts to reach agreement on the appointment of one
(1) internationally-recognized independent accounting firm to determine the
matter, (ii) if the Parties cannot reach agreement on such accounting firm, then
each Party shall appoint one (1) internationally-recognized accounting firm to
determine the matter, and (iii) if such firms cannot reach agreement, such firms
shall choose a third internationally-recognized independent accounting firm to
make the final determination). Interest shall be payable on any disputed amounts
determined to be due in the same manner as

                                      -44-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

provided for in Section 9.9, with interest accruing from the end of the [**]day
period during which such payment should have been made.

                  (c) The Divisional Vice President and Controller, Global
Pharmaceutical Research and Development and Portfolio Analysis, of Abbott shall
certify in writing the correctness and completeness of each report submitted by
Abbott hereunder. The Chief Financial Officer, Vice President, Finance and/or
Treasurer of Millennium shall certify in writing the correctness and
completeness of each report submitted by Millennium hereunder.

              4.6.3 COMMERCIAL SALE OF JOINT PRODUCTS. The Parties agree that
upon the commencement of commercial sale of a Joint Product, the Parties will
in good faith consider the integration of Development Expenses with respect
to such Joint Product into the determination of Operating Margin/Profit as
such determination is set forth in EXHIBIT G and the manner in which
reimbursement of such Development Expenses will be integrated into such
Operating Margin/Profit determination. The Parties agree that if such
integration is made, [**]

          4.7 DISCONTINUED DEVELOPMENT.

              4.7.1 NOTICE OF DISCONTINUANCE. Each Party shall have the right,
on written notice to the other Party (a "Notice of Discontinuance") to
discontinue its participation in the Development of a Joint DDC (a) at any time
for safety concerns, (b) at any time during the conduct of preclinical studies;
and (c) for a period of [**] days after the occurrence of each of the following
events with respect to such Joint DDC: at the completion of Phase I Studies; at
the completion of Phase IIA Studies; at the completion of Phase IIB Studies; and
at the completion of Phase IIIA Studies.

              4.7.2 ELECTION BY PARTY TO CONTINUE. Upon receipt of a Notice of
Discontinuance, the other Party may elect to continue the Development of such
Joint DDC outside the Development Program by providing written notice of such
election to the other Party within [**] days of receipt of the Notice of
Discontinuance, in which case such Joint DDC shall thereafter be a Unilateral
DDC (and not a Joint DDC).

              4.7.3 CLASSIFICATION AS SUSPENDED DDC. In the event that (a) both
Parties (i) elect not to continue their participation in the Development of a
Joint DDC, or (ii) fail to exercise reasonable efforts in undertaking such
Development and do not commence the exercise of such reasonable efforts within
[**] days after receipt of written notice from a Party asserting such failure
(PROVIDED THAT if the first Party to receive such written notice responds within
such [**]day period with a notice to the other Party asserting that such other
Party has also failed to exercise reasonable efforts in undertaking such
Development, both written notices shall, for purposes of this subsection, be
deemed to have been given concurrently on the date that the first notice was
given) or (b) the Developing Party (i) elects not to continue the Development of
a Unilateral DDC and provides written notice to the non-Developing Party to such
effect, or (ii) fails to exercise reasonable efforts within [**] days after
receipt of written notice from the other Party asserting such failure, then such
Joint DDC or Unilateral DDC, as the case may be, shall thereafter be a Suspended
DDC (and not a Joint DDC or Unilateral DDC) and, if such event

                                      -45-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

occurs prior to the expiration of the Research Program Term, its related target
shall be a Suspended Target (and Program Target) subject to the terms of Section
3.9.

         4.8 SUSPENDED DDC.

              4.8.1 ELECTION TO RE-INITIATE. Either Party shall have the right
to elect to re-initiate Development activities with respect to a Suspended DDC;
PROVIDED THAT such Party first gives notice of its desire to include such
Suspended DDC in the Development Program, and provides the other Party with any
new data, results, materials or information related to such Suspended DDC which
was not previously provided to the other Party.

              4.8.2 DECLINED BY OTHER PARTY. If the other Party acknowledges
that it does not at such time desire to include such Suspended DDC in the
Development Program, or fails to indicate its desire to participate in the
Development of such Suspended DDC within the time period specified in Section
4.8.3, the electing Party may resume Development of such Suspended DDC and such
Suspended DDC shall thereafter be a Unilateral DDC (and not a Suspended DDC or a
Joint DDC) and its Development shall be governed by the provisions set forth in
Section 4.9.

              4.8.3 ACCEPTED BY OTHER PARTY. If the other Party desires to
participate in the Development of such Suspended DDC and so notifies the
electing Party within [**]days of receipt of notice from the notifying Party,
such Suspended DDC shall thereafter be a Joint DDC (and not a Suspended DDC or a
Unilateral DDC) for the purposes of this Agreement.

         4.9 UNILATERAL DEVELOPMENT.

              4.9.1 GENERAL. A Party undertaking the development of a Unilateral
DDC (the "Developing Party") shall do so at its own expense and, other than as
provided in this Section 4.9, independent of the other Party; PROVIDED THAT the
Developing Party shall provide the Joint Executive Committee with a brief annual
report concerning the status of the Development of the Unilateral DDC. The
Parties will cooperate to the extent practicable and at the Developing Party's
expense to transition such Joint DDC to a Unilateral DDC.

              4.9.2 ONGOING STUDIES. With respect to a Unilateral DDC that was
previously a Joint DDC, upon designation of such compound as a Unilateral DDC,
the Parties shall transition any ongoing pre-clinical and clinical studies in
order to preserve, to the maximum extent practicable, the results, clinical site
participation and validity of such studies. Without limiting the generality of
the foregoing, the non-Developing Party shall, at the request of the Developing
Party, continue any such ongoing pre-clinical and clinical studies, at the
expense of the Developing Party, until such studies can be effectively
transitioned to the Developing Party.

              4.9.3 REGULATORY REQUIREMENTS. The Parties will cooperate to
ensure that the Developing Party, at its sole expense, has access to any INDs or
Regulatory Approvals obtained under the Development Plan prior to the Notice of
Discontinuance that are relevant to such Unilateral DDC as shall be reasonably
necessary to enable the Developing Party to continue the Development and
Commercialization of such Unilateral DDC. Such access shall be provided by

                                      -46-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

license under the applicable INDs or Regulatory Approvals, transfer of the
applicable INDs or Regulatory Approvals, or a letter of reference with respect
to the applicable INDs or Regulatory Approvals, or such other action as shall be
mutually agreed by the Parties.

              4.9.4 INFORMATION TRANSFER. As soon as reasonably practicable, the
non-Developing Party will transfer any material, data, information or results
obtained in the Development under the Development Plan of the Joint DDC (as
predecessor of the Unilateral DDC) to the Developing Party.

              4.9.5 MANUFACTURE OF CLINICAL SUPPLY OF UNILATERAL DDC.

                  (a) If the non-Developing Party is manufacturing the
Unilateral DDC, then the Parties will meet to discuss the long-term supply
requirements for such Unilateral DDC, including the supply by such
non-Developing Party of such requirements or the transfer of manufacturing
technology from the non-Developing Party to the Developing Party, all with the
objective of enabling the Developing Party to continue the Development and
Commercialization of the Unilateral DDC on an uninterrupted basis. If the
Parties enter into a supply agreement, the terms of such agreement shall govern
the supply of such Unilateral DDC to the Developing Party.

                  (b) If the Parties do not enter into a supply agreement as
contemplated in subsection (a), the non-Developing Party will, for a reasonable
transition period not to exceed [**] years, use reasonable efforts to supply the
Developing Party with sufficient quantities of Unilateral DDC to enable the
Developing Party to continue the Development of the Unilateral DDC in accordance
with the scope of the Development Plan as it existed as of the date of the
Notice of Discontinuance. In such event, the non-Developing Party shall supply
the Unilateral DDC to the Developing Party at Standard Cost of Goods Sold plus a
reasonable profit to be negotiated (not to exceed [**] percent ([**]%)), and
upon such other reasonable and customary terms as to forecasting, shipment,
delivery and similar matters as may be agreed. Further, if the Parties do not
enter into a supply agreement as contemplated in subsection (a), the
non-Developing Party will transfer to the Developing Party such manufacturing
technology as is reasonably useful or necessary for the Developing Party to
continue the Development and Commercialization of the Unilateral DDC on an
uninterrupted basis, it being understood that the non-Developing Party shall not
be required to transfer proprietary manufacturing technology developed by it
apart from the research and Development of the Unilateral DDC so long as the
initial use of such proprietary technology shall have been approved by the Joint
Manufacturing Committee pursuant to Section 6.1.3(a) of this Agreement.

         4.10 RIGHT TO AUDIT. Each Party shall ensure that the other Party's
authorized representatives, and regulatory authorities to the extent permitted
by Law, may, during regular business hours, (a) examine and inspect the
facilities of any laboratory, manufacturer, subcontractor or any investigator
site used in the Development involving a Joint DDC, and (b) inspect and copy all
data, documentation and work products relating to the activities performed by
the subcontractor or investigator site, including, without limitation, the
medical records of any

                                      -47-
<PAGE>
   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

patient participating in any clinical study. A Party's right to inspect and copy
all data, documentation, and work products relating to a Joint DDC study shall
survive the completion of the study for a period of fifteen (15) years after the
study is completed, or such longer period as shall be required by Law.

         4.11 DISCLOSURE OF DEVELOPMENT PROGRAM RESULTS. Except as provided
below, each Party will disclose to the other all Program Technology discovered,
invented, or made by such Party during the course of the Development Program
that pertains to Joint DDCs. Such Program Technology will be promptly disclosed
to the other Party, with meaningful discoveries or advances being communicated
as promptly as practicable after such information is obtained or its
significance is appreciated. The disclosure obligations set forth in the
preceding two sentences shall be subject to a Party's confidentiality
obligations to any Third Party, PROVIDED THAT (a) each Party will use reasonable
efforts to obtain consent from such Third Party to the disclosures contemplated
by this Section 4.11 and (b) neither Party will involve a Third Party in the
Development Program to the extent that such involvement would, because of any
such confidentiality obligations, materially impair the rights of the other
Party under this Agreement. Each Party will provide the other with copies of the
raw data generated in the course of the Development Program, if reasonably
necessary to the other Party's work under the Development Program. Any
information disclosed pursuant to this Section 4.11 shall only be used by the
other Party solely for the purposes of the Development Program or as otherwise
expressly permitted in this Agreement.

         4.12 DEVELOPMENT PROGRAM MATERIAL TRANSFER. In order to facilitate
the Development Program, each Party shall provide [**] and [**] to the extent
required to enable the other Party to carry out its assigned responsibilities
under the Development Plans, PROVIDED THAT this Section 4.12 shall not apply
to Joint DDCs and related materials intended for use in human clinical
trials. Either Party may also provide to the other Party certain additional
Program Materials Controlled by the supplying Party for limited use by the
other Party in furtherance of the Development Program. Except as otherwise
provided under this Agreement, all such [**] and [**] delivered to the other
Party shall remain the sole property of the supplying Party, shall be used
only in furtherance of the Development Program and solely under the control
of the other Party and its Affiliates, shall not be used or delivered to or
for the benefit of any Third Party without the prior written consent of the
supplying Party, and shall not be used in research or testing involving human
subjects except as specified in the Development Plans and in accordance with
applicable laws. The [**] and [**] supplied under this Section 4.12 must be
used with prudence and appropriate caution in any experimental work, since
not all of their characteristics may be known. THE MATERIALS ARE PROVIDED "AS
IS" AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR
ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

                                      -48-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    ARTICLE 5

                                   DIAGNOSTICS

         5.1 PROGRAM DIAGNOSTICS.

              5.1.1 DETERMINATION.

                  (a) The Joint Development Committee shall, in consultation
with a non-voting representative from the diagnostics division of Abbott ("ADD")
and a non-voting representative from the equivalent group at Millennium, from
time to time during the Research Program Term and the term of the Development of
a Joint DDC, convene meetings to assess whether a candidate for designation as a
pre-platform Program Diagnostic exists with respect to such Joint DDC or the
Joint Product that contains such Joint DDC. If the Joint Development Committee
determines that there is such a candidate, then ADD shall advise the Joint
Development Committee in writing, on a timely basis, but in no event more than
[**] days from such determination, as to whether or not it believes such a
pre-platform Program Diagnostic candidate is capable of development. If ADD
indicates that it believes such a pre-platform Program Diagnostic candidate is
capable of development, it shall, within [**] days of notifying the Joint
Development Committee of its belief, prepare, in consultation with diagnostic
representatives from Millennium, a development and Commercialization plan
("Program Diagnostic Plan") and budget ("Program Diagnostic Budget") for such
candidate, and submit such Program Diagnostic Plan and Program Diagnostic Budget
to the Joint Development Committee and the Joint Executive Committee for
approval. If the Joint Development Committee and the Joint Executive Committee
approve the Program Diagnostic Plan and the Program Diagnostic Budget and
designate such candidate as a pre-platform Program Diagnostic, each shall notify
ADD, and ADD shall then notify the Joint Development Committee and the Joint
Executive Committee in writing within [**] days thereafter whether or not it is
interested in Commercializing such pre-platform Program Diagnostic.

                  (b) Upon ADD confirming its interest in Commercializing a
pre-platform Program Diagnostic in accordance with Section 5.1.1(a), such
pre-platform Program Diagnostic shall be designated a "Joint Program
Diagnostic." The Parties shall co-develop each pre-platform Joint Program
Diagnostic in accordance with the relevant Program Diagnostic Plan and Program
Diagnostic Budget, it being understood that the Parties may elect to subcontract
some or all of such development work. The Parties acknowledge that ADD has the
exclusive right to Commercialize Joint Program Diagnostics under the oversight
of the Joint Commercialization Committee and consistent with the Program
Diagnostic Plan and Program Diagnostic Budget, subject to Millennium's right to
co-promote such Joint Program Diagnostic to referring physicians, patients and
the research community. Each Party shall [**]the Diagnostic Development Expenses
associated with pre-platform Joint Program Diagnostics.

                                      -49-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) If ADD declines to develop and Commercialize a
pre-platform Program Diagnostic pursuant to Section 5.1.1(a), then such
pre-platform Program Diagnostic shall be designated a "Third Party Program
Diagnostic" and the Joint Development Committee shall identify a Third Party
to develop and Commercialize such pre-platform Third Party Program Diagnostic
on terms agreed upon by the Joint Development Committee pursuant to a Program
Diagnostic Plan and Program Diagnostic Budget. In negotiating with any such
Third Party, the Parties shall [**] to the [**] to be [**] for the [**] of
the [**] in the [**] Each Party shall [**] the Diagnostic Development
Expenses allocated to the collaboration associated with pre-platform Third
Party Program Diagnostics.

              5.1.2 PLATFORM DETERMINATION

                  (a) If, at any time after the designation of a pre-platform
Joint Program Diagnostic, the Joint Development Committee, in consultation with
ADD, determines that it is advisable to automate such pre-platform Joint Program
Diagnostic onto a diagnostic platform, it shall notify ADD to determine if ADD
is interested in automating the pre-platform Joint Program Diagnostic onto an
Abbott Diagnostic Platform. Within [**] days, ADD shall advise the Joint
Development Committee whether or not it is interested in automating the
pre-platform Joint Program Diagnostic onto an Abbott Diagnostic Platform.

                      (i) If ADD advises the Joint Development Committee that it
is interested in automating the pre-platform Joint Program Diagnostic onto an
Abbott Diagnostics Platform, then within [**] days (or such other reasonable
time period determined by the Joint Development Committee), it shall determine
the feasibility of such automation, it being understood that the Joint
Development Committee and the Joint Executive Committee shall approve, prior to
initiation of such [**]day period, the budget for any necessary feasibility
studies. If such feasibility determination is positive, ADD shall propose
amendments to the Program Diagnostic Plan and Program Diagnostic Budget to
incorporate such automation tasks and expenses. If the Joint Development
Committee and the Joint Executive Committee approve the amendments to the
Program Diagnostic Plan and Program Diagnostic Budget, then ADD shall proceed
with such automation onto an Abbott Diagnostic Platform in accordance with the
applicable Program Diagnostic Plan and Program Diagnostic Budget.

                      (ii) If ADD finds that the automation of a Joint Program
Diagnostic onto an Abbott Diagnostic Platform is feasible, but ADD does not have
the resources or time to automate such Joint Program Diagnostic, then ADD, with
advice from the Joint Development Committee, shall contract with a Third Party
to develop such Joint Program Diagnostic onto an Abbott Diagnostic Platform in
accordance with an agreed upon Program Diagnostic Plan and Program Diagnostic
Budget.

                                      -50-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                      (iii) If ADD determines that the automation of a Joint
Program Diagnostic onto an Abbott Diagnostic Platform is not feasible, then the
Joint Development Committee, in consultation with ADD, shall identify a Third
Party who is capable of automating such Joint Program Diagnostic onto a Third
Party Diagnostic Platform in accordance with an agreed upon Program Diagnostic
Plan and Program Diagnostic Budget, and such Joint Program Diagnostic shall
thereupon cease to be a Joint Program Diagnostic and shall be designated a Third
Party Program Diagnostic. In negotiating with any such Third Party, the Parties
shall use reasonable efforts to retain rights to the assay and other product
technology to be developed by such Third Party for the purpose of maximizing the
flexibility of the Parties in the event the Third Party Program Diagnostic
becomes a Unilateral Program Diagnostic.

                  (b) If, at any time after the designation of a pre-platform
Third Party Program Diagnostic, the Joint Development Committee, in consultation
with ADD, determines that it is advisable to automate such pre-platform Third
Party Program Diagnostic, it shall follow the procedures set forth in Sections
5.1.2(a) of this Agreement for pre-platform Joint Program Diagnostics unless the
Joint Development Committee shall have entered into an agreement with a Third
Party, pursuant to Section 5.1.1(c) of this Agreement, which precludes the
involvement of ADD in the automation of the pre-platform Third Party Program
Diagnostic. In such case, the terms of the agreement with such Third Party shall
govern the automation of such pre-platform Third Party Program Diagnostic. A
Third Party Program Diagnostic automated on an Abbott Diagnostic Platform shall
be deemed a Joint Program Diagnostic.

                  (c) Abbott shall assume [**] percent ([**]%) and Millennium
shall assume [**] percent ([**]%) of the Diagnostic Development Expenses
associated with the automation of a pre-platform Joint Program Diagnostic onto
an Abbott Diagnostic Platform (including the costs of any feasibility studies).
Millennium and Abbott shall [**] the Diagnostic Development Expenses associated
with the automation of a Third Party Program Diagnostic.

              5.1.3 PROGRAM DIAGNOSTIC ADDITIONAL TERMS. Each Party shall use
reasonable efforts to conduct the development and Commercialization activities
assigned to it in any Program Diagnostic Plan and will devote sufficient
resources consistent with the Program Diagnostic Budget to carry out such
responsibilities. To the extent permissible under applicable Law, the names and
logos of both Parties shall appear with equal prominence on all product
labeling, packaging, promotional and marketing materials that pertain to
pre-platform Joint Program Diagnostics. With respect to a Joint Program
Diagnostic automated onto an Abbott Diagnostic Platform, to the extent
permissible under applicable Law, Abbott's and Millennium's name and logo shall
appear on all product labeling, packaging, promotional and marketing materials
that pertain to such Joint Program Diagnostic, but Millennium's name and logo
will not carry the same level of prominence. All labeling, written and
electronic materials associated with each Program Diagnostic shall indicate that
such Program Diagnostic was developed with the use of Millennium and Abbott
technology. Each Party shall grant the other Party an appropriate trademark
license for the foregoing purpose and either the licensor Party or an Affiliate
designated by the licensor Party shall have the right to monitor the quality of
such Program Diagnostic in accordance with reasonable procedures to be agreed
upon by the Parties.

                                      -51-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              5.1.4 PROGRAM DIAGNOSTIC REPORTING. Each Party shall report, in
the same manner as set forth in Section 4.6.2, Diagnostic Development Expenses
incurred with respect to each Joint Program Diagnostic and Third Party Program
Diagnostic. Each Party shall report the Program Diagnostic Operating
Margin/Profit in the manner set forth in Section 9.3.2.

         5.2 ABBOTT RELEASED DIAGNOSTICS.

              5.2.1 ABBOTT RELEASED DIAGNOSTICS DETERMINATION. If the Joint
Development Committee determines that a Program Target (including any Associated
Chemistry and any Associated Biotherapeutics) will have no utility with respect
to any Program Diagnostic, then such Program Target shall also be deemed a
"Released Target," and Abbott's rights with respect to use of such Released
Target to develop and Commercialize Abbott Released Diagnostics shall be
governed by the license grant set forth in Section 8.1.2(c)(iii).

              5.2.2 EXPENSES. ADD shall [**] the expenses associated with the
development of the Abbott Released Diagnostics.

              5.2.3 PRODUCT LABELING. Abbott's name and logo shall appear on all
product labeling, packaging, promotional and marketing materials that pertain to
Abbott Released Diagnostics. Product insert labeling associated with each Abbott
Released Diagnostic shall indicate that the Abbott Released Diagnostic was
developed with the use of Millennium and Abbott technology. Millennium shall
grant Abbott an appropriate trademark license for the foregoing purpose and
either Millennium or an Affiliate designated by Millennium shall have the right
to monitor the quality of such Abbott Released Diagnostic in accordance with
reasonable procedures to be agreed upon by the Parties.

         5.3 UNILATERAL DIAGNOSTICS.

              5.3.1 ABBOTT UNILATERAL DIAGNOSTICS. In the event that an Abbott
Unilateral Target is designated pursuant to Section 3.8 or an Abbott Unilateral
DDC and an Abbott Unilateral Target are designated as such pursuant to Article
4, Abbott shall have the following rights to develop and Commercialize a related
Unilateral Diagnostic:

                  (a) In the event that a Program Diagnostic for such target or
DDC had not previously been designated by the Joint Executive Committee, Abbott
shall have the right to develop and Commercialize an Abbott Unilateral
Diagnostic with respect to such Abbott Unilateral Target and/or Abbott
Unilateral DDC, pursuant to the license grant set forth in Section 8.1.2(c)(ii).

                  (b) In the event that a Joint Program Diagnostic for such
target or DDC had previously been designated by the Joint Executive Committee,
(i) such Joint Program Diagnostic shall cease to be a Joint Program Diagnostic
and shall be deemed an Abbott Unilateral Diagnostic, (ii) Abbott shall have the
right to develop and Commercialize an Abbott Unilateral Diagnostic with respect
to such Abbott Unilateral Target and/or Abbott Unilateral DDC, pursuant to the
license grant set forth in Section 8.1.2(c)(ii), and (iii) Millennium shall

                                      -52-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

disclose to Abbott any and all Program Technology and provide to Abbott any and
all Program Materials (other than tissue samples) in its possession relevant to
such Abbott Unilateral Diagnostic to ensure the uninterrupted development and
Commercialization of such Abbott Unilateral Diagnostic.

                  (c) In the event that a Third Party Program Diagnostic for
such target or DDC had previously been designated by the Joint Executive
Committee, subject to the terms of the agreement entered into with the Third
Party, (i) such Third Party Program Diagnostic shall cease to be a Third Party
Program Diagnostic and shall be deemed an Abbott Unilateral Diagnostic, (ii)
Abbott shall have the right to develop and Commercialize an Abbott Unilateral
Diagnostic with respect to such Abbott Unilateral Target and/or Abbott
Unilateral DDC, pursuant to the license grant set forth in Section 8.1.2(c)(ii),
(iii) Millennium shall transfer its rights and responsibilities under the
agreement with the Third Party to Abbott upon terms mutually agreed to by
Millennium and Abbott, and (iv) Millennium shall disclose to Abbott any and all
Program Technology and provide to Abbott any and all Program Materials (other
than tissue samples) in its possession relevant to such Diagnostic to ensure the
uninterrupted development and Commercialization of such Abbott Unilateral
Diagnostic.

              5.3.2 MILLENNIUM UNILATERAL DIAGNOSTICS. In the event that a
Millennium Unilateral Target is designated pursuant to Section 3.8 or a
Millennium Unilateral DDC and a Millennium Unilateral Target are designated as
such pursuant to Article 4, Millennium shall have the following rights to
develop and Commercialize a related Unilateral Diagnostic:

                  (a) (i) In the event that a Program Diagnostic for such target
            or DDC had not previously been designated by the Joint Executive
            Committee, Millennium shall have the right, subject to the
            provisions set forth in Section 5.3.2(a)(ii), to develop and
            Commercialize a Millennium Unilateral Diagnostic with respect to
            such Millennium Unilateral Target and/or Millennium Unilateral DDC,
            pursuant to the license grant set forth in Section 8.2.2(c)(ii).

                      (ii) In the event that Millennium decides to seek a party
to develop a Millennium Unilateral Diagnostic pursuant to Section 5.3.2(a)(i),
Millennium shall first provide written notice to Abbott of such decision,
including the terms upon which it expects to develop such Millennium Unilateral
Diagnostic. Abbott shall have the right to enter into good faith negotiations
relating to such development opportunity for such Millennium Unilateral
Diagnostic based upon such terms (or such other terms upon which the Parties may
mutually agree) by providing written notice to Millennium within [**] days after
receipt of Millennium's notice. If Abbott provides such notice to Millennium
within such [**]day period, the Parties shall negotiate in good faith relating
to such development opportunity for a period of up to [**] days, or such shorter
or longer period mutually agreed to by the Parties, it being understood that
Millennium may consider various factors in deciding whether to enter into an
agreement with Abbott concerning such development opportunity, including
Abbott's capabilities and capacity to undertake the required responsibilities
relative to Third Parties. If the Parties are unable to reach mutual agreement
as to Abbott's participating in such development opportunity within

                                      -53-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

such [**]day period, or if Abbott does not provide notice to Millennium within
such initial [**]day period, then Millennium shall be free to enter into an
arrangement with a Third Party.

                  (b) In the event that a Joint Program Diagnostic for such
            target or DDC had previously been designated by the Joint Executive
            Committee, (i) such Joint Program Diagnostic shall continue to be
            developed and/or Commercialized in accordance with the applicable
            Program Diagnostic Plan and Program Diagnostic Budget pursuant to
            the provisions of Section 5.1.1(b) or Section 5.1.2, and (ii)
            Millennium shall not have any right to develop and Commercialize
            Unilateral Diagnostics for such Millennium Unilateral Target and/or
            Millennium Unilateral DDC, PROVIDED THAT, if, within [**] days
            following the designation of a Millennium Unilateral Target and/or a
            Millennium Unilateral DDC, Abbott provides Millennium with written
            notice of its election to discontinue the development and
            Commercialization of the Joint Program Diagnostic related to such
            target or DDC, then (A) such Joint Program Diagnostic shall cease to
            be a Joint Program Diagnostic and shall be deemed a Millennium
            Unilateral Diagnostic, (B) Millennium shall have the right to
            develop and Commercialize a Millennium Unilateral Diagnostic with
            respect to such Millennium Unilateral Target and/or Millennium
            Unilateral DDC, pursuant to the license grant set forth in Section
            8.2.2(c)(ii), and (C) Abbott shall disclose to Millennium any and
            all Program Technology and provide to Millennium any and all Program
            Materials (other than tissue samples) in its possession relevant to
            such Diagnostic to ensure the uninterrupted development and
            Commercialization of such Millennium Unilateral Diagnostic.

                  (c) In the event that a Third Party Program Diagnostic for
            such target or DDC had previously been designated by the Joint
            Executive Committee, subject to the terms of the agreement entered
            into with the Third Party, (i) such Third Party Program Diagnostic
            shall cease to be a Third Party Program Diagnostic and shall be
            deemed a Millennium Unilateral Diagnostic, (ii) Millennium shall
            have the right to develop and Commercialize a Millennium Unilateral
            Diagnostic with respect to such Millennium Unilateral Target and/or
            Millennium Unilateral DDC, pursuant to the license grant set forth
            in Section 8.2.2(c)(ii), (iii) Abbott shall transfer its rights and
            responsibilities under the agreement with the Third Party to
            Millennium upon terms mutually agreed to by Abbott and Millennium,
            and (iv) Abbott shall disclose to Millennium any and all Program
            Technology and provide to Abbott any and all Program Materials
            (other than tissue samples) in its possession relevant to such Third
            Party Program Diagnostic to ensure the uninterrupted development and
            Commercialization of such Millennium Unilateral Diagnostic.

                                      -54-
<PAGE>

                                    ARTICLE 6

                                  MANUFACTURING

         6.1 JOINT MANUFACTURING COMMITTEE.

              6.1.1 FORMATION AND MEMBERSHIP; ADMINISTRATIVE MATTERS. As soon as
practicable after the formation of the Joint Research Committee, the Parties
shall establish the Joint Manufacturing Committee to oversee the decisions and
procedures relating to the Manufacturing of Joint DDCs and Joint Products. The
Joint Manufacturing Committee shall be comprised of an equal number of
representatives designated by each of Abbott and Millennium, each of whom shall
have sufficient experience and seniority to enable him or her to make
Manufacturing decisions on behalf of the Parties. In addition, the Joint
Manufacturing Committee shall follow the organizational and meeting procedures
set forth in Sections 3.3.2 and 3.3.4 with respect to the Joint Research
Committee.

              6.1.2 DECISION MAKING. Each Party shall have one vote on the Joint
Manufacturing Committee. Both Parties must vote in the affirmative to allow the
Joint Manufacturing Committee to take any action that requires the vote of the
Joint Manufacturing Committee. Action on any matter may be taken at a meeting,
by teleconference or videoconference or by written agreement. If the Joint
Manufacturing Committee is unable to reach unanimous agreement, such issue shall
be resolved in accordance with the provisions of Article 13.

              6.1.3 RESPONSIBILITIES. The Joint Manufacturing Committee shall be
responsible for the following with respect to each Joint DDC and/or Joint
Product:

                  (a) determining the best Manufacturing procedures and
processes to be used to produce necessary volumes of such Joint DDC and/or Joint
Product with reproducible high quality and at a competitive cost (including
whether or not to authorize the use of a proprietary manufacturing technology of
a Party that such Party would be unwilling to transfer to the other Party
pursuant to Section 4.9.5);

                  (b) determining the Lead Manufacturing Party for such Joint
DDC and/or Joint Product in accordance with the provisions of Section 6.3;

                  (c) maintaining global oversight over all Manufacturing
activities relating to such Joint DDC and/or Joint Product;

                  (d) overseeing the preparation of all Manufacturing Plans for
such Joint DDC and/or Joint Product, subject to review by the Joint Executive
Committee;

                  (e) monitoring the Parties' compliance with their respective
obligations under the Manufacturing Plans;

                  (f) overseeing regulatory compliance with respect to
Manufacturing activities;

                                      -55-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (g) reviewing a detailed breakdown of the components of
Standard Cost of Goods Sold for such Joint DDC and/or Joint Product;

                  (h) determining (i) whether the Manufacturing of such Joint
DDC and/or Joint Product requires any Special Purpose Equipment; (ii) the
budgeted capital costs for the acquisition of such Special Purpose Equipment and
the manner in which such capital costs shall be financed (e.g., whether the
Parties will share the costs up-front or whether the Lead Manufacturing Party
shall incur such costs and recover such costs over the Capital Recovery Period);
(iii) the period over which the capital costs relating to such Special Purpose
Equipment shall be recovered and reflected in Standard Cost of Goods Sold (the
"Capital Recovery Period"); and (iv) the manner in which the Lead Manufacturing
Party (or the Parties if the capital costs are shared up-front) shall recover
any unrecovered capital costs in the event that the Joint Manufacturing
Committee terminates the Manufacturing rights of the Lead Manufacturing Party
prior to the expiration of the Capital Recovery Period; and

                  (i) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

         6.2 MANUFACTURING PLANS. The Joint Manufacturing Committee shall
prepare a global product manufacturing plan for each Joint DDC and/or Joint
Product (a "Global Manufacturing Plan") and a detailed manufacturing plan for
the initial [**] months of such manufacturing (an "Initial Manufacturing Plan"),
each for review and approval by the Joint Executive Committee. A manufacturing
plan for each subsequent [**]month period will be prepared by the Joint
Manufacturing Committee for review and approval by the Joint Executive
Committee. The Global Manufacturing Plan, the Initial Manufacturing Plan and the
subsequent Manufacturing Plans approved by the Joint Executive Committee shall
be referred to as "Manufacturing Plans." The Manufacturing Plans shall cover all
aspects of Manufacturing relating to a Joint DDC/Joint Product, including
production scale-up, pre-clinical and clinical supplies, commercial-scale
manufacturing, and strategies relating to secondary manufacturing sources.

         6.3 DESIGNATION OF LEAD MANUFACTURING PARTY.

              6.3.1 DESIGNATION OF ABBOTT. Subject to the provisions of Sections
6.3.2 and 6.3.3, Abbott shall be designated as the Party with responsibility for
Manufacturing of Joint DDCs and Joint Products on a worldwide basis. If neither
Abbott nor Millennium satisfies the conditions set forth in Section 6.3.3 with
respect to a particular Joint DDC or Joint Product, or if neither Party wishes
to Manufacture a particular Joint DDC and/or Joint Product, the Joint
Manufacturing Committee shall identify a Third Party to undertake such
Manufacturing responsibilities. If a Party is designated as the Party with
responsibility for Manufacturing a Joint DDC and/or Joint Product, such Party is
referred to as the "Lead Manufacturing Party." If neither Party wishes to
undertake such responsibility with respect to a particular Joint DDC and/or
Joint Product, the Joint Manufacturing Committee shall oversee Manufacturing of
such Joint DDC and/or Joint Product with such Third Party contractors as it may
designate and are approved by the Joint Executive Committee.

                                      -56-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              6.3.2 MILLENNIUM MANUFACTURING RIGHT. In the event that Millennium
meets the conditions set forth in Section 6.3.3 with respect to the Manufacture
of a particular Joint DDC and/or Joint Product at the time that the Joint
Manufacturing Committee decides to designate a Lead Manufacturing Party
therefor, Millennium shall have the right to submit a written proposal to the
Joint Manufacturing Committee with respect to such Joint DDC and/or Joint
Product and to be considered equally with Abbott as the Lead Manufacturing Party
for such Joint DDC and/or Joint Product on a worldwide basis.

              6.3.3 REQUIREMENTS. In order to qualify as the Lead Manufacturing
Party for a Joint DDC and/or Joint Product, Abbott and/or Millennium shall
provide reasonable evidence to the Joint Manufacturing Committee that it (or its
Affiliates) satisfies (or has the capability to satisfy) the following
conditions:

                  (a) it has the ability to Manufacture such Joint DDC and/or
Joint Product in sufficient quantities (based upon the Manufacturing Plans) and
in accordance with applicable specifications;

                  (b) it has the experience of Manufacturing compounds of
similar type, complexity and modality to such Joint DDC and/or Joint Product;

                  (c) it has the ability to Manufacture such Joint DDC and/or
Joint Product in accordance with all relevant laws and regulations;

                  (d) it has an approved or "approvable" facility for such Joint
DDC and/or Joint Product as defined by the FDA or similar Regulatory Authority;
and

                  (e) it is a Market Competitive Supplier (as defined below).

         As used above, the term "Market Competitive Supplier", with respect to
a specific Joint DDC and/or Joint Product, means [**]. In making the initial and
periodic determination described below as to whether a Party is a Market
Competitive Supplier, the Joint Manufacturing Committee may solicit written
quotes from Third Party GMP manufacturers meeting the requirements of the
foregoing clauses (a), (b), (c) and (d), and will also consider the amount of
effort involved in the process development, formulation and scale-up of
Manufacturing capabilities, as well as the amount of effort involved to
technically support such Manufacturing capabilities going forward. At the time
of initial designation of a Lead Manufacturing Party, the Joint Manufacturing
Committee shall determine whether a Party meets the foregoing requirements.
After the initial designation of a Lead Manufacturing Party, the Joint
Manufacturing Committee shall (unless otherwise agreed by the Party that is not
the Lead Manufacturing Party) assess whether the Lead Manufacturing Party
continues to satisfy the foregoing requirements at the following points in time:
(i) within [**] days following the [**] anniversary of the commencement of
commercial supply of the Joint DDC or Joint Product Manufactured by the Lead
Manufacturing Party ("Manufacturing Commencement Date"), and (ii) within [**]
days following the [**] anniversary of the Manufacturing Commencement Date. If
the Joint Manufacturing Committee finds in any such assessment that the Lead
Manufacturing

                                      -57-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Party continues to satisfy such requirements, then the Lead Manufacturing Party
shall continue as the Lead Manufacturing Party. In the event the Joint
Manufacturing Committee finds in any such assessment that the Lead Manufacturing
Party has not satisfied such requirements, the Joint Manufacturing Committee
shall make a determination as to whether alternative arrangements for
Manufacturing should be implemented, and, if so, the identity of the alternative
Manufacturer and the terms relating to such Manufacture. If the other Party
becomes the Lead Manufacturing Party, it shall be subject to the requirements
set forth in this Section 6.3.3. If a Third Party becomes the Manufacturer, it
shall be subject to the requirements set forth in the agreement with such Third
Party. In either event, the Lead Manufacturing Party shall use reasonable
efforts to facilitate any Manufacturing transition and to ensure an
uninterrupted supply. In addition, if there is a change in the Lead
Manufacturing Party as a result of the assessments set forth in this Section
6.3.3, the arrangements relating to Special Purpose Equipment established by the
Joint Manufacturing Committee pursuant to Section 6.1.3(h) shall be implemented.

              6.3.4 SECONDARY MANUFACTURING SOURCES. The Parties agree that it
is a typical and prudent business practice to qualify and maintain a secondary
source for a small portion of projected production volumes, and that the
Manufacturing Plans will incorporate a secondary source strategy. If the Party
that is not the Lead Manufacturing Party satisfies the conditions set forth in
Section 6.3.3, the Joint Manufacturing Committee shall give good faith
consideration to the designation of such Party as the secondary manufacturing
source.

              6.3.5 CONTRIBUTION BY NON-MANUFACTURING PARTY. The Parties agree
that the Party that is not the Lead Manufacturing Party may contribute to the
Manufacturing process (i.e. fill/finishing, processing, packaging, etc.) for the
purposes of achieving the objectives set forth in Section 7.4.

         6.4 STANDARD COST OF GOODS SOLD.

              6.4.1 SUPPLY PRICE. If Abbott or Millennium is the Lead
Manufacturing Party, all Joint DDCs and/or Joint Products Manufactured by such
Lead Manufacturing Party shall be supplied at a price equal to Standard Cost of
Goods Sold.

              6.4.2 DEVELOPMENT EXPENSES. The Standard Cost of Goods Sold for
Joint DDCs used for pre-clinical and clinical studies will be included in
Development Expenses and shared by the Parties in accordance with Section 4.6.

              6.4.3 COMMERCIALIZATION EXPENSES. The Standard Cost of Goods Sold
for Joint Products used in Commercialization activities will be included in
Commercialization Expenses and shared by the Parties in accordance with Section
9.1.

         6.5 QUALITY MANUAL. Within [**] days after the appointment of the Lead
Manufacturing Party, representatives of the Parties' quality assurance
departments shall meet to develop and approve a quality manual outlining
responsibilities and key contacts for quality and compliance related issues.
Items to be included in the quality manual include, but are not limited

                                      -58-

<PAGE>

to, annual product reviews, returned goods, regulatory audits, compliance with
GMP, compliance with PDMA, recalls and such other quality-related concerns
deemed appropriate.

                                   ARTICLE 7

                            COMMERCIALIZATION PROGRAM

         7.1 JOINT COMMERCIALIZATION COMMITTEE.

              7.1.1 FORMATION AND MEMBERSHIP; ADMINISTRATIVE MATTERS. As soon as
practicable after the formation of the Joint Research Committee, the Parties
shall establish the Joint Commercialization Committee to oversee the
Commercialization of all Joint DDCs and Joint Products under this Agreement. The
Joint Commercialization Committee shall be comprised of an equal number of
representatives designated by each of Abbott and Millennium, each of whom shall
have sufficient experience and seniority to enable him or her to make
Commercialization decisions on behalf of the Parties. In addition, the Joint
Commercialization Committee shall follow the organizational and meeting
procedures set forth in Sections 3.3.2 and 3.3.4 with respect to the Joint
Research Committee.

              7.1.2 DECISION MAKING. Each Party shall have one vote on the Joint
Commercialization Committee. Both Parties must vote in the affirmative to allow
the Joint Commercialization Committee to take any action that requires the vote
of the Joint Commercialization Committee. Action on any matter may be taken at a
meeting, by teleconference or videoconference or by written agreement. If the
Joint Commercialization Committee is unable to reach unanimous agreement, such
issue shall be resolved in accordance with the provisions of Article 13.

              7.1.3 RESPONSIBILITIES. The Joint Commercialization Committee
shall be responsible for the following with respect to all Joint DDCs and Joint
Products:

                  (a) maintaining global oversight of the Commercialization
process for all Joint DDCs and Joint Products;

                  (b) appointing a global new product pre-launch team at or
prior to the commencement of Phase IIIA Studies for such Joint DDC (a "Global
New Product Pre-Launch Team"), which shall be responsible for the preparation of
the Global Commercialization Framework, pursuant to Section 7.2.1, for such
Joint DDC and the transition of such Global Commercialization Framework to the
U.S. Joint Commercialization Product Team and the ROW Commercialization Product
Team;

                  (c) reviewing and approving the Global Commercialization
Framework for each Joint DDC and Joint Product;

                  (d) appointing a joint commercialization product team
comprised of an equal number of representatives designated by each of Abbott and
Millennium to prepare and implement the U.S. Commercialization Plan and prepare
the U.S. Commercialization Budget for each Joint DDC and Joint Product in the
United States (each a "U.S. Joint Commercialization

                                      -59-
<PAGE>

Product Team") and reviewing recommendations from and advising all U.S. Joint
Commercialization Product Teams;

                  (e) approving the appointment by Abbott of a commercialization
product team comprised of representatives designated by Abbott to prepare and
implement the ROW Commercialization Plan and prepare the ROW Commercialization
Budget for each Joint DDC and/or Joint Product in ROW (each a "ROW
Commercialization Product Team") and reviewing recommendations from and advising
all ROW Commercialization Product Teams;

                  (f) reviewing and approving the U.S. Commercialization Plan
and the ROW Commercialization Plan for each Joint DDC and Joint Product;

                  (g) reviewing and approving the U.S. Commercialization Budget
and the ROW Commercialization Budget for each Joint DDC and Joint Product,
setting permitted deviations therefrom that do not require an amendment to the
budget, and determining the geographic breakdown for the ROW Commercialization
Budget;

                  (h) overseeing the implementation of the Commercialization
Plans for all Joint DDCs and Joint Products;

                  (i) monitoring the Parties' compliance with the requirements
of the Commercialization Plans;

                  (j) monitoring the allocation of Commercialization strategic
activities between the Parties across all of the Joint Products in the United
States to ensure that such allocation is consistent with the provisions of
Sections 7.3 and 7.4;

                  (k) establishing Co-Promotion Guidelines, if applicable,
pursuant to Section 7.6;

                  (l) developing recommendations with the Joint Manufacturing
Committee regarding the manufacturing and supply chain strategy for a Joint DDC
and Joint Product, including, without limitation, which Party (or Third Party)
shall be responsible for specific activities within the supply chain;

                  (m) developing procedures regarding the collection, sharing
and reporting of adverse information related to such Joint Product on a global
basis;

                  (n) making recommendations to the Joint Executive Committee
with respect to any appropriate actions to be taken concerning adverse event
information under any Commercialization Plan;

                  (o) performing duties with respect to Program Diagnostics
pursuant to Article 5;

                  (p) overseeing the preparation of, and approving, protocols
for, and otherwise overseeing and monitoring Phase IV Studies under the
Commercialization Program; and

                                      -60-
<PAGE>

                  (q) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

              7.1.4 U.S. JOINT COMMERCIALIZATION PRODUCT TEAM. Each U.S. Joint
Commercialization Product Team appointed pursuant to Section 7.1.3(d) shall be
responsible for the following with respect to the Joint DDC and Joint Product in
the United States for which it has been established:

                  (a) preparing and implementing the U.S. Commercialization
Plans in the United States for such Joint DDC and/or Joint Product and
amendments thereto, subject to review and approval by the Joint
Commercialization Committee;

                  (b) preparing annually for review and approval by the Joint
Commercialization Committee the budget for Commercialization activities in the
United States set forth in the Commercialization Plan (the "U.S.
Commercialization Budget") and amendments thereto, and monitoring the expenses
of each Party against the U.S. Commercialization Budget for such Joint DDC
and/or Joint Product;

                  (c) monitoring the Parties' compliance with their respective
obligations in the United States under an applicable U.S. Commercialization
Plan;

                  (d) reviewing market research plans and research results,
product development data and results and similar information related to
Commercialization of such Joint Product in the United States;

                  (e) defining the initial customer group or target group to be
covered with respect to a Joint DDC and/or Joint Product in the United States,
including, without limitation, the identification and promotional targeting of
key opinion leaders, physician groups, hospitals and regional buying groups,
including managed care organizations and governmental and
governmental-affiliated buyers, for recommendation to and approval by the Joint
Commercialization Committee;

                  (f) proposing to the Joint Commercialization Committee an
appropriate structure for marketing teams in the United States with respect to a
Joint Product, which proposal shall be made sufficiently in advance to permit
approval by the Joint Commercialization Committee of a structure for marketing
teams in the United States two (2) years prior to launch of such Joint Product;
and

                  (g) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

              7.1.5 ROW COMMERCIALIZATION PRODUCT TEAM. Each ROW
Commercialization Product Team appointed pursuant to Section 7.1.3(e) shall be
responsible for the following with respect to the Joint DDC and Joint Products
in ROW for which it has been established:

                  (a) preparing and implementing the ROW Commercialization Plans
in ROW for such Joint DDC and/or Joint Product and amendments thereto, subject
to review and approval by the Joint Commercialization Committee;

                                      -61-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (b) preparing annually for review and approval by the Joint
Commercialization Committee the budget for Commercialization activities in ROW
set forth in the Commercialization Plan (the "ROW Commercialization Budget")
(which budget shall include geographic breakdowns set by the Joint
Commercialization Committee) and amendments thereto, and monitoring the expenses
of each Party, on a country-by-country basis, against the ROW Commercialization
Budget for such Joint DDC and/or Joint Product;

                  (c) monitoring the Parties' compliance with their respective
obligations in ROW under an applicable ROW Commercialization Plan;

                  (d) reviewing market research plans and research results,
product development data and results and similar information related to
Commercialization of such Joint Product in ROW;

                  (e) defining the initial customer group or target group to be
covered with respect to a Joint DDC and/or Joint Product in ROW, including,
without limitation, the identification and promotional targeting of key opinion
leaders, physician groups, hospitals and regional buying groups, including
managed care organizations and governmental and governmental-affiliated buyers,
for recommendation to and approval by the Joint Commercialization Committee; and

                  (f) performing such other tasks and undertaking such other
responsibilities as may be set forth in this Agreement.

         7.2 COMMERCIALIZATION PLANS.

              7.2.1 PREPARATION. The Global New Product Pre-Launch Team for each
Joint DDC shall prepare a global product Commercialization framework for such
Joint DDC (a "Global Commercialization Framework") that will include, but not be
limited to, product positioning, marketing strategy, product labeling strategy,
general pricing and reimbursement strategy. Based upon the Global
Commercialization Framework, the U.S. Joint Commercialization Product Team and
the ROW Commercialization Product Team (collectively referred to as the
"Commercialization Product Teams") shall prepare a detailed Commercialization
plan for the United States ("U.S. Commercialization Plan") and ROW ("ROW
Commercialization Plan"), respectively, for the initial [**] months of such
Commercialization (collectively, an "Initial Commercialization Plan"), each for
review and approval by the Joint Commercialization Committee. A
Commercialization plan for each subsequent [**] month period will be prepared by
the applicable Commercialization Product Team, consistent with the Global
Commercialization Framework, for review and approval by the Joint
Commercialization Committee. The Initial Commercialization Plan and the
subsequent Commercialization plans approved by the Joint Commercialization
Committee shall be referred to as "Commercialization Plans". The
Commercialization Plans shall (a) include, but not be limited to, the marketing
strategy, the advertising and promotional strategy, product sampling plan,
medical plan, product labeling plan, pricing and reimbursement plan, target
customer

                                      -62-
<PAGE>

groups and budgets with respect thereto, (b) detail the Commercialization
activities to be conducted by each Party with respect to each Joint Product, and
(c) include a description of staffing requirements and an expense budget in
accordance with Section 7.1.

              7.2.2 APPROVAL. The Joint Commercialization Committee's oversight
of Commercialization Plans for all Joint Products shall include approval of
recommendations of the Commercialization Product Teams. With respect to approval
of an appropriate structure for marketing teams in the United States for a Joint
Product, the Joint Commercialization Committee shall be guided by the principle
of achieving optimal coordination between the Parties to achieve maximum
commercial success. For illustration purposes only, choices with respect to
appropriate structures for marketing teams in the United States for a Joint
Product include (a) operation of the marketing team at each Party simultaneously
or (b) operation of a single marketing team that may be physically located in a
single place with equal representation from each Party.

              7.2.3 COORDINATION. The U.S. Joint Commercialization Product Team
and the ROW Commercialization Product Team for each Joint Product shall
coordinate with each other in order to ensure consistency in the
Commercialization of such Joint Product on a global basis. Such Teams shall meet
at least twice annually to consider modifications to the Global
Commercialization Framework, review the implementation of the Commercialization
Plans for the current year and discuss the preparation of Commercialization
Plans for the following year.

         7.3 COMMERCIALIZATION ACTIVITIES.

              7.3.1 GENERAL. The Commercialization of each Joint Product shall
be conducted in accordance with the applicable Commercialization Plans. Each
Party shall use reasonable efforts to conduct the Commercialization activities
assigned to it in the Commercialization Plans and will devote sufficient
resources to carry out such responsibilities. Furthermore, each Party agrees to
conduct such Commercialization activities in compliance with all Laws that are
applicable to the Commercialization of Joint Products. Each Party shall ensure
that no claims or representations in respect of the Joint Products or the
characteristics thereof are made by or on behalf of it (by members of its sales
force or otherwise) which do not represent an accurate summary or explanation of
the labeling of the Joint Product or a portion thereof.

              7.3.2 ASSIGNMENT AND RESPONSIBILITY FOR COMMERCIALIZATION
ACTIVITIES.

                  (a) Each Party shall participate in the range of
Commercialization activities to be conducted in the United States with respect
to each Joint Product ("U.S. Commercialization Activities"). The U.S.
Commercialization Plans shall specify the allocation and assignment of U.S.
Commercialization Activities between the Parties with the goal that each Party's
participation shall be substantially equal on an ongoing basis, taking into
account the levels of participation in prior years and the participation
specified in the Commercialization Plans for the following year. Particular
Commercialization tasks and responsibilities shall be assigned consistent with
each Party's respective capabilities, capacity and expertise.

                  (b) Abbott will perform all Commercialization activities
directed specifically to ROW ("ROW Commercialization Activities") with respect
to each Joint Product

                                      -63-


<PAGE>

in accordance with the applicable Commercialization Plans, subject to the
co-promotion provisions set forth in Section 7.6.

                  (c) The Parties agree that there may be certain joint
Commercialization activities that would simultaneously benefit U.S.
Commercialization Activities and ROW Commercialization Activities and that would
be appropriate and beneficial for the Parties to perform on a global basis
(e.g., Phase IV clinical trials and medical symposia directed toward a worldwide
audience) ("U.S./ROW Joint Commercialization Activities"). If the Parties deem
it appropriate to perform U.S./ROW Joint Commercialization Activities, the
Commercialization Plans shall specify the allocation and assignment of U.S./ROW
Joint Commercialization Activities between the U.S. Joint Commercialization
Product Team and ROW Commercialization Product Team. Particular
Commercialization tasks and expenditures shall be assigned to a team based upon
a team's respective capabilities, capacity and expertise, as well as the degree
to which such activities involve the United States and ROW.

                  (d) To the extent permissible under applicable Law, the names
and logos of both Parties shall appear with equal prominence on all product
labeling, packaging, promotional and marketing materials that pertain to Joint
Products. All labeling, written and electronic materials associated with each
Joint Product shall indicate that the Joint Product was developed with the use
of Millennium and Abbott technology. Each Party shall grant the other Party an
appropriate trademark license for the foregoing purpose and either the licensor
Party or an Affiliate designated by the licensor Party shall have the right to
monitor the quality of such Joint Product in accordance with reasonable
procedures to be agreed upon by the Parties.

                  (e) All promotional materials shall be consistent with the
final labeling approved by the applicable Regulatory Authorities for the Joint
Products. Any promotional materials related to Joint Products to be used in the
United States or, in the event of a Co-Promoted Joint Product, the Co-Promotion
Territory, shall be reviewed and approved by the Parties' respective regulatory
promotions departments. Both Parties will share equally in product liability
costs related to such promotional materials.

                  (f) All other ROW promotional materials shall be prepared,
reviewed and approved by Abbott, it being understood that, notwithstanding the
provisions of Article 9 and EXHIBIT G, Abbott shall be responsible for one
hundred percent (100%) of the costs associated with any and all product
liability claims to the extent that such claims have been determined to result
from the failure of such promotional materials to be consistent with the final
labeling approved by the appropriate Regulatory Authorities for the Joint
Products.

              7.3.3 PRODUCT MANAGEMENT.

              (a) Each Party shall appoint one of its designees on each
Commercialization Product Team to serve as product manager with responsibility
for overseeing the day-to-day activities of the Parties with respect to
Commercialization of the applicable Joint Product and for being the primary
point of contact between the Parties with respect to such Commercialization.

                                      -64-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (b) Where the Joint Commercialization Committee has approved
the operation of a single marketing team for a Joint Product in the United
States, the Joint Commercialization Committee shall designate one of the product
managers for such Joint Product to be the "Senior Product Manager." A Senior
Product Manager shall serve to coordinate marketing activities between the
Parties, in accordance with Commercialization Plans, so as to achieve optimal
coordination for the purpose of achieving maximum commercial success for a Joint
Product.

                  (c) For the first Joint Product where the Joint
Commercialization Committee has approved operation of a single marketing team in
the United States, the product manager appointed by Abbott for such Joint
Product shall serve as Senior Product Manager.

                  (d) For the second Joint Product where the Joint
Commercialization Committee has approved operation of a single marketing team in
the United States, the product manager appointed by Millennium for such Joint
Product shall serve as the Senior Product Manager; thereafter, for each Joint
Product where the Joint Commercialization Committee has approved operation of a
single marketing team in the United States, the product managers appointed by
Abbott and Millennium shall serve as the Senior Product Manager on an
alternating basis, starting with Abbott.

         7.4 SALES IN THE UNITED STATES. To the extent permissible under
applicable Law, the Parties shall cooperate to coordinate the
Commercialization activities so that, throughout the course of
Commercialization of Joint Products in the United States, [**] for Joint
Products in the United States [**] of all the aggregate gross sales of Joint
Products in the United States made by the Parties under this Agreement. [**].

         7.5 COMMERCIALIZATION EXPENSES AND BUDGET. Each Party shall undertake
Commercialization activities assigned to it in the Commercialization Plans in
accordance with the applicable Commercialization Budget. Millennium and Abbott
shall share Commercialization Expenses pursuant to Section 9.1.

         7.6 CO-PROMOTION OF JOINT PRODUCTS.


              7.6.1 DECISION MILESTONE AND OTHER TERMS. As used in this
Agreement, the term "Decision Milestone" shall mean the decision by the Parties
to file an application for Regulatory Approval in any country in the
Co-Promotion Territory (which decision is expected to occur approximately [**]
months prior to filing each application). Upon reaching any Decision Milestone
with respect to a Joint DDC, the Joint Development Committee shall notify the
Joint Executive Committee in writing of such Decision Milestone. As used in this
Agreement, the term "First Joint DDC' and "First Joint Product" shall mean the
first Joint DDC to meet the Decision Milestone and its related Joint Product.
The term "Second Joint DDC' and "Second

                                      -65-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Joint Product" shall mean the Second Joint DDC to meet the Decision Milestone
and its related Joint Product.

              7.6.2 FIRST JOINT PRODUCT. In the event that [**] in all or part
of the Co-Promotion Territory, [**] all of the conditions provided for in
Section 7.6.4 of this Agreement ([**] and/or the [**] shall be [**], then
Millennium shall have the right [**] for the First Joint Product by providing
written notice to Abbott within [**] days after receipt of Abbott's notice. If
Millennium provides such notice to Abbott within such [**] day period [**] then
the Parties [**]as is mutually agreed to by the Parties. In connection with [**]
the Parties understand that [**] concerning such co-promotion opportunity,
including, but not limited to, [**]. If Millennium [**], then [**]. If
Millennium [**] and the Parties [**] reach mutual agreement [**], then [**] on
terms [**] that are [**] with Millennium.

              7.6.3 CO-PROMOTION RIGHT TO SECOND AND SUBSEQUENT JOINT PRODUCTS.
Millennium shall have the right, but not the obligation, to co-promote in the
Co-Promotion Territory the Second Joint Product and all subsequent Joint
Products arising from Joint DDCs, subject to, and in accordance with, the
provisions of this Section 7.6. If Millennium has met the conditions required
under Section 7.6.4 of this Agreement, it shall declare its intent to co-promote
a Joint Product within [**]days of written notification made by the Joint
Development Committee to the Joint Executive Committee of the Decision
Milestone. Failure to provide such written notice within such [**]day period
shall be deemed an election by Millennium not to exercise such co-promotion
right for such Joint Product.

                  (a) If (i) the First Joint DDC is not approved in the
Co-Promotion Territory, (ii) Millennium [**] the First Joint Product, and
(iii) a [**] or prior to the time the applicable Regulatory Authority informs
the Parties that the First Joint DDC has not been approved, then, if
Millennium shall have exercised its right to do so, [**], and the [**] with
Millennium [**], as provided in Section 7.6.2 of this Agreement.

                  (b) If (i) the First Joint DDC is not approved in the
Co-Promotion Territory, (ii) Millennium has entered into an agreement with
Abbott for [**] the First Joint Product, and (iii) a [**] at or prior to the
time the applicable Regulatory Authority informs the Parties that the First
Joint DDC has not been approved, then, if Millennium shall have exercised its
right to do so, [**] and the [**], with Millennium having the [**] First Joint
Product on terms substantially the same as those agreed to for the failed
First Joint Product.

                                      -66-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) If (i) the First Joint DDC is not approved in the
Co-Promotion Territory, (ii) Millennium [**] the First Joint Product, and
(iii) a [**] at or prior to the time the applicable Regulatory Authority
informs the Parties that the First Joint DDC has not been approved, then [**],
with Millennium [**] of this Agreement.

                  (d) If (i) the First Joint DDC is not approved in the
Co-Promotion Territory, (ii) Millennium [**] the First Joint Product, and
(iii) a [**] at or prior to the time the applicable Regulatory Authority
informs the Parties that the First Joint DDC has not been approved, then the
[**], with Millennium [**] First Joint Product [**]

              7.6.4 LIMIT ON MILLENNIUM'S RIGHT TO EXERCISE CO-PROMOTION
RIGHT. Notwithstanding the provisions of Sections 7.6.2 and 7.6.3, Millennium
shall not have the right to co-promote any Joint Product in the Co-Promotion
Territory unless the following conditions are satisfied:

                  (a) The Millennium sales force to co-promote the Joint Product
must be owned and managed by Millennium, have substantially all of the sales
representatives and managers of such sales force in place at least [**] months
prior to the launch of the Joint Product, and [**]months;

                  (b) The size (numbers of representatives and managers) of the
sales force employed by Millennium shall be subject to country-by-country
minimums to be established in the Commercialization Plans, subject to subsequent
modification as may be recommended by the Joint Commercialization Committee;

                  (c) Millennium must commit its sales force to [**] required to
commercialize the Joint Product throughout the Co-Promotion Territory; and

                  (d) Millennium's co-promotion and its sales force are in full
compliance with applicable Laws.

In countries of the Co-Promotion Territory where co-promotion is not legally
permissible, if any, Abbott and Millennium will each co-market their own brand
of the Joint Product consistent with the points provided in this Section 7.6.

              7.6.5 CO-PROMOTION GUIDELINES. With respect to each Co-Promoted
Joint Product, Millennium shall assume responsibility for [**] percent ([**]%)
of the annual budgeted detailing effort on a country-by-country basis. If the
Parties co-promote, sales management teams from each Party shall cooperate in
good faith to coordinate detailing activities in order to maximize product sales
by, for example, maximizing geographic coverage in the Co-Promotion Territory,
eliminating unnecessary duplication, and enhancing market penetration. Promptly
following exercise by Millennium of the co-promotion right for any Joint
Product, the ROW Commercialization Product Team shall propose modifications to
the relevant Commercialization Plans to provide for the co-promotion of the
Co-Promoted Joint Product in the Co-Promotion

                                      -67-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Territory (the "Co-Promotion Guidelines"), which modifications shall be subject
to approval by the Joint Commercialization Committee. The proposed modifications
shall address the following matters:

                  (a) the annual budgeted total detailing effort for each
country in the Co-Promotion Territory;

                  (b) the allocation of such total detailing effort between the
Parties (it being understood that the total detailing effort will be allocated
[**] percent ([**]%) to Abbott and [**] percent ([**]%) to Millennium, and that
neither Party's percentage detailing effort will vary on a country-by-country
basis unless otherwise mutually agreed upon by the Parties);

                  (c) the number and position of details and categories of
professionals or institutions to be targeted, and the allocation of such
professionals or institutions between the Parties; and

                  (d) policies and procedures relating to product sampling.

The Joint Commercialization Committee shall have the same overall authority
regardless of whether or not Millennium exercises it co-promotion rights under
Section 7.6.2 and Section 7.6.3. Notwithstanding the foregoing, in the event of
a disagreement over the tactical elements of the sales force utilization,
Abbott, as the lead marketing Party, shall have the final authority to resolve
such issues.

              7.6.6 CO-PROMOTION ACTIVITIES. Each Party shall be responsible for
staffing, training, supervising and compensating (including incentives) its own
sales personnel. Abbott shall be responsible for development of product-specific
training materials, with input from Millennium, and each Party shall use the
same training materials for its respective sales personnel. Each Party shall use
reasonable efforts to perform those tasks and responsibilities assigned to it in
the Co-Promotion Guidelines with respect to each Co-Promoted Joint Product.

              7.6.7 CO-PROMOTION DETAIL RECORDS AND METRICS.

                  (a) It is anticipated that during the calendar year the total
number of annual budgeted details will not change, unless mutually agreed by the
Parties. Each Party shall manage in good faith its monthly, quarterly,
semi-annual and annual detailing on a basis consistent with the
Commercialization Plan or as amended in a final detail plan approved by the
Joint Commercialization Committee ("Final Detail Plan"). Each Party shall keep
track of the number and position of details performed by its representatives in
accordance with its normal internal reporting procedures, subject to guidelines
approved by the Joint Commercialization Committee. Within [**] days after the
last day of each calendar month, each Party shall submit to the other Party a
report with respect to the number of details performed by its representatives
during such calendar month. Unless specifically provided for in an amendment to
the Commercialization Plan, or as amended by a Final Detail Plan, neither Party
shall be entitled to charge as Commercialization Expenses the cost of performing
any detail in excess of the number

                                      -68-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

of annual budgeted details plus [**] percent ([**]%) of such budgeted details
for which it is responsible.

                  (b) If, with respect to a particular Joint Product, Millennium
fails to perform at least [**] percent ([**]%) of its share of budgeted details
(as set forth in the Commercialization Plan or as amended by a Final Detail
Plan) for any [**] month period (the first such period commencing with the start
of co-promotion activities by Millennium) and Abbott also fails to perform at
least [**] percent ([**]%) of its share of budgeted details (as set forth in the
Commercialization Plan or as amended by a Final Detail Plan) for such [**] month
period, there shall be no consequence to Millennium.

                  (c) If, with respect to a particular Joint Product, Millennium
fails to perform at least [**] percent ([**]%) of its share of budgeted details
(as set forth in the Commercialization Plan or as amended by a Final Detail
Plan) for any [**] month period (the first such period commencing with the start
of co-promotion activities by Millennium) and Abbott performs at least [**]
percent ([**]%) of its share of budgeted details (as set forth in the
Commercialization Plan or as amended by a Final Detail Plan) for such [**] month
period, then Millennium's share of Operating Margin/Profit for the Co-Promotion
Territory shall revert to [**] percent ([**]%) for such [**] month period.

                  (d) If, with respect to a particular Joint Product, Millennium
fails to perform at least [**] percent ([**]%) of its share of budgeted
details (as set forth in the Commercialization Plan or as amended by a Final
Detail Plan) for any [**] month periods and Abbott also fails to perform at
least [**] percent ([**]%) of its share of budgeted details (as set forth in
the Commercialization Plan or as amended by a Final Detail Plan) for such [**]
month periods, there shall be no consequence to Millennium.

                  (e) If, with respect to a particular Joint Product, Millennium
fails to perform at least [**] percent ([**]%) of its share of budgeted details
(as set forth in the Commercialization Plan or as amended by a Final Detail
Plan) for any [**] month periods and Abbott performs at least [**] percent
([**]%) of its share of budgeted details (as set forth in the Commercialization
Plan or as amended by a Final Detail Plan) for such [**] month periods, then
Millennium shall commence a [**] to begin on the first day of the first month
immediately following the [**] month period. Abbott shall provide written notice
[**]days of receiving Millennium's last monthly report for such [**] month
period. If Millennium fails to perform at least [**] percent ([**]%) of its
share of budgeted details (as set forth in the Commercialization Plan or as
amended by a Final Detail Plan) for [**] months during any rolling [**] month
period [**] PROVIDED THAT Abbott shall have performed at least [**] percent
([**]%) of its share of budgeted details (as set forth in the Commercialization
Plan or as amended by a Final Detail Plan) for any [**] month period.

              7.6.8 AUDIT. At the request of either Party, but not more than
once a year by such Party, a special external audit of the detail effort of both
Parties' with respect to each Co-Promoted Joint Product shall be performed, the
cost of which shall be paid by the requesting

                                      -69-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

Party. If the audit reveals that a Party's reporting of its detailing efforts
was inaccurate such that the Party's details for the calendar year (or for any
[**] month periods) were less than [**] percent ([**]%) of its respective
details for either such period, then that Party shall be responsible for the
full cost of such audit. If the audit reveals that both Parties' reporting of
their detailing efforts was inaccurate such that the Parties' details for the
calendar year (or for any [**] month periods) were less than [**] percent
([**]%) of their respective details for either such period, then the cost of the
audit shall be shared equally by the Parties.

         7.7 SAFETY ISSUES AND RECALLS.

              7.7.1 GENERAL. Each Party shall keep the other Party informed,
commencing within forty-eight (48) hours of notification of any action by, or
notification or other information which it receives (directly or indirectly)
from Regulatory Authorities, (a) which raises any material concerns regarding
the safety or efficacy of any Joint Product, (b) which indicates or suggests a
potential material liability for either Party to Third Parties arising in
connection with any Joint Product, or (c) which is reasonably likely to lead to
a recall or market withdrawal of any Joint Product. Information that shall be
disclosed pursuant to this Section 7.7.1 shall include, but not be limited to:

                  (a) governmental or regulatory inspections of manufacturing,
distribution or other related facilities used for Joint DDCs or Joint Products;

                  (b) inquiries by governmental or regulatory authorities
concerning clinical investigation activities (including inquiries of
investigators, clinical monitoring organizations and other related parties)
relating to Joint DDCs or Joint Products;

                  (c) any communication from governmental or regulatory
authorities pertaining to the manufacture, sale, promotion or distribution of
Joint DDCs or Joint Products;

                  (d) any other governmental or regulatory authority reviews or
inquiries relating to Joint DDCs or Joint Products;

                  (e) receipt of a warning letter relating to any of the Joint
DDCs or Joint Products; and

                  (f) an initiation of any governmental or regulatory authority
investigation, detention, seizure or injunction concerning any Joint DDCs or
Joint Products.

              7.7.2 JOINT PRODUCTS. With respect to each Joint Product, the
Joint Commercialization Committee shall, in consultation with appropriate
representatives from the Medical Service Groups of Abbott and their counterparts
at Millennium, and subject to the oversight of the Joint Executive Committee,
establish specific policies for the exchange of adverse event information (as
well as periodic reporting responsibilities and other regulatory safety
obligations), product complaints, medical review and medical information
inquiries, all in

                                      -70-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

order to allow each Party to meet its regulatory requirements in the Territory.
Such policies shall be established at least [**] days prior to the initiation of
marketing of each Joint Product.

              7.7.3 ACTIONS OF JOINT EXECUTIVE COMMITTEE. The Joint Executive
Committee shall be responsible for making all determinations concerning recalls
of Joint DDCs or Joint Products.

         7.8 UNILATERAL COMMERCIALIZATION. The Researching Party and the
Developing Party with respect to a Unilateral Target and Unilateral DDC,
respectively, shall have the right, and shall use reasonable efforts, to
Commercialize related Unilateral Products on a worldwide basis. The Developing
Party shall provide the other Party with a brief annual report concerning the
status of its Commercialization of any such Unilateral Products.

                                    ARTICLE 8

                                    LICENSES

         8.1 MILLENNIUM GRANTS.

              8.1.1 RESEARCH LICENSES.

                  (a) Subject to the terms and conditions of this Agreement and
any applicable Burdened Technology Obligations, Millennium hereby grants to
Abbott a worldwide, co-exclusive (with Millennium), non-royalty-bearing license
during the Research Program Term, under Millennium's rights to the Program
Intellectual Property, to (i) [**] as the case may be, in the Metabolic Disease
Field, (ii) [**] as the case may be, in the Metabolic Disease Field, (iii) [**]
in the conduct of the Research Program and (iv) undertake such other activities
as may be necessary in furtherance of the Research Program. Such license shall
further include the right to grant sublicenses to Affiliates of Abbott and to
Third Parties that are contemplated by Section 3.4.4. For purposes of clarity,
Millennium's co-exclusive right retained under this Section 8.1.1(a) includes
the right to grant sublicenses to Affiliates of Millennium and to Third Parties
pursuant to Section 3.4.4.

                  (b) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.3)
[**], Millennium hereby grants to Abbott a worldwide, non-exclusive,
non-royalty-bearing license, under Millennium's rights to the Program
Intellectual Property, to (i) [**], as the case may be, in the Metabolic Disease
Field, and (iii) [**] PROVIDED THAT with respect to each [**], such license
shall be limited to know-how disclosed to Abbott prior to, and to Patent Rights
which exist as of or which claim priority from Patent Rights which exist as of,
the date such target is designated an [**]. Such license shall further include
the right to grant sublicenses to Affiliates of Abbott and to Third Parties in
accordance with the terms set forth in Section 8.3.

                                      -71-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.7)
[**], Millennium hereby grants to Abbott a worldwide, non-exclusive,
non-royalty-bearing license, under Millennium's rights to the Program
Intellectual Property, to use the [**] for internal research purposes only;
PROVIDED THAT with respect to each [**], such license shall be limited to
know-how developed prior to, and to Patent Rights which exist as of or which
claim priority from Patent Rights which exist as of, the date such compound is
designated a [**]. Such license shall not include the right to grant any
sublicenses.

              8.1.2 DEVELOPMENT AND COMMERCIALIZATION LICENSES.

                  (a) Subject to the terms and conditions of this Agreement
[**], Millennium hereby grants to Abbott a worldwide, co-exclusive (with
Millennium) license, under Millennium's rights to the Program Intellectual
Property, to (i) Develop and Manufacture Joint DDCs for use as Joint Products;
(ii) make, have made (subject, in the case of any sublicense, to the provisions
of Section 8.3), use, sell, offer for sale, import and export Joint Products in
the Territory; and (iii) undertake such other activities as may be necessary in
furtherance of the Development Program and the Commercialization Program. Such
license shall carry an obligation of profit-sharing with respect to Joint
Products sold in the Territory, as set forth in Section 9.1. Such license shall
further include the right to grant sublicenses to Affiliates of Abbott and to
Third Parties in accordance with the terms set forth in Section 8.3. For
purposes of clarity, Millennium's co-exclusive right retained under this Section
8.1.2(a) includes the right to grant sublicenses to Affiliates of Millennium and
to Third Parties in accordance with the terms set forth in Section 8.3.

                  (b) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.3)
[**], Millennium hereby grants to Abbott (i) a worldwide, non-exclusive,
non-royalty-bearing license, under Millennium's rights to the Program
Intellectual Property, to [**] as the case may be, [**] (ii) a worldwide,
exclusive, non-royalty-bearing license, under Millennium's rights to the Program
Intellectual Property, to Develop and Manufacture [**] in each case, for use as
[**], and (iii) a worldwide, exclusive, royalty-bearing license, under
Millennium's rights to Program Intellectual Property, to make, have made
(subject, in the case of any sublicense, to the provisions of Section 8.3), use,
sell, offer for sale, import and export [**] in the Territory; PROVIDED THAT
with respect to each [**], as the case may be, such licenses shall be limited to
know-how disclosed to Abbott prior to, and to Patent Rights which exist as of or
which claim priority from Patent Rights which exist as of, the date such target
is designated an [**] or the date such compound is designated an [**] is
designated an Abbott Unilateral Target or the Drug Development Candidate
contained in such [**] is designated an [**], as the case may be. Such licenses
shall further include the right to grant sublicenses to Affiliates of Abbott and
to Third Parties in accordance with the terms set forth in Section 8.3.

                                      -72-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (c) (i) Subject to the terms and conditions of this Agreement
[**], Millennium hereby grants to Abbott (A) a worldwide, co-exclusive (with
Millennium) license, under Millennium's rights to the Program Intellectual
Property, to develop, make, have made (subject, in the case of any sublicense,
to the provisions of Section 8.3), use, sell, offer for sale, import and export
[**] in the Territory, and (B) (1) a worldwide, co-exclusive (with Millennium)
license, under Millennium's rights to the [**] in the Territory and (2) a
worldwide, exclusive license, under Millennium's rights to the Program
Intellectual Property, to make, have made (subject, in the case of any
sublicense, to the provisions of Section 8.3), use, sell, offer for sale, import
and export [**] in the Territory subject to Millennium's right to co-promote in
accordance with Section 5.1.1(b). Such licenses shall [**] sold in the
Territory, as set forth in Section 9.3. Such licenses shall further include the
right to grant sublicenses to Affiliates of Abbott and to Third Parties in
accordance with the terms set forth in Section 8.3. For purposes of clarity,
Millennium's co-exclusive rights with respect to Third Party Program Diagnostics
and Joint Program Diagnostics retained under this Section 8.1.2 (c)(i) include
the right to grant sublicenses to Affiliates of Millennium and to Third Parties
in accordance with the terms set forth in Section 8.3.

                      (ii) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.5)
[**], Millennium hereby grants to Abbott a worldwide, royalty-bearing license,
under Millennium's rights to the Program Intellectual Property, to develop,
make, have made (subject, in the case of any sublicense, to the provisions of
Section 8.3), use, sell, offer for sale, import and export [**] in the
Territory. Such license shall be exclusive with respect to an [**], and shall be
non-exclusive with respect to any other [**]. Such license shall further include
the right to grant sublicenses to Affiliates of Abbott and to Third Parties in
accordance with the terms set forth in Section 8.3.

                      (iii) Subject to the terms and conditions of this
Agreement (including, but not limited to, the exclusivity provisions of Section
2.1.6) [**], Millennium hereby grants to Abbott (A) a worldwide, co-exclusive,
non-royalty-bearing license, under Millennium's rights to the [**] and (B) a
worldwide, exclusive, royalty-bearing license, under Millennium's rights to the
Program Intellectual Property, to make, have made (subject, in the case of any
sublicense, to the provisions of Section 8.3), use, sell, offer for sale, import
and export [**] in the Territory. Such licenses shall further include the right
to grant sublicenses to Affiliates of Abbott and to Third Parties in accordance
with the terms set forth in Section 8.3. For purposes of clarity, Millennium's
co-exclusive right retained under subsection (A) of this Section 8.1.2(c)(iii)
includes the right to grant sublicenses to Affiliates of Millennium and to any
Third Party engaged in a bona fide collaboration with Millennium, in accordance
with the terms set forth in Section 8.3.

                                      -73-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         8.2 ABBOTT GRANTS.

              8.2.1 RESEARCH LICENSES.

                  (a) Subject to the terms and conditions of this Agreement
[**], Abbott hereby grants to Millennium a worldwide, co-exclusive (with
Abbott), non-royalty-bearing license during the Research Program Term, under
Abbott's rights [**] as the case may be, in the Metabolic Disease Field, (ii)
[**] as the case may be, in the Metabolic Disease Field, (iii) [**] in the
conduct of the Research Program, and (iv) undertake such other activities as may
be necessary in furtherance of the Research Program. Such license shall further
include the right to grant sublicenses to Affiliates of Millennium and to Third
Parties that are contemplated by Section 3.4.4. For purposes of clarity,
Abbott's co-exclusive right retained under this Section 8.2.1(a) includes the
right to grant sublicenses to Affiliates of Abbott and to Third Parties pursuant
to Section 3.4.4.

                  (b) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.3)
[**], Abbott hereby grants to Millennium a worldwide, non-exclusive,
non-royalty-bearing license, under Abbott's rights to [**] as the case may be,
in the Metabolic Disease Field, (ii) [**] as the case may be, in the Metabolic
Disease Field, and (iii) [**]; PROVIDED THAT with respect to each Millennium
Unilateral Target, such license shall be limited to know-how disclosed to
Millennium prior to, and to Patent Rights which exist as of or which claim
priority from Patent Rights which exist as of, the date such target is
designated a [**]. Such license shall further include the right to grant
sublicenses to Affiliates of Millennium and to Third Parties in accordance with
the terms set forth in Section 8.3.

                  (c) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.7)
[**], Abbott hereby grants to Millennium a worldwide, non-exclusive,
non-royalty-bearing license, under Abbott's rights to the Program Intellectual
Property, to use the [**] for internal research purposes only; PROVIDED THAT
with respect to each [**], such license shall be limited to know-how developed
prior to, and to Patent Rights which exist as of or which claim priority from
Patent Rights which exist as of, the date such compound is designated an [**].
Such license shall not include the right to grant any sublicenses.

              8.2.2 DEVELOPMENT AND COMMERCIALIZATION LICENSES.

                  (a) Subject to the terms and conditions of this Agreement
[**], Abbott hereby grants to Millennium a worldwide, co-exclusive (with Abbott)
license, under Abbott's rights to the Program Intellectual Property, to (i)
Develop and Manufacture Joint DDCs for use as Joint Products; (ii) make, have
made (subject, in the case of any sublicense, to the provisions of Section 8.3),
use, sell, offer for sale, import and export Joint Products in the Territory;
and (iii) undertake such other activities as may be necessary in furtherance of
the Development Program and the Commercialization Program. Such license shall
carry an obligation of profit-sharing

                                      -74-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

with respect to Joint Products sold in the Territory, as set forth in Section
9.1. Such license shall further include the right to grant sublicenses to
Affiliates of Millennium and to Third Parties in accordance with the terms set
forth in Section 8.3. For purposes of clarity, Abbott's co-exclusive right
retained under this Section 8.2.2(a) includes the right to grant sublicenses to
Affiliates of Abbott and to Third Parties in accordance with the terms set forth
in Section 8.3.

                  (b) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.3)
[**], Abbott hereby grants to Millennium (i) a worldwide, non-exclusive,
non-royalty-bearing license, under [**] (ii) a worldwide, exclusive,
non-royalty-bearing license, under Abbott's rights to [**], and (C) [**] and
(iii) a worldwide, exclusive, royalty-bearing license, under Abbott's rights to
[**] in the Territory, PROVIDED THAT with respect to each [**] as the case may
be, such licenses shall be limited to know-how disclosed to Millennium prior to,
and to Patent Rights which exist as of or which claim priority from Patent
Rights which exist as of, the date such target is designated a [**] or the date
such compound is designated a [**] or the date the target used to identify,
evaluate, optimize and/or Develop such [**] is designated a [**] contained in
such [**], as the case may be. Such licenses shall further include the right to
grant sublicenses to Affiliates of Millennium and to Third Parties in accordance
with the terms set forth in Section 8.3.

                  (c) (i) Subject to the terms and conditions of this Agreement
[**], Abbott hereby grants to Millennium a worldwide, co-exclusive (with Abbott)
license, under Abbott's rights to the Program Intellectual Property, (A) to
develop, make, have made (subject, in the case of any sublicense, to the
provisions of Section 8.3), use, sell, offer for sale, import and export [**] in
the Territory, and (B) to develop [**] in the Territory. Such license shall [**]
in the Territory, as set forth in Section 9.3. Such license shall further
include the right to grant sublicenses to Affiliates of Millennium and to Third
Parties in accordance with the terms set forth in Section 8.3. For purposes of
clarity, Abbott's co-exclusive right retained under this Section 8.2.2 (c)
includes the right to grant sublicenses to Affiliates of Abbott and to Third
Parties in accordance with the terms set forth in Section 8.3.

                      (ii) Subject to the terms and conditions of this Agreement
(including, but not limited to, the exclusivity provisions of Section 2.1.5 and
Section 5.3.2) [**] Abbott hereby grants to Millennium a worldwide,
royalty-bearing license, under Abbott's rights to the Program Intellectual
Property, to develop, make, have made (subject, in the case of any sublicense,
to the provisions of Section 8.3), use, sell, offer for sale, import and export
[**] in the Territory. Such license shall be exclusive with respect to a [**]
that (A) [**] and shall be non-exclusive with respect to any other [**]. Such
license shall further include the right to grant sublicenses to Affiliates of
Millennium and to Third Parties in accordance with the terms set forth in
Section 8.3.

                                      -75-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         8.3 SUBLICENSE RIGHTS. Each Party may grant sublicenses to any of its
Affiliates without any prior notice to, or consent from, the other Party.
Wherever in this Agreement either Party is granted or retains the right to grant
sublicenses to Third Parties subject to this Section 8.3, the sublicensing Party
shall promptly notify the other Party of any sublicenses, including the identity
of such Third Party sublicensee, and such Third Party sublicense shall occur
pursuant to a written agreement that subjects such Third Party sublicensee to
all relevant restrictions and limitations in this Agreement; PROVIDED THAT the
foregoing notice shall not be required in the case of sublicenses to academic
collaborators and/or subcontractors where no commercial rights are granted to
such Third Parties and there is no adverse impact on the Commercialization
rights of the Parties hereunder. Furthermore, to the extent that any such
sublicense relates to Development, Manufacture or Commercialization activities
for a Joint Product or to development, manufacture or Commercialization
activities for a Joint Program Diagnostic or a Third Party Program Diagnostic,
the prior written approval of the other Party shall be required. Each Party
shall be jointly and severally responsible with its Affiliates and Third Party
sublicensees for failure by its Affiliates and Third Party sublicensees to
comply with, and each Party guarantees the compliance by each of its
sublicensees with, all such applicable restrictions and limitations in
accordance with the terms and conditions of this Agreement.

         8.4 RETAINED RIGHTS.

              8.4.1 ABBOTT RETAINED RIGHTS. Any rights of Abbott not expressly
granted to Millennium under the provisions of this Agreement shall be retained
by Abbott, including, without limitation, [**]for (a) any diagnostic or
therapeutic rights not otherwise granted in this Agreement (including the right
to [**] the Research Program [**] and (b) [**]

              8.4.2 MILLENNIUM RETAINED RIGHTS. Any rights of Millennium not
expressly granted to Abbott under the provisions of this Agreement shall be
retained by Millennium, including, without limitation, [**] for (a) any
diagnostic or therapeutic rights not otherwise granted in this Agreement
(including the right to use [**] to the Research Program [**], and (b)
[**]

              8.4.3 INDEPENDENT DIAGNOSTIC PROGRAMS. The Parties acknowledge
that each Party currently has Diagnostic activities and capabilities in the
Metabolic Disease Field and that, except as expressly prohibited under
Section 2.1.4 (Program Diagnostic Exclusivity), Section 2.1.5 (Unilateral
Diagnostic Exclusivity) and Section 2.1.6 (Released Target Exclusivity) of
this Agreement, each Party will have the right to continue to pursue,
independent and outside of this Agreement, the research, development and
Commercialization of Diagnostics in the Metabolic Disease Field.

         8.5 SECTION 365(N) OF THE BANKRUPTCY CODE. All rights and licenses
granted under or pursuant to any section of this Agreement are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy
Code, licenses of rights to "intellectual property" as defined under Section
101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise
all of their respective rights and elections under the Bankruptcy Code. Upon the
bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a
complete duplicate of (or complete access to, as appropriate) any such
intellectual property, and such, if not already in its

                                      -76-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

possession, shall be promptly delivered to the non-bankrupt Party, unless the
bankrupt Party elects to continue, and continues, to perform all of its
obligations under this Agreement.

         8.6 NOTICE OF THIRD PARTY BREACH. Each Party agrees to notify the other
Party in writing within [**] days of obtaining actual knowledge of any (a)
default or claim of default by any Third Party against such Party, or (b)
default or claim of default by such Party against any Third Party, in either
case, relating to any license agreement with any Third Party which has
application to the licenses granted the other Party pursuant to this Agreement.

                                   ARTICLE 9

                              FINANCIAL PROVISIONS

         9.1 OPERATING MARGIN/PROFIT.

              9.1.1 SHARING OF OPERATING MARGIN/PROFIT. The Parties shall share
equally in U.S. Territory Operating Margin/Profit. In recognition of
infrastructure costs to be borne by Abbott, the sharing of ROW Territory
Operating Margin/Profit shall be as follows: [**] percent ([**]%) to Abbott and
[**] percent ([**]%) to Millennium. The calculation of U.S. Territory Operating
Margin/Profit and ROW Territory Operating Margin/Profit shall be made in
accordance with EXHIBIT G. Notwithstanding the foregoing, with respect to each
Co-Promoted Joint Product, ROW Territory Operating Margin/Profit in the
Co-Promotion Territory for such Co-Promoted Joint Product shall be allocated
[**] percent ([**]%) to Abbott and [**] percent ([**]%) to Millennium for so
long as Millennium satisfies its co-promotion obligations under Section 7.6 of
this Agreement.

              9.1.2 QUARTERLY REPORTING AND RECONCILIATION.

                  (a) Within [**] days after the end of each calendar quarter,
each Party shall submit a written report to the other Party setting forth in
reasonable detail, separately with respect to each Joint DDC and Joint Product
in the United States during such calendar quarter, as applicable, Joint Product
Net Sales of each Joint Product, Standard Cost of Goods Sold, Distribution
Expenses and Commercialization Expenses incurred by or on behalf of the
reporting Party in the United States during such calendar quarter. Such report
shall provide supporting detail for the Standard Cost of Goods Sold,
Distribution Expenses and Commercialization Expenses.

                  (b) Within [**] days after the end of each calendar quarter,
each Party shall submit a written report to the other Party setting forth in
reasonable detail, separately with respect to each Joint DDC and Joint Product
in ROW during the most recently ended reporting quarter for ROW purposes (it
being understood that there is a one (1) month lag behind calendar quarters in
ROW reporting - e.g., the fourth reporting quarter for ROW covers September,
October and November), as applicable, Joint Product Net Sales of each Joint
Product, Standard Cost of Goods Sold, Distribution Expenses and
Commercialization Expenses, incurred by or on behalf of the reporting Party in
ROW during such reporting quarter. Such report shall provide

                                      -77-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

supporting detail for Standard Cost of Goods Sold, Distribution Expenses and
Commercialization Expenses and shall specifically identify, if applicable, all
such expenses with respect to the Co-Promotion Territory and ROW Minus the
Co-Promotion Territory.

                  (c) Commercialization Expenses reported pursuant to
subsections (a) or (b) shall be included in the determination of U.S. Territory
Operating Margin/Profit and ROW Territory Operating Margin/Profit, as
applicable, only to the extent made or incurred in conjunction with an approved
budget line item in the applicable Commercialization Budget or as otherwise may
be approved by the Joint Commercialization Committee.

                  (d) Costs and expenses included in Standard Cost of Goods
Sold, Distribution Expenses and Commercialization Expenses, as well as the
deductions taken from Joint Product Net Sales, shall not be double counted
(i.e., any item of expense included in any expense category shall not also be
included in any other expense category).

                  (e) Within [**] days following the receipt of each Party's
reports under subsections (a) and (b), Abbott shall submit to Millennium a
written report setting forth in reasonable detail the calculation of U.S.
Territory Operating Margin/Profit, ROW Territory Operating Margin/Profit and, if
applicable, Co-Promotion Territory Operating Margin/Profit and ROW Minus the
Co-Promotion Territory Operating Margin/Profit and the calculation of any net
amount owed by Millennium to Abbott or by Abbott to Millennium, as the case may
be, in order to ensure the sharing of Operating Margin/Profit specified in
Section 9.1.1.

                  (f) The net amounts payable under subsection (e) shall be paid
by Abbott or Millennium, as the case may be, within [**] days after receipt of
each such written report, PROVIDED THAT, in the event of a dispute as to the
amounts under subsection (e), the disputing Party shall pay the amount not in
dispute and shall provide written notice within such [**] day period after
receipt of the written report in question, specifying in detail such dispute.
The Parties shall promptly thereafter meet and negotiate in good faith a
resolution to such dispute. In the event that the Parties are unable to resolve
such dispute within [**]days after notice by the disputing Party, the matter
shall be resolved in a manner consistent with the procedures set forth in
Article 13 (PROVIDED THAT, in the case that the matter has not been resolved by
the Executive Officers, rather than invoking ADR under Section 13.5, the Parties
shall (i) use reasonable efforts to reach agreement on the appointment of one
(1) internationally-recognized independent accounting firm to determine the
matter, (ii) if the Parties cannot reach agreement on such accounting firm, then
each Party shall appoint one (1) internationally-recognized accounting firm to
determine the matter, and (iii) if such firms cannot reach agreement, such firms
shall choose a third internationally-recognized independent accounting firm to
make the final determination). Interest shall be payable on any disputed amounts
determined to be due in the same manner as provided for in Section 9.9, with
interest accruing from the end of the [**]day period during which such payment
should have been made.

                                      -78-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                  (g) The Divisional Vice President, Controller for the
Pharmaceutical Products Division of Abbott and the Divisional Vice President,
Controller for the International Division of Abbott, shall certify in writing
the correctness and completeness of each report submitted by Abbott hereunder.
The Chief Financial Officer, Vice President, Finance and/or Treasurer of
Millennium shall certify in writing the correctness and completeness of each
report submitted by Millennium hereunder.

                  (h) With respect to each calendar quarter (and the
corresponding reporting quarter), each Party shall provide to the other Party
reports setting forth (i) actual Joint Product Net Sales for each of the first
[**] months in such quarter (on a country-by-country basis), to be provided
within [**] days after the end of each such month, (ii) actual Joint Product Net
Sales for such quarter (on a country-by-country basis), to be provided within
[**] business days after the end of such quarter, and (iii) the most current
forecast of Standard Cost of Goods Sold and Commercialization Expenses for such
quarter (broken down on a monthly basis), to be provided within [**] days after
the end of such quarter. The Parties recognize that the forecasts provided
pursuant to subsection (iii) are estimates only, and the Party providing such
forecast shall have no liability to the other Party based thereon. The Parties
agree to consider in good faith the utilization of more rapid and detailed
reporting mechanisms in order to meet the reporting requirements of the Parties.

         9.2 ROYALTIES ON UNILATERAL PRODUCTS.

              9.2.1 ROYALTY PERCENTAGES. The Royalty-Paying Party shall pay
royalties to the other Party on aggregate worldwide Unilateral Product Net Sales
made during the term set forth in Section 9.2.4 of each Unilateral Product as
follows:

<TABLE>
<CAPTION>

ANNUAL WORLDWIDE NET SALES LEVEL                                         OPT-OUT-PHASE
--------------------------------                 -----------------------------------------------------------------
                                                   Pre-Drug             Drug Development
                                                  Development             Candidate to             Post-Phase IIA
                                                   Candidate          Phase IIA Completion           Completion
                                                  -----------         --------------------         --------------
<S>                                               <C>                 <C>                           <C>

$[**] million                                        [**]%                   [**]%                     [**]%
GREATER THAN $[**]                                   [**]%                   [**]%                     [**]%
GREATER THAN $[**]                                   [**]%                   [**]%                     [**]%
GREATER THAN $[**]                                   [**]%                   [**]%                   [**]%[**]
</TABLE>


                                      -79-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         Royalties on Unilateral Product Net Sales of each Unilateral Product in
a calendar year shall be paid at the rate applicable to the portion of
Unilateral Product Net Sales within each of the Unilateral Product Net Sales
levels above during such calendar year. For example, if, during a calendar year,
with respect to a Unilateral Product with an Opt-Out Phase after designation as
a Drug Development Candidate but prior to Phase IIA completion, Unilateral
Product Net Sales were equal to $[**] million, the Royalty-Paying Party would
calculate royalties due by adding (i) royalties with respect to the first $[**]
million at the first level percentage of [**] percent ([**]%) ($[**] million x
[**] = $[**]million), to (ii) royalties with respect to the remaining $[**]
million at the second level percentage of [**] percent ([**]%) ($[**] million x
[**]= $[**]million) to create a total royalty amount of $[**] million.

              9.2.2 OPT-OUT PHASE. In the table above, "Opt-Out Phase" means the
most advanced development phase with respect to the applicable Unilateral
Product when the other Party elected not to participate further in Development
or Commercialization thereof. In the event of a disagreement between the Parties
as to which Opt-Out Phase applies, the matter shall be referred to the Joint
Executive Committee.

              9.2.3 EXCEPTIONS. Anything to the contrary notwithstanding, in the
event that (a) a Party contributes a Program Target to the Research Program, (b)
in the case of [**], during the conduct of the Research Program (i) [**] of such
Program Target and (ii) [**]Program Target has been[**]during the conduct of the
Research Program a Party has not validated such Program Target in the [**]of (A)
[**] such Program Target or (B) [**] such Program Target, and (c) [**] such
Program Target [**]

              9.2.4 TERM. Royalties shall be payable, on a country-by-country
basis, for the longer of (a) the term of any Patent Rights Controlled by
Abbott or Millennium with a Valid Claim Covering the composition of matter or
therapeutic use of the Unilateral Product in such country or (b) [**] years
after the First Commercial Sale of such Unilateral Product in such country.

              9.2.5 REDUCTIONS. Notwithstanding the foregoing, the
Royalty-Paying Party shall be entitled to reduce the amount of royalties
payable to the other Party pursuant to Section 9.2.1 if, with respect to a
given country, [**] in the case of [**] of the [**] which [**] (a "Competitor
Product"). If such circumstances occur, the following royalty reductions
shall apply with respect to royalties in such country, PROVIDED THAT in no
event shall the royalty be reduced to less than [**]percent ([**]%) of
Unilateral Product Net Sales:

                                      -80-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

<TABLE>
<CAPTION>

        MARKET SHARE OF THIRD PARTY(IES)                    PERCENTAGE REDUCTION IN ROYALTY
        --------------------------------                    -------------------------------
<S>                                                         <C>
                    [**]% to [**]%                                        [**]
       GREATER THAN [**]% to [**]%                                        [**]%
       GREATER THAN [**]% to [**]%                                        [**]%
       GREATER THAN [**]%                                                 [**]%
</TABLE>


         For purposes of the foregoing analysis, in the case of a Small Molecule
Drug, "Close Competitor" shall mean (a) other enantiomeric forms of the
compounds contained in the Unilateral Product, (b) other salt forms of the
compound contained in the Unilateral Product, or (c) a pro-drug that is
metabolized to the same active moiety as the compound contained in the
Unilateral Product and, in the case of a Therapeutic Antibody Product, "Close
Competitor" shall mean an Antibody directed to the same Program Target as the
Therapeutic Antibody Product. For purposes of the foregoing analysis, the market
share of the Close Competitor's products shall be calculated in accordance with
the formula A/A + B, where "A" represents the number of units of the Close
Competitor's products sold in the applicable country and "B" represents the
number of units of the Unilateral Product sold in the applicable country. Data
regarding the number of units shall be obtained from a mutually-acceptable
company using a mutually-acceptable research methodology, such as IMS Health
Data Corp. or some other comparable entity.

              9.2.6 THIRD PARTY FEES AND ROYALTIES. With respect to each
Unilateral Product, the Royalty-Paying Party shall be responsible for all fees
and royalties due Third Parties, including commitments to Third Parties made by
the other Party and disclosed to the Royalty-Paying Party as Burdened Technology
Obligations.

         9.3 PROGRAM DIAGNOSTIC OPERATING MARGIN/PROFIT.

              9.3.1 OPERATING MARGIN/PROFIT SHARING. The sharing of Program
Diagnostic Operating Margin/Profit shall be as follows: if the Program
Diagnostic is a Joint Program Diagnostic automated onto the Abbott Diagnostic
Platform, [**] percent ([**]%) to Abbott and [**] percent ([**]%) to Millennium;
otherwise, the Parties shall share equally in Program Diagnostic U.S. Territory
Operating Margin/Profit for Program Diagnostics not automated onto the Abbott
Diagnostic Platform and shall share Program Diagnostic ROW Territory Operating
Margin/Profit[**] percent ([**]%) to Abbott and [**]percent ([**]%) to
Millennium for Program Diagnostics not automated onto the Abbott Diagnostic
Platform. The calculation of Program Diagnostic U.S. Territory Operating
Margin/Profit and Program Diagnostic ROW Territory Operating Margin/Profit shall
be made in accordance with EXHIBIT H.

                                      -81-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

              9.3.2 PROGRAM DIAGNOSTIC REPORTING AND RECONCILIATION.

                  (a) Within [**] days after the end of each calendar quarter,
each Party shall submit a written report to the other Party setting forth in
reasonable detail, separately with respect to each Program Diagnostic in the
United States during such calendar quarter, Program Diagnostic Net Sales of each
Joint Program Diagnostic and each Third Party Program Diagnostic, Program
Diagnostic Standard Cost of Goods Sold, Program Diagnostic Distribution Expenses
and Program Diagnostic Commercialization Expenses incurred by or on behalf of
the reporting Party in the United States during such calendar quarter. Such
report shall provide supporting detail for each of the categories of expenses
included within Program Diagnostic Standard Cost of Goods Sold, Program
Diagnostic Distribution Expenses and Program Diagnostic Commercialization
Expenses.

                  (b) Within [**] days after the end of each calendar quarter,
each Party shall submit a written report to the other Party setting forth in
reasonable detail, separately with respect to each Program Diagnostic in ROW
during the most recently ended reporting quarter for ROW purposes (it is
understood that there is a one (1) month lag behind calendar quarters in ROW
reporting - e.g., the fourth reporting quarter for ROW covers September, October
and November), Program Diagnostic Net Sales of each Joint Program Diagnostic and
each Third Party Program Diagnostic, Program Diagnostic Standard Cost of Goods
Sold, Program Diagnostic Distribution Expenses and Program Diagnostic
Commercialization Expenses incurred by or on behalf of the reporting Party in
ROW during such reporting quarter. Such report shall provide supporting detail
for each of the categories of expenses included within Program Diagnostic
Standard Cost of Goods Sold, Program Diagnostic Distribution Expenses and
Program Diagnostic Commercialization Expenses.

                  (c) Program Diagnostic Commercialization Expenses reported
pursuant to subsections (a) or (b) shall be included in the determination of
Program Diagnostic U.S. Territory Operating Margin/Profit and Program Diagnostic
ROW Territory Operating Margin/Profit, as applicable, only to the extent made or
incurred in conjunction with an approved budget line item in the applicable
Program Diagnostic Budget or as otherwise may be approved by the Joint
Development Committee.

                  (d) Costs and expenses included in Program Diagnostic Standard
Cost of Goods Sold, Program Diagnostic Distribution Expenses and Program
Diagnostic Commercialization Expenses, as well as the deductions taken for
Program Diagnostic Net Sales, shall not be double counted (i.e., any item of
expense included in any expense category shall not also be included in any other
expense category).

                  (e) Within [**] days following the receipt of each Party's
reports under subsections (a) and (b), Abbott shall submit to Millennium a
written report setting forth in reasonable detail the calculation of Program
Diagnostic U.S. Territory Operating Margin/Profit and Program Diagnostic ROW
Territory Operating Margin/Profit and the calculation of any net

                                      -82-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

amount owed by Millennium to Abbott or by Abbott to Millennium, as the case may
be, in order to ensure the sharing of Operating Margin/Profit specified in
Section 9.3.1.

                  (f) The net amounts payable under subsection (e) shall be paid
by Abbott or Millennium, as the case may be, within [**] days after receipt of
each such written report, PROVIDED THAT in the event of a dispute as to the
amounts under subsection (e), the Parties shall resolve such dispute in
accordance with Section 9.1.2(f).

                  (g) The Divisional Vice President and Controller, ADD, of
Abbott shall certify in writing the correctness and completeness of each report
submitted by Abbott hereunder. The Chief Financial Officer, Vice President,
Finance and/or Treasurer of Millennium shall certify in writing the correctness
and completeness of each report submitted by Millennium hereunder.

                  (h) With respect to each calendar quarter (and the
corresponding reporting quarter), each Party shall provide to the other Party
reports setting forth (i) actual Program Diagnostic Net Sales for each of the
first [**] months in such quarter (on a country-by-country basis), to be
provided within [**] days after the end of each such month, (ii) actual Program
Diagnostic Net Sales for such quarter (on a country-by-country basis), to be
provided within [**] days after the end of such quarter, and (iii) the most
current forecast of Program Diagnostic Standard Cost of Goods Sold and Program
Diagnostic Commercialization Expenses for such quarter (broken down on a monthly
basis), to be provided within [**] days after the end of such quarter. The
Parties recognize that the forecasts provided pursuant to subsection (iii) are
estimates only, and the Party providing such forecast shall have no liability to
the other Party based thereon. The Parties agree to consider in good faith the
utilization of more rapid and detailed reporting mechanisms in order to meet the
reporting requirements of the Parties.

         9.4 ABBOTT RELEASED DIAGNOSTIC ROYALTIES AND UNILATERAL DIAGNOSTIC
ROYALTIES.

              9.4.1 ABBOTT RELEASED DIAGNOSTIC ROYALTIES. Abbott shall pay
royalties to Millennium on aggregate worldwide Abbott Released Diagnostic Net
Sales made during the term set forth in Section 9.4.4 of each Royalty-Bearing
Abbott Released Diagnostic as follows:



                                      -83-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

<TABLE>
<CAPTION>

        ANNUAL WORLDWIDE SALES LEVEL                        PERCENTAGE
        <S>                                                 <C>
        $[**] million                                       [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
</TABLE>


         Royalties on Abbott Released Diagnostic Net Sales of each
Royalty-Bearing Abbott Released Diagnostic in a calendar year shall be paid at
the rate applicable to the portion of Abbott Released Unilateral Net Sales
within each of the Abbott Released Diagnostic Net Sales levels above during each
calendar year. A "Royalty-Bearing Abbott Released Diagnostic" shall mean an
Abbott Released Diagnostic Covered by a Valid Claim included in a Millennium
Patent Right.

              9.4.2 UNILATERAL DIAGNOSTIC ROYALTIES. The Royalty-Paying Party
shall pay royalties to the other Party on aggregate worldwide Unilateral
Diagnostic Net Sales of each Royalty-Bearing Unilateral Diagnostic as follows:

<TABLE>
<CAPTION>

        ANNUAL WORLDWIDE SALES LEVEL                        PERCENTAGE
        <S>                                                 <C>
        $[**] million                                       [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
        GREATER THAN $[**] million                          [**]%
</TABLE>


         Royalties on Unilateral Diagnostic Net Sales of each Royalty-Bearing
Unilateral Diagnostic in a calendar year shall be paid at the rate applicable to
the portion of Unilateral Diagnostic Net Sales within each of the Unilateral
Diagnostic Net Sales levels above during each calendar year. A "Royalty-Bearing
Unilateral Diagnostic" shall mean a Unilateral Diagnostic Covered by a Valid
Claim included in a Patent Right of the Party other than the Royalty-Paying
Party.

                                      -84-
<PAGE>

              9.4.3 ADJUSTMENTS.

                  (a) It is understood by the Parties that an Abbott Released
Diagnostic or Unilateral Diagnostic may be sold under a reagent agreement plan,
or analogous agreement, where a purchaser is provided an instrument for use in
conjunction with such Diagnostic and the costs associated with the placement and
use of the instrument are not separately billed, but instead represent some
portion of the purchase price of such Diagnostic. In such instance, the
transaction does not enable an accurate determination of the Abbott Released
Diagnostic Net Sales or Unilateral Diagnostic Net Sales, as the case may be.
Accordingly, the Abbott Released Diagnostic Net Sales or Unilateral Diagnostic
Net Sales for those units of a Diagnostic which are sold on a reagent agreement
plan or analogous basis shall be calculated by multiplying for each such
Diagnostic, on a country-by-country basis, (i) the average Abbott Released
Diagnostic Net Sales per unit or the average Unilateral Diagnostic Net Sales per
unit, as the case may be, when such Diagnostic is sold during the royalty paying
period in question to end users on other than a reagent agreement plan or
analogous basis, by (ii) the number of such units of such Diagnostic sold on a
reagent agreement plan or analogous basis during the period for which the Abbott
Released Diagnostic Net Sales or Unilateral Diagnostic Net Sales, as the case
may be, is being calculated.

                  (b) If no Abbott Released Diagnostic or Unilateral Diagnostic,
as the case may be, is sold other than under a reagent agreement plan or
analogous basis during the period for which Abbott Released Diagnostic Net Sales
or Unilateral Diagnostic Net Sales, as the case may be, is being calculated,
then the Abbott Released Diagnostic Net Sales or Unilateral Diagnostic Net Sales
for purposes of determining royalty payments shall be the Abbott Released
Diagnostic Net Sales or Unilateral Diagnostic Net Sales, as the case may be,
reduced by the amount of allocated instrument price, that amount being
calculated by multiplying the number of cumulative installed instruments
amortized for that period, by that portion of amortization applicable for such
products and period, that amortization being established in accordance with
United States generally accepted accounting principles.

              9.4.4 TERM. With respect to each Abbott Released Diagnostic and
each Abbott Unilateral Diagnostic, royalties pursuant to this Section 9.4 shall
be payable by Abbott, on a country-by-country basis, for the term of any Patent
Rights Controlled by Millennium with a Valid Claim covering the composition of
matter, use, assay configuration or manufacture of such Abbott Released
Diagnostic or Abbott Unilateral Diagnostic in such country. With respect to each
Millennium Unilateral Diagnostic, royalties pursuant to this Section 9.4 shall
be payable by Millennium, on a country-by-country basis, for the term of any
Patent Rights Controlled by Abbott with a Valid Claim covering the composition
of matter, use, assay configuration or manufacture of such Millennium Unilateral
Diagnostic in such country.

              9.4.5 DIAGNOSTIC THIRD PARTY FEES AND ROYALTIES. With respect to
each Abbott Released Diagnostic or Unilateral Diagnostic, the Royalty-Paying
Party shall be responsible for all fees and royalties due Third Parties,
including commitments to Third Parties made by the other Party and disclosed to
the Royalty-Paying Party as Burdened Technology Obligations.

                                      -85-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         9.5 ROYALTY REPORTS; PAYMENTS. Within [**] days after the end of each
calendar quarter in which a Party is the Royalty-Paying Party with respect to
Net Sales of any Royalty-Bearing Product subject to any of the provisions of
Sections 9.2 and 9.4, such Party shall submit to the other Party a report, on
the basis of each product and country, providing in reasonable detail an
accounting of all Net Sales (as adjusted pursuant to Section 9.4.3) of all
Royalty-Bearing Products made during such calendar quarter and the calculation
of the applicable royalty under Section 9.2 and/or Section 9.4. Concurrently
with such report, the Royalty-Paying Party submitting the report shall pay to
the other Party all royalties payable by it under Section 9.2 and/or Section 9.4
as indicated in the report.

         9.6 AUDITS. Each Party shall keep complete and accurate records of the
underlying revenue and expense data relating to the reports and payments
required by Sections 9.1, 9.3 and 9.5. Each Party shall have the right once
annually at its own expense to have an independent, certified public accountant,
selected by such Party and reasonably acceptable to the other Party, review any
such records of the other Party in the location(s) where such records are
maintained by the other Party upon reasonable notice and during regular business
hours and under obligations of strict confidence, for the sole purpose of
verifying the basis and accuracy of payments made under Sections 9.1, 9.3 and
9.5, in each case within the prior twenty-four (24) month period. If the review
of such records reveals that the other Party has failed to accurately report
information pursuant to Section 9.1, Section 9.3 and Section 9.5, then the other
Party shall promptly pay to the auditing Party any resulting amounts due under
Section 9.1, Section 9.3 or Section 9.5, together with interest calculated in
the manner provided in Section 9.9. If any amounts due under Section 9.1,
Section 9.3 or Section 9.5 as a result of such audit are greater than five
percent (5%) of the amounts actually due for a calendar year under Section 9.1,
Section 9.3 or Section 9.5, as applicable, the other Party shall pay the
reasonable costs of such review. If a Party in good faith disputes any
conclusion of the accounting firm under this Section 9.6, including that such
Party owes additional amounts, then such Party shall inform the other Party by
written notice within thirty (30) days of receipt of a copy of the audit in
question, specifying in detail such dispute. The Parties shall promptly
thereafter meet and negotiate in good faith a resolution to such dispute. In the
event that the Parties are unable to resolve such dispute within sixty (60) days
after notice by the disputing Party, the matter shall be resolved in a manner
consistent with the procedures set forth in Article 13 (PROVIDED THAT, in the
case that the matter has not been resolved by the Executive Officers, rather
than invoking ADR under Section 13.5, the Parties shall (i) use reasonable
efforts to reach agreement on the appointment of one (1)
internationally-recognized independent accounting firm to determine the matter,
(ii) if the Parties cannot reach agreement on such accounting firm, then each
Party shall appoint one (1) internationally-recognized accounting firm to
determine the matter, and (iii) if such firms cannot reach agreement, such firms
shall choose a third internationally-recognized independent accounting firm to
make the final determination), and interest shall be payable on any disputed
amounts determined to be due in the same manner as provided for in Section 9.9.

         9.7 TAX MATTERS. Any income or other taxes which a paying Party is
required by law to pay or withhold on behalf of a receiving Party with respect
to royalties or other payments payable to a receiving Party under this Agreement
shall be deducted from the amount of such

                                      -86-
<PAGE>

royalties or other payments due, and paid or withheld as appropriate, by the
paying Party on behalf of the receiving Party. Any such tax required by law to
be paid or withheld shall be an expense of, and borne solely by, the receiving
Party. The paying Party shall furnish the receiving Party with the best
available evidence of such payment or amount withheld as soon as practicable
after such payment is made or such amount is withheld. The Parties will
reasonably cooperate in completing and filing documents required under the
provisions of any applicable tax laws or under any other applicable law in
connection with the making of any required tax payment or withholding payment,
in connection with a claim of exemption from, or entitlement to, a reduced rate
of withholding or in connection with any claim to a refund of or credit for any
such payment. The Parties acknowledge that this Agreement constitutes a
partnership for United States federal income tax purposes. Accordingly, the
Parties agree to file all required federal, state, and local tax returns and to
make any appropriate elections, including an election to deduct currently
research and development expenditures incurred by the partnership pursuant to
Section 174(a) of the Internal Revenue Code. In addition, the Parties agree that
Abbott shall act as the tax matters partner within the meaning of Section
6231(a)(7) of the Internal Revenue Code and in any similar capacity under state
or local law with all the rights and duties of a tax matters partner set forth
in Sections 6221 through 6234 of the Code; PROVIDED THAT the Parties shall
consult and agree upon any election to be made, return to be filed or action to
be taken in Abbott's capacity as tax matters partner.

         9.8 CURRENCY EXCHANGE. With respect to Net Sales invoiced or expenses
incurred in United States dollars, the Net Sales, expense amounts and amounts
due to the receiving Party hereunder shall be expressed in United States
dollars. With respect to Net Sales invoiced or expenses incurred in a currency
other than United States dollars, the Net Sales or expense shall be expressed in
the domestic currency of the entity making the sale or incurring the expense,
together with the United States dollar equivalent, calculated using the
arithmetic average of the spot rates on the second to last business day of each
month of the calendar quarter in which Net Sales were made or the expense was
incurred. The exchange rates for the conversion of foreign currency into United
States dollars established by Reuters as of 9:00 a.m. Central Standard Time on
the second to last business day of each month in the relevant calendar quarter
shall be used as the source of spot rates to calculate the average as defined in
the preceding sentence. All payments shall be made in United States dollars in
immediately available funds. If at any time legal restrictions in any country in
the Territory prevent the prompt remittance of any payments with respect to
sales in that country, the paying Party shall have the right and option to make
such payments by depositing the amount thereof in local currency to the
receiving Party's account in a bank or depository in such country.

         9.9 LATE PAYMENTS. The paying Party shall pay interest to the receiving
Party on the aggregate amount of any payments that are not paid on or before the
date such payments are due under this Agreement at a rate per annum equal to the
lesser of the prime rate of interest plus one percent (1%), as reported by THE
WALL STREET JOURNAL, or the highest rate permitted by applicable law, calculated
on the number of days such payments are paid after the date such payments are
due.

         9.10 MODE OF PAYMENT. Unless otherwise agreed by the Parties, all
payments required to be made under this Agreement shall be made via wire
transfer to an account designated in advance by the receiving Party.

                                      -87-
<PAGE>

         9.11 EFFECT OF FUTURE CHANGES. The Parties understand that some length
of time may pass before products are Commercialized and that generally accepted
accounting principles and internal procedures of the Parties may change during
that time. Accordingly, the Parties may, by mutual agreement, make appropriate
future adjustments to the reports required under Section 9.1.2 and Section 9.3.2
to account for such changes.

                                   ARTICLE 10

         INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS

         10.1 OWNERSHIP.

              10.1.1 INVENTIONS. Inventorship for patentable inventions
conceived or reduced to practice during the course of the performance of
activities pursuant to this Agreement shall be determined in accordance with
United States patent laws for determining inventorship. Subject to the
provisions set forth in Section 10.1.2, ownership shall be initially determined
based on inventorship. In the event of a dispute regarding inventorship, if the
Parties are unable to resolve such inventorship dispute, in lieu of the
requirements set forth in Article 13, the Joint Executive Committee shall
establish a procedure to resolve such dispute, which may include engaging a
Third Party patent attorney jointly selected by the Parties to resolve such
dispute, which resolution by such patent attorney shall be binding upon the
Parties.

              10.1.2 ASSIGNMENT OF OWNERSHIP.

                  (a) In the event a Party is deemed an owner or joint owner of
a patentable invention conceived or reduced to practice in the conduct of the
Research Program and that invention directly relates to (i) a target (including,
without limitation, a Druggable Target, a Biotherapeutic Gene, Antibodies
directed to such target, Antisense Molecules or Other Molecules directed to or
derived from such target and Proteins corresponding to such target)
(collectively a "Target Family"), (ii) the utility of such Target Family, or
(iii) the use of such Target Family for target validation and identification
activities, then such Party or Parties, as the case may be, shall assign its or
their entire right, title and interest in such invention to the Party or
Parties, if any, that owns such target or first identified such target to the
Research Program pursuant to Section 3.6.1(b). Any inventions covered by both
Section 10.1.2(a) and 10.1.2(b) shall be governed by Section 10.1.2(b).

                  (b) In the event a Party is deemed an owner or joint owner of
a patentable invention conceived or reduced to practice in the conduct of the
Research Program that directly relates to (i) a Program Compound or a Small
Molecule in its Program Compound Family, (ii) a use of a Program Compound or a
Small Molecule in its Program Compound Family, or (iii) a method of making a
Program Compound or a Small Molecule in its Program Compound Family, then the
Party or Parties, as the case may be, shall assign its or their entire right,
title and interest in such invention to the Party or Parties, if any, that owns
the Small Molecule chemical library from which such Program Compound originated
or was derived.

         10.2 PROSECUTION AND MAINTENANCE OF PATENT RIGHTS.

                                      -88-
<PAGE>

              10.2.1 PRIMARY PROSECUTION RIGHTS. The responsibility for (a)
preparing, filing and prosecuting patent applications (including reissue,
continuing, divisional, and substitute applications and any foreign counterparts
thereof); (b) for maintaining any Patent Rights; and (c) for managing any
interference or opposition proceedings relating to the foregoing ("Patent
Prosecution") Covering an invention conceived or reduced to practice during the
course of the performance of activities pursuant to this Agreement shall be the
responsibility of the Party owning such invention, PROVIDED HOWEVER, that with
respect to any such invention that is jointly owned by the Parties, such
responsibility shall be shared by the Parties as determined by agreement of the
Parties on a case-by-case basis. All Patent Prosecution expenses, including
attorneys' fees, incurred by a Party in the performance of Patent Prosecution
shall be borne by such Party or, in the case of an invention that is jointly
owned, shared by the Parties as agreed.

              10.2.2 SECONDARY PROSECUTION RIGHTS. If the prosecuting Party
elects not to continue pursuing Patent Prosecution with respect to any rights
within Patent Rights and the other Party has rights under such Patent Rights,
then the prosecuting Party shall, subject to any contractual obligations to
Third Parties, notify the other Party in writing of such election at least
thirty (30) days prior to the last available date for action to preserve such
Patent Rights. If such other Party elects to continue Patent Prosecution, such
other Party may do so at its sole expense.

              10.2.3 COOPERATION. Each Party hereby agrees:

                  (a) to make its employees, agents and consultants reasonably
available to the other Party (or to the other Party's authorized attorneys,
agents or representatives), to the extent reasonably necessary to enable the
prosecuting Party to undertake Patent Prosecution,

                  (b) to provide the other Party with copies of all material
correspondence pertaining to Patent Prosecution with the United States Patent
and Trademark Office or its foreign counterparts;

                  (c) to cooperate, if necessary and appropriate, with the other
Party in gaining patent term extensions wherever applicable to Patent Rights;
and

                  (d) to endeavor in good faith to coordinate its efforts with
the other Party to minimize or avoid interference with the Patent Prosecution of
the other Party's patent applications.

         10.3 EXPLOITATION OF JOINT INVENTIONS. Subject to any provision of this
Agreement to the contrary, each of the Parties shall be free to exploit any
invention conceived or reduced to practice during the course of the performance
of activities pursuant to this Agreement and that is jointly owned by the
Parties without payment of any additional compensation to the other Party;
provided THAT either Party may only sell, license or otherwise transfer its
rights in any such invention without the consent of the other Party in a manner
that is consistent with the licenses granted pursuant to this Agreement and is
otherwise consistent with this Agreement.

                                      -89-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         10.4 THIRD PARTY INFRINGEMENT.

              10.4.1 NOTICE. Each Party shall promptly provide the other Party
with written notice reasonably detailing any known or alleged infringement of
the other Party's Program Patent Rights by a Third Party.

              10.4.2 JOINT PRODUCTS AND PROGRAM DIAGNOSTICS.

                  (a) The Joint Executive Committee shall make all
determinations concerning the institution and direction of legal proceedings
against any Third Party believed to be infringing Patent Rights that Cover the
composition of matter or use of any Joint Product or any Program Diagnostic or
that Cover Manufacturing processes, formulations or assay configurations
specific to any such Joint Product or any such Program Diagnostic
("Product-Specific Patent Rights"). All costs, including attorneys' fees,
relating to such legal proceedings shall be included in Commercialization
Expenses for the Joint Product or Program Diagnostic, as applicable. All
recoveries resulting from such legal proceedings shall be deemed to be Joint
Product Net Sales of the applicable Joint Product or Program Diagnostic Net
Sales of the applicable Program Diagnostic.

                  (b) Each Party shall have the sole right, but not the
obligation, to institute and direct legal proceedings against any Third Party
believed to be infringing any Patent Rights other than Product-Specific Patent
Rights of such Party ("Owning Party"), that Covers an invention that relates to
a Joint Product or a Program Diagnostic; PROVIDED THAT the Parties shall
mutually agree on a course of action for instituting and directing legal
proceedings against any Third Party believed to be infringing any such Patent
Rights that are jointly owned by the Parties. If the Owning Party, (a) within
ninety (90) days of a notice of infringement pursuant to Section 10.4.1, has not
provided written notice of potential infringement to such Third Party, or (b)
within one hundred eighty (180) days of a notice of infringement pursuant to
Section 10.4.1, has not commenced bona fide discussions with such Third Party
concerning such infringement or instituted appropriate legal proceedings against
such Third Party, the other Party may request consent from the Owning Party to
institute and direct legal proceedings against such Third Party, including in
the name of the Owning Party, which consent shall not be unreasonably withheld.
The Owning Party shall respond to such request within thirty (30) days of
receipt of such request in writing. All out-of-pocket costs, including
attorneys' fees, relating to such legal proceedings shall be borne by the Party
that owns such Patent Rights or, in the case of Patent Rights that are jointly
owned, shared by the Parties as agreed by the Parties. If the Parties share the
expense, any recoveries shall be divided between the Parties in proportion with
their contribution to the expenses. If only one Party is bearing the expense,
then the Party not bearing any of the expense shall receive [**] percent ([**]%)
of all recoveries directed to compensatory damages and [**] percent ([**]%) of
all recoveries directed to punitive or other damages in excess of such Party's
costs, including attorney's fees.

              10.4.3 UNILATERAL DDCS, UNILATERAL DIAGNOSTICS AND UNILATERAL
PRODUCTS. Each Party shall have the sole right, but not the obligation, to
institute and direct legal proceedings

                                      -90-
<PAGE>

against any Third Party believed to be infringing the Program Patent Rights
owned by such Party that Covers an invention that relates to a Unilateral DDC,
Unilateral Diagnostic or Unilateral Product sold by such Party or sold by the
other Party, PROVIDED THAT the Parties shall mutually agree on a course of
action for instituting and directing legal proceedings against any Third Party
believed to be infringing any such Program Patent Rights that are jointly owned
by the Parties. All out-of-pocket costs, including attorneys' fees, or
recoveries relating to such legal proceedings shall be borne by the Party that
owns such Program Patent Rights or, in the case of Program Patent Rights that
are jointly owned, shall be shared by the Parties as agreed. All recoveries
resulting from such legal proceeding in excess of the Party's or Parties' costs,
including attorney's fees, shall be deemed to be Net Sales of the applicable
Unilateral Diagnostic or Unilateral Product.

              10.4.4 FAILURE TO INSTITUTE PROCEEDINGS. With respect to Program
Patent Rights which are solely owned by a Party ("Non-Selling Party") Covering a
Unilateral DDC, Unilateral Diagnostic or Unilateral Product sold by the other
Party ("Selling Party"), if the Non-Selling Party, (a) within ninety (90) days
of a notice of infringement pursuant to Section 10.4.1, has not provided written
notice of potential infringement to such Third Party, or (b) within one hundred
eighty (180) days of a notice of infringement from the Selling Party pursuant to
Section 10.4.1, has not commenced bona fide discussions with such Third Party
that is selling a product or providing a service in competition with such
Selling Party's product or service concerning such infringement or instituted
appropriate legal proceedings against such Third Party, such Selling Party may
request consent from the Non-Selling Party to institute such legal proceedings,
including in the name of the Non-Selling Party, which consent shall not be
unreasonably withheld. The Non-Selling Party shall respond to such request
within thirty (30) days of receipt of such request in writing. All costs,
including attorneys' fees, relating to such legal proceedings shall be borne by
the Selling Party. Any recoveries in excess of costs incurred by the Selling
Party in pursuing any such legal proceedings ("Excess Recovery") shall belong to
the Selling Party; PROVIDED THAT the Selling Party shall pay to the Non-Selling
Party the amount of any royalty that would be due to the Non-Selling Party if
such Excess Recovery had been Net Sales made by the Selling Party of such
Selling Party's product.

              10.4.5 COOPERATION IN PATENT INFRINGEMENT PROCEEDINGS. In the
event that either Abbott or Millennium takes action pursuant to this Section
10.4 ("Acting Party"), the other Party shall cooperate to the extent reasonably
necessary and at the Acting Party's sole expense. Such cooperation shall
include, without limitation, providing information, documents, witnesses and
consultation to the Acting Party; PROVIDED THAT such cooperation shall not
include the obligation to assert any patent rights or other intellectual
property rights Controlled by the other Party that such other Party is not
obligated to assert or allow the Acting Party to assert except as otherwise
expressly provided in this Agreement. Upon the reasonable request of the Acting
Party, such other Party shall join the suit and shall be represented in any such
legal proceedings using counsel of its own choice. Neither Party shall settle
any claim or proceeding relating to Program Patent Rights owned in whole or in
part by the other Party without the prior written consent of such other Party,
which consent shall not be unreasonably withheld.

         10.5 OTHER INTELLECTUAL PROPERTY INFRINGEMENT.

              10.5.1 NOTICE.

                                      -91-
<PAGE>

                  (a) Each Party shall notify the other in writing of any
allegations it receives from a Third Party that Program Materials, Program
Technology, any Joint Product, any Program Diagnostic, any Unilateral Diagnostic
or any Unilateral Product infringes the intellectual property rights of such
Third Party. Such notice shall be provided promptly, but in no event after more
than fifteen (15) days following receipt of such allegations. In the event that
a Party receives notice that it or any of its Affiliates have been individually
named as a defendant in a legal proceeding by a Third Party alleging
infringement of a Third Party patent or other intellectual property right as a
result of the manufacture, production, use, development, sale or distribution of
Program Materials, Program Technology, any Joint Product, any Program
Diagnostic, any Unilateral Diagnostic or any Unilateral Product, such Party
shall immediately notify the other Party in writing and in no event notify them
later than ten (10) days after the receipt of such notice. Such written notice
shall include a copy of any summons or complaint (or the equivalent thereof)
received regarding the foregoing.

                  (b) Each Party shall provide to the other Party copies of any
notices it receives from Third Parties regarding any patent nullity actions, any
declaratory judgment actions, any alleged infringement of Program Patent Rights
or any alleged misappropriation of intellectual property with respect to Program
Materials, Program Technology, any Joint Product, any Program Diagnostic, any
Unilateral Diagnostic or any Unilateral Product. Such notices shall be provided
promptly, but in no event after more than fifteen (15) days following receipt
thereof.

              10.5.2 COOPERATION IN INTELLECTUAL PROPERTY INFRINGEMENT
PROCEEDINGS. In all cases where a claim is made by a Third Party and for which
notice was given in accordance with Section 10.5.1, the Parties shall cooperate
and mutually determine a course of action and shall share expenses equally. If
such claim is against only one Party with respect to a Unilateral DDC,
Unilateral Diagnostic or Unilateral Product, such Party shall have sole
discretion in determining and executing an appropriate course of action at its
sole expense. Such cooperation by a Party shall include, without limitation,
providing information, documents, witnesses and consultation to the other Party;
PROVIDED THAT such cooperation shall not include the obligation to assert any
patent rights or other intellectual property rights Controlled by the Party that
such Party is not obligated to assert or allow the other Party to assert as
expressly provided in this Agreement.

         10.6 TRADEMARKS.

              10.6.1 OWNERSHIP OF TRADEMARKS. The Joint Commercialization
Committee shall select the trademarks and service marks associated with
Commercializing a Joint Product or a Program Diagnostic (collectively, "Marks").
The Joint Executive Committee shall determine for each Joint DDC which Party
(the "Trademark-Owning Party") shall own the Marks. The Trademark-Owning Party
shall be responsible for filing and maintaining the Marks (including payment of
costs associated therewith) subject to reimbursement of such costs as
Commercialization Expenses. The Trademark-Owning Party shall consider in good
faith the comments of the other Party. The Trademark-Owning Party shall also own
any domain names including any Marks.

              10.6.2 LICENSE. The Trademark-Owning Party shall grant to the
other Party a license to such Marks and domain names solely for the purposes of
performing its obligations and exercising its rights relating to the Development
and Commercialization of a Joint Product or


                                      -92-
<PAGE>

a Program Diagnostic or a Joint Product or Program Diagnostic that becomes a
Unilateral Diagnostic or Unilateral Product subsequent to the filing of the
Marks. Each Party shall have the right to monitor the quality of such products
in accordance with reasonable procedures to be agreed upon by the Parties.

              10.6.3 NO OTHER RIGHTS. Except as expressly stated in this
Agreement, the other Party shall not have any right, title, interest or other
license in or to any of the Marks, and all uses of such Marks shall inure solely
to the benefit of the Trademark-Owning Party.

              10.6.4 AGREEMENT NOT TO CONTEST. Each Party agrees not to contest
the validity of, by act or omission jeopardize, or take any action inconsistent
with, the other Party's rights or goodwill in any of its Marks in any country,
including, without limitation, attempted registration of any such Mark, or use
or attempted registration of any confusingly similar names, trademarks or logos.

              10.6.5 THIRD PARTY INFRINGEMENT. In the event that either Party
becomes aware of any infringement of a Mark by a Third Party, it shall promptly
notify the other and the Parties shall consult with each other and jointly
determine the best way to prevent such infringement, including without
limitation by the institution of legal proceedings against such Third Party. All
out-of-pocket costs, including attorneys' fees, relating to such legal
proceedings shall be included in Commercialization Expenses. All recoveries
resulting from such legal proceedings shall be deemed to be Joint Product Net
Sales of the Joint Product or Program Diagnostic Net Sales of the Program
Diagnostic with which the infringed Mark is used.

         10.7 PATENT TERM EXTENSIONS. Each Party shall provide (a) notice of
patents relevant to Regulatory Approvals in the United States, prior to the time
the related applications for Regulatory Approvals are filed, and (b) immediate
notice of the issuance of any patent which will be a patent relevant to a Joint
Product or a Unilateral Product, giving the date of issue and patent number for
each such patent and the Parties will jointly decide within thirty (30) days of
the patent issue if the patent is to be listed pursuant to any Regulatory
Approval submission for such Joint Product or such Unilateral Product.
Similarly, the Parties shall provide immediate notice of any approved Regulatory
Approval submission and of patent term extensions in any country. The Parties
will cooperate with each other in the preparation and filing of patent listings
and patent term extensions relating to Joint Products and Unilateral Products,
and shall mutually determine whether one or both Parties will proceed in filing
of appropriate listing and patent term extension documents.

         10.8 MANUFACTURING PROCESS INQUIRIES. Each Party will provide prompt
notice to the other of any inquiries as to any relevant patent which has claims
to Manufacturing processes, which inquiries are provided pursuant to 35 USC ss.
271(g), and will cooperate with respect to responses thereto. Each Party shall
file any patent term extensions that the Parties determine should be filed. If
the Parties cannot agree on whether or not patent term extensions should be
filed or on which eligible patent should be extended, such issue shall be
decided in accordance with Section 13.5; PROVIDED THAT in such case the Neutral
shall be an individual experienced in patent term extension issues (including
proper strategies for selection of appropriate patents for extension). Each
Party shall file any patent term extensions that the Neutral determines should
be filed.

                                      -93-
<PAGE>

                                   ARTICLE 11

                                 CONFIDENTIALITY

         11.1 CONFIDENTIAL INFORMATION. All Confidential Information disclosed
by a Party or its Affiliates to the other Party or its Affiliates during the
term of this Agreement shall not be used by the receiving Party or its
Affiliates except in connection with the activities contemplated by this
Agreement or in order to further the purposes of this Agreement, shall be
maintained in confidence by the receiving Party and its Affiliates and shall not
otherwise be disclosed by the receiving Party or its Affiliates to any Third
Party who is not an Affiliate or consultant of, or an advisor to, the receiving
Party, without the prior written consent of the disclosing Party, except to the
extent that the Confidential Information: (a) was known or used by the receiving
Party or its Affiliates prior to its date of disclosure to the receiving Party,
as demonstrated by legally admissible evidence available to the receiving Party
or its Affiliates; (b) either before or after the date of the disclosure to the
receiving Party is lawfully disclosed to the receiving Party or its Affiliates
by sources other than the disclosing Party rightfully in possession of the
Confidential Information and not bound by confidentiality obligations to the
disclosing Party; (c) either before or after the date of the disclosure to the
receiving Party or its Affiliates becomes published or generally known to the
public through no fault or omission on the part of the receiving Party or its
Affiliates; or (d) is independently developed by or for the receiving Party or
its Affiliates without reference to or reliance upon the Confidential
Information, as demonstrated by competent written records. In addition, the
provisions of this Section 11.1 shall not preclude the receiving Party or its
Affiliates from disclosing Confidential Information to the extent such
Confidential Information is required to be disclosed by the receiving Party or
its Affiliates to comply with applicable laws, to defend or prosecute litigation
or to comply with governmental regulations, PROVIDED THAT the receiving Party
provides prior written notice of such disclosure to the disclosing Party,
provides the disclosing Party, to the extent possible, with sufficient time and
opportunity to obtain a protective order for such Confidential Information and
takes reasonable and lawful actions to avoid and/or minimize the degree of such
disclosure. Specific information shall not be deemed to be within any of the
foregoing exclusions merely because it is embraced by more general information
falling within these exclusions. All Confidential Information disclosed by a
Party pursuant to the Confidential Disclosure Agreement between the Parties
dated January 5, 2000, as amended, shall be deemed to have been disclosed by the
disclosing Party under this Agreement.

         11.2 EMPLOYEE AND ADVISOR OBLIGATIONS. Millennium and Abbott each agree
that they shall provide Confidential Information received from the other Party
only to their respective employees, consultants and advisors, and to the
employees, consultants and advisors of such Party's Affiliates, who have a need
to know such Confidential Information to assist such Party in fulfilling its
obligations under this Agreement, PROVIDED THAT such employees, consultants and
advisors agree to treat such information and materials as confidential.

                                      -94-
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

         11.3 TERM. All obligations of confidentiality imposed under this
Article 11 shall expire [**] years following termination or expiration of this
Agreement.

         11.4 PUBLICATIONS. Subject to the restrictions provided below, either
Party may publish or present the results of research or Development carried out
on any Joint DDC or Unilateral DDC or the results of development carried out on
any Diagnostic, subject to the prior review by the other Party for all purposes
in the case of a Joint DDC or a Program Diagnostic and for patentability and
protection of such other Party's Confidential Information in the case of an
Abbott Released Diagnostic, a Unilateral DDC or a Unilateral Diagnostic. Each
Party shall provide to the other Party the opportunity to review and approve any
proposed abstracts, manuscripts or summaries of presentations which cover the
results of research or Development of such Joint DDC or Unilateral DDC or
development of such Diagnostic. Each Party shall designate a person who shall be
responsible for approving such publications. Such designated person shall
respond in writing promptly and in no event later than sixty (60) days after
receipt of the proposed material with either approval of the proposed material
or a specific statement of concern, based upon any concern in the case of a
Joint DDC or Program Diagnostic and based upon either the need to seek patent
protection or concern regarding competitive disadvantage arising from the
proposal in the case of the Abbott Released Diagnostic, Unilateral DDC or
Unilateral Diagnostic. In the event of concern in the case of a Joint DDC or
Program Diagnostic, the submitting Party agrees not to submit such publication
or to make such presentation that contains such information until the other
Party has provided its written approval. In the event of concern in the case of
an Abbott Released Diagnostic, Unilateral DDC or Unilateral Diagnostic, the
submitting Party agrees not to submit such publication or to make such
presentation that contains such information until the other Party is given a
reasonable period of time (not to exceed ninety (90) days) to seek patent
protection for any material in such publication or presentation which it
believes is patentable or to resolve any other issues. With respect to any
proposed abstracts, manuscripts or summaries of presentations by investigators
or other Third Parties, such materials shall be subject to review under this
Section 11.4 to the extent that Abbott or Millennium, as the case may be, has
the right to do so.

                                   ARTICLE 12

                              TERM AND TERMINATION

         12.1 TERM. This Agreement becomes effective as of the Effective Date
and may be terminated as set forth in this Article 12.

         12.2 TERMINATION FOR MATERIAL BREACH.

              12.2.1 TERMINATION RIGHTS. Upon a material breach of this
Agreement by Abbott or Millennium (in such capacity, the "Breaching Party"), the
other Party (in such capacity, the "Non-Breaching Party") may provide written
notice (a "Breach Notice") to the Breaching Party specifying the material
breach. If the Parties dispute whether a Party has materially breached the
Agreement, the matter shall be referred to ADR under Section 13.5. If (i) the
Breaching Party

                                      -95-
<PAGE>

fails to cure such material breach during the sixty (60) day period (or, if such
material breach, by its nature, is a curable breach that is not curable within
the sixty (60) day period, such longer period as would be reasonably necessary
for a diligent party to cure such material breach) following the date on which
the Breach Notice is provided (subject to extension as provided in Section
12.3), or (ii) such material breach, by its nature, is incurable, then the
Agreement shall terminate, PROVIDED THAT (A) if there is a dispute as to whether
a material breach has been cured or is incurable, such matter shall be referred
to ADR and termination shall be stayed pending resolution of such ADR
proceedings, and (B) to the extent specified in Sections 12.2.2 through 12.2.7,
this Agreement itself shall not terminate but rather certain provisions or
rights and obligations of the Parties shall terminate. The Parties shall use
reasonable efforts to work together to cure any breach, and shall endeavor in
good faith to work together to avoid the termination of a Party's rights where
reasonably possible.

              12.2.2 MATERIAL BREACH RELATING TO THE RESEARCH PROGRAM. If the
material breach relates to the Breaching Party's obligations under the Research
Program, then only the Research Program shall terminate.

              12.2.3 MATERIAL BREACH RELATING TO EXCLUSIVITY PROVISIONS. If the
material breach relates to the Breaching Party's obligations under Section 2.1,
the Non-Breaching Party may terminate any of the covenants set forth in Sections
2.1.1, 2.1.3, 2.1.4, 2.1.5, 2.1.6 and 2.1.7 as it applies to the Non-Breaching
Party, as one of its remedies and not to the exclusion of any other remedy such
Party may have.

              12.2.4 MATERIAL BREACH RELATING TO THE RESEARCH OF A UNILATERAL
TARGET OR THE DEVELOPMENT OR COMMERCIALIZATION OF A UNILATERAL DDC OR A
UNILATERAL PRODUCT. If the material breach relates to the Breaching Party's
obligations relating to the (a) research of a Unilateral Target or (b) the
Development and/or Commercialization of a Unilateral DDC and/or a Unilateral
Product, then this Agreement shall not terminate in its entirety, but (i) the
licenses granted to the Breaching Party under this Agreement with respect to the
(A) research of such Unilateral Target or (B) the Development and
Commercialization of such Unilateral DDC or Unilateral Product, shall terminate;
(ii) the Breaching Party hereby grants to the Non-Breaching Party a worldwide,
exclusive (even as to the Breaching Party), non-royalty bearing, perpetual
license under the sole or undivided one half (as applicable) right, title and
interest in the Program Patent Rights or other intellectual property of the
Breaching Party previously assigned by the Non-Breaching Party to the Breaching
Party pursuant to Section 10.1.2 directly relating to either such Unilateral
Target or such Unilateral DDC and/or Unilateral Product, for either the research
of such Unilateral Target or the development and Commercialization of such
Unilateral DDC or Unilateral Product, and (iii) the licenses granted to the
Breaching Party under this Agreement with respect to the development and
Commercialization of any related Unilateral Diagnostic shall also terminate,
provided THAT, if, at the time of such termination, such Unilateral Diagnostic
is being marketed by the Breaching Party or is automated onto the Abbott
Diagnostic Platform or a Third Party Diagnostic Platform, then, in lieu of such
termination, the licenses granted herein to the Breaching Party shall become
non-exclusive and the exclusivity provisions of Section 2.1.5 with respect to
such Unilateral Target shall terminate. The exclusivity provisions set forth in
Section 2.1.3 shall not apply to the Non-Breaching Party with respect to such
Unilateral Target, Unilateral DDC, or Unilateral Product.


                                      -96-
<PAGE>

              12.2.5 MATERIAL BREACH RELATING TO THE DEVELOPMENT OR
COMMERCIALIZATION OF AN ABBOTT RELEASED DIAGNOSTIC OR A UNILATERAL DIAGNOSTIC.
If the material breach relates to the Breaching Party's obligations relating to
the development and/or Commercialization of an Abbott Released Diagnostic or a
Unilateral Diagnostic, then this Agreement shall not terminate in its entirety,
but (a) the licenses granted to the Breaching Party under this Agreement with
respect to the development and Commercialization of such Abbott Released
Diagnostic or Unilateral Diagnostic, shall terminate; and (b) the Breaching
Party hereby grants to the Non-Breaching Party a worldwide, exclusive (even as
to the Breaching Party), non-royalty bearing, perpetual license under the sole
or undivided one half (as applicable) right, title and interest in the Program
Patent Rights or other intellectual property of the Breaching Party previously
assigned by the Non-Breaching Party to the Breaching Party pursuant to Section
10.1.2 directly relating to such Abbott Released Diagnostic or Unilateral
Diagnostic and for the development and Commercialization of such Abbott Released
Diagnostic or Unilateral Diagnostic. The exclusivity provisions set forth in
Section 2.1.5 or Section 2.1.6, as the case may be, shall not apply to the
Non-Breaching Party with respect to such Diagnostics.

              12.2.6 MATERIAL BREACH RELATING TO THE DEVELOPMENT OR
COMMERCIALIZATION OF A JOINT DDC, JOINT PRODUCT OR PROGRAM DIAGNOSTIC. If the
material breach relates to the Breaching Party's obligations relating to the
Development and/or Commercialization of a Joint DDC, Joint Product and/or
Program Diagnostic (including, without limitation, a material breach in the
exercise of reasonable efforts to undertake Development and/or Commercialization
of such Joint DDC, Joint Product and/or Program Diagnostic), then this Agreement
shall not terminate in its entirety, but (a) the licenses granted to the
Breaching Party under this Agreement with respect to the Development and
Commercialization of such Joint DDC, Joint Product and/or Program Diagnostic
shall terminate; (b) the licenses granted by the Breaching Party with respect to
such Joint DDC, Joint Product and/or Program Diagnostic set forth in Article 8
shall continue in full force and effect, and the Non-Breaching Party shall have
the right to Develop and Commercialize such Joint DDC, Joint Product and/or
Program Diagnostic worldwide, either alone or in collaboration with Third
Parties, without any financial obligation to the Breaching Party; and (c) the
rights and obligations of the Parties under Article 10 with respect to Patent
Rights relating to such Joint DDC, Joint Product and/or Program Diagnostic shall
continue in effect.

              12.2.7 MATERIAL BREACH OF INVESTMENT AGREEMENT. If Abbott commits
a material breach of its obligations to purchase common stock of Millennium
under the Investment Agreement and does not cure such breach within sixty (60)
days after written notice thereof by Millennium, then Millennium may terminate
the licenses granted under this Agreement to Abbott and upon any termination
under this Section 12.2.7, Abbott hereby grants to Millennium a worldwide,
exclusive (even as to Abbott), non-royalty-bearing, perpetual license under the
sole or undivided one-half (as applicable) right, title and interest in the
Program Patent Rights or other intellectual property of Millennium assigned to
Abbott pursuant to Section 10.1.2, for all purposes.

         12.3 DISPUTE RESOLUTION. Termination under this Article 12 for whatever
reason will be automatically stayed for the duration of any ADR proceedings
initiated under Article 13, and any applicable cure periods shall commence upon
the resolution of such proceedings.

                                     -97-
<PAGE>

         12.4 RESIDUAL RIGHTS. Upon termination of this Agreement, except as
specifically provided herein to the contrary, all rights and obligations of the
Parties under this Agreement shall cease, except as follows: (a) obligations to
pay amounts accruing hereunder up to the date of termination; (b) the
obligations regarding confidentiality as set forth in Article 11; (c) all
obligations for record keeping and accounting reports; (d) the Parties' right to
inspect books and records of each other as set forth in Section 9.6; (e) the
Parties' rights with respect to the ownership of intellectual property as set
forth in Article 10; and (f) obligations of defense and indemnity, which
obligations shall continue in full force and effect for an unlimited period.

         12.5 CHANGE OF CONTROL. If a Change of Control occurs with respect to a
Party ("Change of Control Party") during the Research Program Term, such Change
of Control Party shall promptly notify the other Party in writing, and such
other Party may, at its sole discretion, elect to terminate the Research Program
and effect the distribution of certain assets and rights relating to the
Research Program in accordance with the provisions of Section 3.11 (a "Change of
Control Election"). A Change of Control Election may be made by such other Party
by giving the Change of Control Party written notice within sixty (60) days
after the other Party's receipt of notice of such Change of Control, such Change
of Control Election to be effective sixty (60) days after provision of written
notice thereof. If such other Party makes a Change of Control Election, then the
provisions of Section 3.11 shall determine the rights of the Parties hereunder.

                                   ARTICLE 13

                               DISPUTE RESOLUTION

         13.1 JOINT EXECUTIVE COMMITTEE.

              13.1.1 FORMATION AND MEMBERSHIP. As soon as practicable after the
Effective Date, Abbott and Millennium shall establish a Joint Executive
Committee comprised of three (3) senior executives of Abbott and three (3)
senior executives of Millennium. Each Party may change any one or more of its
representatives to the Joint Executive Committee at any time upon written notice
to the other Party.

              13.1.2 RESPONSIBILITIES. The Joint Executive Committee shall meet
at least two times annually to:

                  (a) assess the progress of the Research Program pursuant to
Section 3.1.2(b);

                  (b) review the efforts and assess the progress of the Parties
in the conduct of the Research Program, the Development Program and the
Commercialization Program;

                  (c) designate Drug Development Candidates pursuant to Section
4.1.3 and Joint DDCs, Unilateral DDCs and Suspended DDCs pursuant to Section
4.1.5;

                  (d) designate the Lead Regulatory Party for each Joint DDC
pursuant to Section 4.5.1;

                                      -98-
<PAGE>

                  (e) designate the Lead Manufacturing Party for each Joint DDC
and Joint Product pursuant to Article 6;

                  (f) make any necessary determinations concerning recalls of
Joint DDCs and Joint Products pursuant to Section 7.7.1;

                  (g) attempt to resolve any disputes relating to this Agreement
that may arise between the Parties that are referred to the Joint Executive
Committee by the Joint Research Committee, the Ad Hoc Committee, the Joint
Development Committee, the Joint Manufacturing Committee, the Joint
Commercialization Committee or either of the Parties;

                  (h) extend the term of the Research Program if mutually agreed
by the Parties;

                  (i) designation of Program Diagnostics pursuant to Section
5.1.1; and

                  (j) perform such other tasks and undertake such other
responsibilities as may be set forth in this Agreement.

              13.1.3 ADMINISTRATIVE MATTERS. The location of such meetings of
the Joint Executive Committee shall be as agreed by the Parties. The Joint
Executive Committee may also meet by means of a telephone conference call or by
videoconference. Each Party shall use reasonable efforts to cause its
representatives to attend the meetings of the Joint Executive Committee. If a
representative of a Party is unable to attend a meeting, such Party may
designate an alternative to attend such meeting in place of the absent
representative, and such alternate shall have full voting power at such meeting.
In addition, each Party may, at its discretion, invite non-voting employees,
and, with the consent of the other Party, consultants or scientific advisors, to
attend meetings of the Joint Executive Committee.

              13.1.4 DECISION MAKING. Each Party shall have one vote on the
Joint Executive Committee. Both Parties must vote in the affirmative to allow
the Joint Executive Committee to take any action that requires the vote of the
Joint Executive Committee. Action on any matter may be taken at a meeting, by
teleconference, videoconference or by written agreement. Either Party may
convene a special meeting of the Joint Executive Committee for the purpose of
resolving disputes.

         13.2 REFERRAL OF UNRESOLVED MATTERS TO JOINT EXECUTIVE COMMITTEE. If
the Joint Research Committee, the Ad Hoc Committee, the Joint Development
Committee, Joint Manufacturing Committee, or the Joint Commercialization
Committee is unable to reach a decision on any matter within the scope of its
responsibilities within thirty (30) days after such matter is first considered
by it, either Party may refer such unresolved matter to the Joint Executive
Committee for consideration and resolution. Unresolved matters pertaining to
intellectual property matters shall be governed by Article 10. In such event, a
meeting of the Joint Executive Committee shall be convened as soon as
practicable in order to consider and resolve the unresolved matter. Any
determination by the Joint Executive Committee shall be final and binding upon
the Parties.

                                      -99-
<PAGE>

         13.3 REFERRAL OF UNRESOLVED MATTERS TO EXECUTIVE OFFICERS. If the Joint
Executive Committee is unable to resolve any matter referred to it under Section
13.2 within thirty (30) days after the matter is referred to it, the matter
shall be referred to the Executive Officers to be resolved by negotiation in
good faith as soon as is practicable but in no event later than thirty (30) days
after referral. Such resolution, if any, of a referred issue by the Executive
Officers shall be final and binding on the Parties.

         13.4 INDEPENDENT EXPERTS. Each Executive Officer shall have the right
to engage the services of any number of independent experts in the field in
question (the individual(s) so engaged by each Executive Officer to be engaged
under obligations of confidentiality) to assist the Executive Officer in making
a determination on the unresolved matter, and each Executive Officer shall be
obligated to consider in good faith the analyses and opinions of any such
independent experts engaged by either of them in making a determination.

         13.5 ALTERNATIVE DISPUTE RESOLUTION. If the matter has not been
resolved by the Executive Officers within thirty (30) days of referral in
accordance with Section 13.3, or if the Executive Officers fail to meet within
such thirty (30) days, either Party may initiate binding alternative dispute
resolution ("ADR") in accordance with the terms set forth on EXHIBIT I Unless
otherwise mutually agreed upon by the Parties, the ADR proceedings shall be
conducted at the location chosen by the Party not originally requesting the
resolution of the dispute. Each Party shall have the right, at its own expense,
to be represented by counsel in such a proceeding. Each Party shall have the
right to enforce a judgment or ruling entered in the ADR proceeding in a court
of competent jurisdiction (including, without limitation, a judgment for
specific performance or injunctive relief).

                                   ARTICLE 14

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

         14.1 REPRESENTATION OF AUTHORITY; CONSENTS. Millennium and Abbott each
represents and warrants to the other Party that it has full right, power and
authority to enter into this Agreement and to perform its respective obligations
under this Agreement; it has the right to grant to the other Party the licenses
and sublicenses granted pursuant to this Agreement; this Agreement has been duly
executed by such Party and constitutes a legal, valid and binding obligation of
such Party, enforceable in accordance with its terms, and all necessary
consents, approvals and authorizations of all government authorities and other
persons required to be obtained by such Party as of the Effective Date in
connection with the execution, delivery and performance of this Agreement have
been and shall be obtained by the Effective Date.

         14.2 NO CONFLICT. Each Party represents to the other Party that
notwithstanding anything to the contrary in this Agreement, the execution and
delivery of this Agreement and the performance of such Party's obligations
hereunder (a) do not and will not conflict with or violate such Party's
corporate charter and bylaws or any requirement of applicable laws or
regulations existing as of the Effective Date and (b) do not and will not
conflict with, violate, breach or constitute a default under, any contractual
obligation of such Party or any of its Affiliates existing as of the Effective
Date.

                                     -100-

<PAGE>

         14.3 EMPLOYEE AND CONSULTANT OBLIGATIONS. Each Party represents and
warrants that, unless prohibited by, or inconsistent with, applicable Laws, all
of its employees, officers, consultants and advisors who are supporting the
performance of its obligations under this Agreement shall have executed or will
have executed agreements or have existing obligations under law requiring
assignment to such Party of all intellectual property made during the course of
and as the result of their association with such Party and obligating the
individual to maintain as confidential such Party's Confidential Information as
well as confidential information of a Third Party which such Party may receive,
to the extent required to support such Party's obligations under this Agreement.
Each Party represents and warrants that to its knowledge, none of its employees
who are or will be involved in the performance of obligations hereunder are, as
a result of the nature of such obligations to be conducted by the Parties as set
forth herein, in violation of any covenant in any contract with a third party
relating to non-disclosure of proprietary information, non-competition or
non-solicitation. Each Party represents and warrants that, to its knowledge,
none of its employees are in breach of any agreement with any Third Party which
would affect such Party's obligations under this Agreement.

         14.4 BURDENED TECHNOLOGY OBLIGATIONS. Set forth on EXHIBIT J is a list,
which is true, complete and correct in all material respects, of each agreement
between a Third Party and Abbott which exists as of the Effective Date pursuant
to which any Burdened Technology Obligations could arise. Set forth on EXHIBIT K
is a list, which is true, complete and correct in all material respects, of each
agreement between a Third Party and Millennium which exists as of the Effective
Date pursuant to which any Burdened Technology Obligations could arise.

         14.5 INTELLECTUAL PROPERTY. Each Party represents and warrants to the
other that as of the Effective Date:

                  (a) it is not aware of any claim made against it asserting the
invalidity, misuse, unregisterability, unenforceability or non-infringement of
any of its intellectual property which is the subject of this Agreement (the
"Intellectual Property") or is not aware of any claim made against it
challenging its right to use or ownership of any of the Intellectual Property or
making any adverse claim of ownership thereof; and

                  (b) there is not any pending or, to its knowledge, threatened
claim or litigation or, to the knowledge of such Party, written claim or demand
of any Third Party has been received, which alleges that its activities to date
relating to the Intellectual Property have violated, or by conducting its
business as currently proposed to be conducted hereunder would violate, the
intellectual property rights of any Third Party.

                  (c) it is not aware of any default or claim of default by it
or by any Third Party relating to any license agreement with any Third Party
which has application to the licenses granted the other Party to this Agreement.

         14.6 KNOWLEDGE OF PENDING OR THREATENED LITIGATION. Each Party
represents and warrants to the other Party that there is no claim,
investigation, suit, action or proceeding pending or, to the knowledge of such
Party, expressly threatened, against such Party before or by any governmental
entity or arbitrator that, impair the ability of such Party to perform any

                                     -101-
<PAGE>

obligation under this Agreement or prevent or materially delay or alter the
consummation of any or all of the transactions contemplated hereby.

         14.7 DISCLAIMER OF WARRANTY. Nothing in this Agreement shall be
construed as a representation made or warranty given by either Party that any
patents will issue based on pending applications or that any such pending
applications or patents issued thereon will be valid. EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND
RENOUNCES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                                   ARTICLE 15

                            MISCELLANEOUS PROVISIONS

         15.1 INDEMNIFICATION.

              15.1.1 ABBOTT. Abbott agrees to defend Millennium and its
Affiliates at Abbott's cost and expense, and will indemnify and hold Millennium
and its Affiliates and their respective directors, officers, employees and
agents (the "Millennium Indemnified Parties") harmless from and against any
losses, costs, damages, fees or expenses arising out of any Third Party claim
relating to (a) any breach by Abbott of any of its representations, warranties
or obligations pursuant to this Agreement, (b) the gross negligence or willful
misconduct of Abbott, or (c) injuries resulting from any Abbott Released
Diagnostic, Abbott Unilateral Diagnostic, Abbott Unilateral Product or any other
product or service offered by Abbott, its Affiliates and/or its licensees or
collaborators outside of the Research Program, Development Program and/or
Commercialization Program. In the event of any such claim against the Millennium
Indemnified Parties by any Third Party, Millennium shall promptly notify Abbott
in writing of the claim and Abbott shall manage and control, at its sole
expense, the defense of the claim and its settlement, keeping Millennium
reasonably apprised of the status of the defense and/or settlement. No
settlement shall be finalized without obtaining Millennium's prior written
consent, which shall not be unreasonably withheld, except that, in the case of a
settlement that does not require an admission or action on the part of
Millennium, Millennium's consent shall not be required so long as Millennium is
unconditionally released from all liability in such settlement. The Millennium
Indemnified Parties shall cooperate with Abbott and may, at their option and
expense, be represented in any such action or proceeding. Abbott shall not be
liable for any litigation costs or expenses incurred by the Millennium
Indemnified Parties without Abbott's prior written authorization. In addition,
Abbott shall not be responsible for the indemnification or defense of any
Millennium Indemnified Party to the extent any Third Party claims arises from
any negligent or intentional acts by any Millennium Indemnified Party, or the
breach by Millennium of any obligation or warranty under this Agreement, or any
claims compromised or settled without its prior written consent.

              15.1.2 MILLENNIUM. Millennium agrees to defend Abbott and its
Affiliates at Millennium's cost, and will indemnify and hold Abbott and its
Affiliates and their respective directors, officers, employees and agents (the
"Abbott Indemnified Parties") harmless from and against any losses, costs,
damages, fees or expenses arising out of any Third Party claim relating

                                     -102-
<PAGE>

to (a) any breach by Millennium of any of its representations, warranties or
obligations pursuant to this Agreement, or (b) the gross negligence or willful
misconduct of Millennium, or (c) injuries resulting from any Millennium
Unilateral Diagnostic, Millennium Unilateral Product or any other product or
service offered by Millennium, its Affiliates and/or its licensees or
collaborators outside of the Research Program, Development Program and/or
Commercialization Program. In the event of any claim against the Abbott
Indemnified Parties by any Third Party, Abbott shall promptly notify Millennium
in writing of the claim and Millennium shall manage and control, at its sole
expense, the defense of the claim and its settlement, keeping Abbott reasonably
advised of the status of the defense and/or settlement. No settlement shall be
finalized without obtaining Abbott's prior written consent, which consent shall
not be unreasonably withheld, except that, in the case of a settlement that does
not require an admission or action on the part of Abbott, Abbott's consent shall
not be required so long as Abbott is unconditionally released from all liability
in such settlement. The Abbott Indemnified Parties shall cooperate with
Millennium and may, at their option and expense, be represented in any such
action or proceeding. Millennium shall not be liable for any litigation costs or
expenses incurred by the Abbott Indemnified Parties without Millennium's prior
written authorization. In addition, Millennium shall not be responsible for the
indemnification or defense of any Abbott Indemnified Party to the extent any
Third Party Claim arises from any negligent or intentional acts by any Abbott
Indemnified Party, or the breach by Abbott of any obligation or warranty under
this Agreement, or any claims compromised or settled without its prior written
consent.

              15.1.3 INSURANCE PROCEEDS. Any indemnification hereunder shall be
made net of any insurance proceeds recovered by the Indemnified Party; PROVIDED
THAT if, following the payment to the Indemnified Party of any amount under this
Section 15.1, such Indemnified Party recovers any insurance proceeds in respect
of the claim for which such indemnification payment was made, the Indemnified
Party shall promptly pay an amount equal to the amount of such proceeds (but not
exceeding the amount of such indemnification payment) to the Indemnifying Party.

         15.2 INSURANCE. Each Party shall maintain insurance, including product
liability insurance, with respect to its activities hereunder. Such insurance
shall be in such amounts and subject to such deductibles as the Parties may
agree based upon standards prevailing in the industry at the time, PROVIDED
THAT, as of the First Commercial Sale, each Party shall maintain a minimum of
Ten Million Dollars ($10,000,000) in product liability insurance. Either Party
may satisfy its obligations under this Section 15.2 through reasonable
self-insurance to the same extent. A Party shall name the other Party as an
additional insured on any policies it maintains pertaining to the clinical
development, manufacturing or marketing and sale of a Joint Product, Program
Diagnostic, Abbott Released Diagnostic, Unilateral Diagnostic or Unilateral
Product performed by such Party.

         15.3 GOVERNING LAW. This Agreement shall be construed and the
respective rights of the Parties determined according to the substantive laws of
the State of New York notwithstanding the provisions governing conflict of laws
under such New York law to the contrary, except matters of intellectual property
law which shall be determined in accordance with United States intellectual
property laws.

                                     -103-
<PAGE>

         15.4 ASSIGNMENT. Neither Millennium nor Abbott may assign this
Agreement in whole or in part without the consent of the other, except if such
assignment occurs in connection with the sale or transfer (by merger or
otherwise) of all or substantially all of the business and assets of Millennium
or Abbott to which the subject matter of this Agreement pertains.
Notwithstanding the foregoing, either Party may assign this Agreement to an
Affiliate, PROVIDED THAT such Party shall guarantee the performance of such
Affiliate.

         15.5 AMENDMENTS. This Agreement and the Exhibits referred to in this
Agreement constitute the entire agreement between the Parties with respect to
the subject matter hereof, and supersede all previous arrangements with respect
to the subject matter hereof, whether written or oral. The Parties acknowledge
that the Exhibits referred to in this Agreement are being simultaneously
delivered by the Parties on or before the Effective Date. The Parties also
acknowledge the simultaneous execution and delivery of the Investment Agreement
and the Technology Exchange and Development Agreement, which shall not be
superseded by this Agreement. Any amendment or modification to this Agreement
shall be made in writing signed by both Parties.

         15.6 NOTICES.

Notices to Millennium shall be addressed to:

Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139
Attention: Chief Executive Officer

with a copy to:

Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139
Attention: General Counsel

Notices to Abbott shall be addressed to:

Abbott Laboratories
100 Abbott Park Road
Bldg. AP6D; Dept. 3RD
Abbott Park, Illinois  60064

Attention: Executive Vice President, Pharmaceuticals and Chief Scientific
Officer

with a copy to:

Abbott Laboratories
100 Abbott Park Road
Bldg. AP6D; Dept. 364
Abbott Park, Illinois  60064

                                     -104-
<PAGE>

Attention: Senior Vice President, Secretary and General Counsel

         Either Party may change its address to which notices shall be sent by
giving notice to the other Party in the manner herein provided. Any notice
required or provided for by the terms of this Agreement shall be in writing and
shall be (a) sent by certified mail, return receipt requested, postage prepaid
or (b) sent via a reputable overnight courier service, in each case properly
addressed in accordance with the paragraph above. The effective date of notice
shall be the actual date of receipt by the Party receiving the same.

         15.7 FORCE MAJEURE. No failure or omission by either Party in the
performance of any obligation of this Agreement shall be deemed a breach of this
Agreement or create any liability if the same shall arise from any cause or
causes beyond the reasonable control of such Party, including, but not limited
to, the following: acts of God; acts or omissions of any government; any
inordinate or unanticipated delays in the regulatory review or governmental
approval progress that are within the sole control of such government or
governmental agency; any rules, regulations or orders issued by any governmental
authority or by any officer, department, agency or instrumentality thereof;
fire; storm; flood; earthquake; accident; war; rebellion; insurrection; riot;
and invasion; PROVIDED THAT such failure or omission resulting from one of the
above causes is corrected as soon as is practicable after the occurrence of one
or more of the above mentioned causes by the Party claiming force majeure taking
all reasonable steps within its power to resume compliance with its obligations
with the least possible delay. The Party claiming force majeure shall notify the
other Party with notice of the force majeure event as soon as practicable, but
in no event longer than ten (10) business days after its occurrence, which
notice shall reasonably identify such obligations under this Agreement and the
extent to which performance thereof will be affected. In such event, the Parties
shall meet promptly to determine an equitable solution to the effects of any
such event.

         15.8 COMPLIANCE WITH EXPORT REGULATIONS. Neither Party shall export any
technology licensed to it by the other Party under this Agreement except in
compliance with United States export laws and regulations.

         15.9 PUBLIC ANNOUNCEMENTS. On the Effective Date, the Parties shall
issue one or more press releases, the timing and content of which shall be
mutually agreed. Any announcements or similar publicity with respect to the
execution of this Agreement shall be agreed upon between the Parties in advance
of such announcement. The Parties understand that this Agreement is likely to be
of significant interest to investors, analysts and others, and that the Parties
therefore may make such public announcements with respect thereto, subject to
the remainder of this Section 15.9. The Parties agree that any such announcement
will not contain confidential business or technical information and, if
disclosure of confidential business or technical information is required by law
or regulation, will make reasonable efforts to minimize such disclosure and
obtain confidential treatment for any such information which is disclosed to a
governmental agency or group. Each Party agrees to provide to the other Party a
copy of any public announcement as soon as reasonably practicable under the
circumstances prior to its scheduled release. Millennium acknowledges that
Abbott's internal process for the review and approval of public announcements
typically requires three (3) weeks from the initiation of review of a proposed
announcement; Abbott acknowledges that Millennium may be required, under certain
circumstances, to issue public announcements relating to material events on an

                                     -105-
<PAGE>

expeditious basis. The Parties shall use reasonable efforts to anticipate
potential public announcements and, where feasible, initiate the preparation and
review of such announcement at least three (3) weeks prior to the anticipated
release date thereof. However, in the event that either Party is required by law
or other circumstances to make an announcement on a more expeditious basis (such
as upon the occurrence of a material event), such Party shall provide the other
Party with an advance copy of such announcement as far in advance of the release
of such announcement as is feasible under the circumstances. Each Party shall
have the right to review and recommend changes to any announcement regarding
this Agreement or the subject matter of this Agreement. Except as otherwise
required by law, the Party whose press release has been reviewed shall remove
any information the reviewing Party reasonably deems to be inappropriate for
disclosure and shall use all reasonable efforts to accommodate the reviewing
Party's other comments. The contents of any such announcement or similar
publicity which has been reviewed and approved by the reviewing Party can be
re-released by either Party without a requirement for re-approval. Furthermore,
each Party shall give the other Party a reasonable opportunity to review all
filings with the United States Securities and Exchange Commission describing the
terms of this Agreement prior to submission of such filings, and shall give due
consideration to any reasonable comments by the non-filing Party relating to
such filing, including suggested redactions and including, without limitation,
the provisions of this Agreement for which confidential treatment should be
sought.

         15.10 INDEPENDENT CONTRACTORS. It is understood and agreed that the
relationship between the Parties is that of independent contractors and that
nothing in this Agreement shall be construed as authorization for either
Millennium or Abbott to act as agent for the other. Members of the Joint
Executive Committee, the Joint Research Committee, the Joint Development
Committee, the Joint Commercialization Committee, the Joint Manufacturing
Committee and any subcommittees or project teams thereof shall be, and shall
remain, employees of Millennium or Abbott, as the case may be. No Party shall
incur any liability for any act or failure to act by members of the Joint
Executive Committee, the Joint Research Committee, the Joint Development
Committee, the Joint Commercialization Committee and any subcommittees or
project teams thereof who are employees of such other Party.

         15.11 NO STRICT CONSTRUCTION. This Agreement has been prepared jointly
and shall not be strictly construed against either Party.

         15.12 HEADINGS. The captions or headings of the sections or other
subdivisions hereof are inserted only as a matter of convenience or for
reference and shall have no effect on the meaning of the provisions hereof.

         15.13 NO IMPLIED WAIVERS; RIGHTS CUMULATIVE. No failure on the part of
Millennium or Abbott to exercise, and no delay in exercising, any right, power,
remedy or privilege under this Agreement, or provided by statute or at law or in
equity or otherwise, shall impair, prejudice or constitute a waiver of any such
right, power, remedy or privilege or be construed as a waiver of any breach of
this Agreement or as an acquiescence therein, nor shall any single or partial
exercise of any such right, power, remedy or privilege preclude any other or
further exercise thereof or the exercise of any other right, power, remedy or
privilege.

                                     -106-
<PAGE>

         15.14 SEVERABILITY. If any provision hereof should be held invalid,
illegal or unenforceable in any respect in any jurisdiction, the Parties hereto
shall substitute, by mutual consent, valid provisions for such invalid, illegal
or unenforceable provisions which valid provisions in their economic effect are
sufficiently similar to the invalid, illegal or unenforceable provisions that it
can be reasonably assumed that the Parties would have entered into this
Agreement with such valid provisions. In case such valid provisions cannot be
agreed upon, the invalid, illegal or unenforceable of one or several provisions
of this Agreement shall not affect the validity of this Agreement as a whole.

         15.15 EXECUTION IN COUNTERPARTS. This Agreement may be executed in
counterparts, each of which counterparts, when so executed and delivered, shall
be deemed to be an original, and all of which counterparts, taken together,
shall constitute one and the same instrument.

         15.16 NO THIRD PARTY BENEFICIARIES. No person or entity other than
Abbott, Millennium and their respective Affiliates and permitted assignees
hereunder shall be deemed an intended beneficiary hereunder or have any right to
enforce any obligation of this Agreement.

         15.17 NO CONSEQUENTIAL DAMAGES. UNLESS RESULTING FROM A PARTY'S WILLFUL
MISCONDUCT, NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS
RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR
RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH
DAMAGES. NOTHING IN THIS SECTION 15.17 IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.

         15.18 EMPLOYEES.

                  (a) Subject to Section 15.18(b):

                      (i) during the Research Program Term and for one (1) year
            thereafter, neither Party shall, directly or indirectly, solicit for
            employment any employee of the other Party if such employee is, or
            was, directly engaged in the Research Program;

                      (ii) from the commencement of the Development Program and
            for five (5) years thereafter, neither Party shall, directly or
            indirectly, solicit for employment any employee of the other Party
            if such employee is, or was, directly engaged in the Development
            Program; and

                      (iii) from the commencement of the Commercialization
            Program and for five (5) years thereafter, neither Party shall,
            directly or indirectly, solicit for employment any employee of the
            other Party if such employee is, or was, directly engaged in the
            Commercialization Program.

                  (b) Notwithstanding the terms set forth in Sections
15.18(a)(i), (ii) and (iii), a Party may solicit any employee of the other Party
at any time after one (1) year following such employee's termination of
employment with the other Party. It shall

                                     -107-
<PAGE>

not be a violation of this Section 15.18 if an employee responds to a Party's
general advertisement of an open position, without solicitation of interest by
such Party. No former employee of one Party hired after the Effective Date by
the other Party shall participate in the Research Program, Development Program
or Commercialization Program.





                                     -108-

<PAGE>

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first set forth above.

                                        MILLENNIUM PHARMACEUTICALS, INC.

                                        By:  Mark J. Levin
                                            ----------------------------------

                                        Title:  CEO
                                              --------------------------------



                                       ABBOTT LABORATORIES

                                       By:  Miles D. White
                                           ------------------------------------

                                       Title:  Chairman of the Board and CEO
                                             -----------------------------------



<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT A

                               EXCLUDED COMPOUNDS

[**]




<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT B

                          ABBOTT THIRD PARTY AGREEMENTS
                                      [**]

1.       [**]







<PAGE>


   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT C

                        MILLENNIUM THIRD PARTY AGREEMENTS
                                      [**]

[**]




<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT D

                                   GUIDELINES

1.       [**]     Program Targets accepted

2.       [**]     Lead Generation programs initiated

3.       [**]     Hit-to-Lead Programs initiated

4.       [**]     Concurrent Lead Optimization Program running





<PAGE>


                                    EXHIBIT E

                       PROGRAM DEVELOPMENT EXPENSE EXAMPLE





<PAGE>


                                    EXHIBIT F

                     DIAGNOSTIC DEVELOPMENT EXPENSE EXAMPLE





<PAGE>


                                    EXHIBIT G

                              FINANCIAL DEFINITIONS

"U.S. TERRITORY" shall mean the United States of America.

"ROW TERRITORY" shall mean all countries of the world, excluding the U.S.
Territory.

"ROW MINUS THE CO-PROMOTION TERRITORY" shall mean the ROW Territory, excluding
the Co-Promotion Territory.

"JOINT PRODUCT NET SALES" shall mean the gross amount invoiced on account of
sales of a Joint Product by a Party and its Affiliates and permitted
sublicensees to Third Parties (including, without limitation, Third Party end
customers, distributors and wholesalers), less the total of the following
deductions directly paid or incurred by a Party with respect to the sale of such
Joint Products:

(a)      trade, cash and/or quantity discounts not already reflected in the
         amount invoiced;

(b)      all excise, sales and other consumption taxes (including VAT) and
         customs duties, whether or not specifically identified as such in the
         invoice to the Third Party;

(c)      amounts repaid or credited by reason of rejections, defects or because
         of chargebacks, retroactive price reductions, refunds or billing
         errors;

(d)      compulsory payments and rebates directly related to the sale of Joint
         Products, accrued, paid or deducted pursuant to agreements (including,
         but not limited to, managed care agreements) or governmental
         regulations; and

(e)      management fees paid to group purchasing organizations and relating
         specifically to the sale of Joint Products to their members.

Use of a Joint Product for sampling purposes and for use in clinical trials
shall not be considered in determining Joint Product Net Sales. In the case of
any sale of a Joint Product between or among a Party and its Affiliates or
sublicensees for resale, Joint Product Net Sales shall be calculated only on the
value charged or invoiced on the first arm's length sale thereafter to a Third
Party. In the case of any other sale for value, such as barter or counter-trade,
of any Joint Product, Joint Product Net Sales shall be calculated as above on
the value of the consideration received. Joint Product Net Sales shall be
calculated separately for (i) the U.S. Territory and (ii) the ROW Territory; or,
if applicable, for (i) the U.S. Territory, (ii) the Co-Promotion Territory and
(iii) the ROW Minus the Co-Promotion Territory.

"STANDARD COST OF GOODS SOLD" shall mean, to the extent that a Joint Product is
sourced from a Party, standard unit cost of manufacture of the Joint Product,
consisting of direct material and direct labor costs plus manufacturing overhead
attributable to the Joint Product (including all directly incurred manufacturing
variances), and the amortization of Special Purpose Equipment agreed upon by the
Joint Manufacturing Committee, all calculated in accordance with generally
accepted accounting principles, consistently applied. Direct material costs will
include the costs


<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

incurred in manufacturing or purchasing materials, including freight-in costs,
sales and excise taxes imposed thereon and customs duty and charges levied by
government authorities, and all costs of packaging components. Direct labor
costs will include the cost of employees engaged in direct manufacturing
activities and direct or indirect quality control and quality assurance
activities who are directly employed in manufacturing and packaging Joint
Product. Overhead attributable to a Joint Product will be calculated and
allocated in a manner consistent with the method used to allocate overhead to
other products manufactured in the same facility. Overhead attributable to Joint
Product will include a reasonable allocation of indirect labor (not previously
included in direct labor costs), a reasonable allocation of administrative
costs, and a reasonable allocation of facilities costs, all in accordance with
generally accepted accounting principles, consistently applied. Overhead will
not include corporate administrative overhead or plant start-up costs or costs
associated with excess capacity. At the time a Party is designated the Lead
Manufacturing Party for a Joint Product, such Lead Manufacturing Party shall
prepare a detailed breakdown of the components of Standard Cost of Goods Sold
for such Joint Product for review by the Joint Manufacturing Committee.

To the extent that a Joint Product is sourced from a Third Party manufacturer,
the actual price paid by a Party to the Third Party for the manufacture, supply
and packaging of such Joint Product shall be the Standard Cost of Goods Sold.
Standard Cost of Goods Sold shall not include royalties paid to Third Parties.
If required, Standard Cost of Goods Sold shall be calculated separately for (i)
the U.S. Territory and (ii) the ROW Territory; or, if applicable, for (i) the
U.S. Territory, (ii) the Co-Promotion Territory, and (iii) the ROW Minus the
Co-Promotion Territory.

"DISTRIBUTION EXPENSES" shall be expressed as a percentage of Joint Product Net
Sales to reflect the experience of the applicable Party with respect to
distribution expenses (which shall include shipping, insurance and warehousing
expenses) as a percentage of Net Sales on a company-wide basis. Abbott has
indicated that, as of the Effective Date, the appropriate percentages are (i)
for the U.S. Territory, [**]percent ([**]%) of Joint Product Net Sales, and (ii)
for the ROW Territory, [**] percent ([**]%) of Joint Product Net Sales. The
Parties shall agree upon the appropriate percentage for each calendar year,
based upon company-wide financial data from the prior calendar year.
Distribution Expenses shall be calculated separately for (i) the U.S. Territory
and (ii) the ROW Territory; or, if applicable, for (i) the U.S. Territory, (ii)
the Co-Promotion Territory, and (iii) the ROW Minus the Co-Promotion Territory.

"DISTRIBUTION MARGIN/PROFIT" shall mean a Party's Joint Product Net Sales minus
(i) the Standard Cost of Goods Sold and (ii) the Distribution Expenses.
Distribution Margin/Profit shall be calculated separately for (i) the U.S.
Territory and (ii) the ROW Territory; or, if applicable, for (i) the U.S.
Territory, (ii) the Co-Promotion Territory, and (iii) the ROW Minus the
Co-Promotion Territory.

"COMMERCIALIZATION EXPENSES" (SG&A) shall mean (i) the costs and expenses
incurred by a Party in the advertising, detailing, sales, marketing and
promotion of any Joint Product, (ii) costs and expenses related to Phase IV
studies related to a Joint Product, (iii) infrastructure required to

<PAGE>

support and maintain patient/safety surveillance as required by applicable
Regulatory Authorities directly attributable to a Joint Product, (iv) reasonable
out-of-pocket patent prosecution, enforcement and/or defense costs and expenses
incurred by a Party in connection with claims instituted by either Party
pursuant to Sections 10.2, 10.4 and 10.5 hereof, (v) the reasonable
out-of-pocket costs and expenses of maintaining Regulatory Approval in the U.S.
or ROW, as the case may be, (vi) royalty and other financial obligations paid by
a Party to Third Parties in connection with the use of Third Party technology
related to the Joint Product, (vii) the costs of product recalls and product
liability claims, (viii) bad debt expense, and (ix) such other costs and
expenses specifically approved by the Joint Commercialization Committee.
Commercialization Expenses shall be calculated separately for (i) the U.S.
Territory and (ii) the ROW Territory; or, if applicable, for (i) the U.S.
Territory, (ii) the Co-Promotion Territory, and (iii) the ROW Minus the
Co-Promotion Territory.

"OPERATING MARGIN/PROFIT" shall mean a Party's Distribution Margin/Profit minus
Commercialization Expenses. Operating Margin/Profit shall be calculated
separately for (i) the U.S. Territory and (ii) the ROW Territory; or, if
applicable, for (i) the U.S. Territory, (ii) the Co-Promotion Territory, and
(iii) the ROW Minus the Co-Promotion Territory.

"NET UNITS OF JOINT PRODUCT SOLD" shall mean the total number of units of Joint
Product which are sold by a Party and its Affiliates to Third Parties during the
given calendar quarter or year, less any returned, recalled, damaged or any
other such units of Joint Product for which the customer has been credited the
original sales price. For any given period, the Net Units of Joint Product Sold
shall equal the number of units of Joint Product included in the calculation of
Joint Product Net Sales for the same period. The Net Units of Joint Product Sold
shall be calculated separately for (i) the U.S. Territory and (ii) the ROW
Territory; or, if applicable, for (i) the U.S. Territory, (ii) the Co-Promotion
Territory, and (iii) the ROW Minus the Co-Promotion Territory.

The calculation of U.S. Territory Operating Margin/Profit is illustrated by the
following example set forth as Schedule 1 to this EXHIBIT G. The calculation of
ROW Territory Operating Margin/Profit is illustrated in the example set forth as
Schedule 2 to this EXHIBIT G.



<PAGE>

                                    EXHIBIT H

                        DIAGNOSTIC FINANCIAL DEFINITIONS



"U.S. TERRITORY" shall mean the United States of America.

"ROW TERRITORY" shall mean all countries of the world, excluding the U.S.
Territory.

"DIAGNOSTIC DEVELOPMENT EXPENSES" shall mean, with respect to a Program
Diagnostic, all expenses incurred in connection with the development (including
through the time Regulatory Approvals are obtained) of such Program Diagnostic
based upon the applicable Program Diagnostic Plan and Program Diagnostic Budget.

"PROGRAM DIAGNOSTIC NET SALES" shall mean the gross amount invoiced on account
of sales of a Program Diagnostic by a Party and its Affiliates and permitted
sublicensees to Third Parties (including, without limitation, Third Party end
customers, distributors and wholesalers), less the total of the following
deductions directly paid or incurred by a Party with respect to the sale of such
Program Diagnostic.

(a)      trade, cash and/or quantity discounts not already reflected in the
         amount invoiced;

(b)      all excise, sales and other consumption taxes (including VAT) and
         customs duties, whether or not specifically identified as such in the
         invoice to the Third Party;

(c)      amounts repaid or credited by reason of rejections, defects or returns
         or because of chargebacks, retroactive price reductions, refunds or
         billing errors;

(d)      compulsory payments and rebates directly related to the sale of Program
         Diagnostics, accrued, paid or deducted pursuant to agreements
         (including, but not limited to, managed care agreements) or
         governmental regulations;

(e)      management fees paid to group purchasing organizations and relating
         specifically to the sale of Program Diagnostics to their members; and

(f)      cost of reagent agreement plans, calculated as provided in Section
         9.4.3.

Program Diagnostic Net Sales shall be calculated only on the value charged or
invoiced on the first arm's length sale to a Third Party.

Program Diagnostic Net Sales shall be calculated separately for (a) (i) the U.S.
Territory and (ii) the ROW Territory, and (b) (i) Program Diagnostics automated
onto an Abbott Diagnostic Platform, and (ii) Program Diagnostics not automated
onto an Abbott Diagnostic Platform.


<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

"PROGRAM DIAGNOSTIC STANDARD COST OF GOODS SOLD" shall mean, to the extent that
a Program Diagnostic is sourced from a Party, standard unit cost of manufacture
of the Program Diagnostic, consisting of direct material and direct labor costs
plus manufacturing overhead attributable to the Program Diagnostic (including
all directly incurred manufacturing variances), and the amortization of any
Special Purpose Equipment agreed to by the Joint Manufacturing Committee, all
calculated in accordance with generally accepted accounting principles,
consistently applied. Direct material costs will include the costs incurred in
manufacturing or purchasing materials, including freight-in costs, sales and
excise taxes imposed thereon and customs duty and charges levied by government
authorities, and all costs of packaging components. Direct labor costs will
include the cost of employees engaged in direct manufacturing activities and
direct or indirect quality control and quality assurance activities who are
directly employed in manufacturing and packaging Program Diagnostics. Overhead
attributable to a Program Diagnostics will be calculated and allocated in a
manner consistent with the method used to allocate overhead to other products
manufactured in the same facility. Overhead attributable to Program Diagnostics
will include a reasonable allocation of indirect labor (not previously included
in direct labor costs), a reasonable allocation of administrative costs, and a
reasonable allocation of facilities costs, all in accordance with generally
accepted accounting principles, consistently applied. Overhead will not include
corporate administrative overhead or plant start-up costs or costs associated
with excess capacity. To the extent that a Program Diagnostic is sourced from a
Third Party manufacturer, the actual price paid by a Party to the Third Party
for the manufacture, supply and packaging of such Program Diagnostic shall be
the Program Diagnostic Standard Cost of Goods Sold. Program Diagnostic Standard
Cost of Goods Sold shall not include royalties paid to Third Parties. If
required, Program Diagnostic Standard Cost of Goods Sold shall be calculated
separately for (a) (i) the U.S. Territory and (ii) the ROW Territory, and (b)
(i) Program Diagnostics automated onto an Abbott Diagnostic Platform, and (ii)
Program Diagnostics not automated onto an Abbott Diagnostic Platform.

"PROGRAM DIAGNOSTIC DISTRIBUTION EXPENSES" shall be expressed as a percentage of
Program Diagnostic Net Sales to reflect the experience of the applicable Party
with respect to distribution expenses (which shall include shipping, insurance
and warehousing expenses) as a percentage of Net Sales on a company-wide basis.
Abbott has indicated that, as of the Effective Date, the appropriate percentages
are (i) for the U.S. Territory, [**] percent ([**]%) of Program Diagnostic Net
Sales, and (ii) for the ROW Territory, [**] percent ([**]%) of Program
Diagnostic Net Sales. The Parties shall agree upon the appropriate percentage
for each calendar year, based upon company-wide financial data from the prior
calendar year. Program Diagnostic Distribution Expenses shall be calculated
separately for (a) (i) the U.S. Territory and (ii) the ROW Territory, and (b)
(i) Program Diagnostics automated onto an Abbott Diagnostic Platform, and (ii)
Program Diagnostics not automated onto an Abbott Diagnostic Platform.

"PROGRAM DIAGNOSTIC DISTRIBUTION MARGIN/PROFIT" shall mean a Party's Program
Diagnostic Net Sales minus (i) the Program Diagnostic Standard Cost of Goods
Sold and (ii) the Program Diagnostic Distribution Expenses. Program Diagnostic
Distribution Margin/Profit shall be calculated separately for (a) (i) the U.S.
Territory and (ii) the ROW Territory, and (b) (i)

<PAGE>

Program Diagnostics automated onto an Abbott Diagnostic Platform, and (ii)
Program Diagnostics not automated onto an Abbott Diagnostic Platform.

"PROGRAM DIAGNOSTIC COMMERCIALIZATION EXPENSES" (SG&A) shall mean (i) the costs
and expenses incurred by a Party in the advertising, detailing, sales, marketing
and promotion of a Program Diagnostic, (ii) infrastructure required to support
and maintain patient/safety surveillance as required by applicable Regulatory
Authorities directly attributable to a Program Diagnostic, (iii) reasonable
out-of-pocket patent prosecution, enforcement and/or defense costs and expenses
incurred by a Party in connection with claims instituted by either Party
pursuant to Sections 10.2, 10.4 and 10.5 hereof, (iv) the reasonable
out-of-pocket costs and expenses of maintaining Regulatory Approvals in the U.S.
or ROW, as the case may be, (v) royalty and other financial obligations paid by
a Party to Third Parties in connection with the use of Third Party technology
related to the Program Diagnostic, (vi) the costs of product recalls and product
liability claims, (vii) bad debt expense and (viii) such other costs and
expenses specifically approved by the Joint Commercialization Committee,
including assay modifications/technical support necessary to improve and support
marketed Program Diagnostics. Program Diagnostic Commercialization Expenses
shall be calculated separately for (a) (i) the U.S. Territory and (ii) the ROW
Territory, and (b) (i) Program Diagnostics automated onto an Abbott Diagnostic
Platform, and (ii) Program Diagnostics not automated onto an Abbott Diagnostic
Platform.

"PROGRAM DIAGNOSTIC OPERATING MARGIN/PROFIT" shall mean a Party's Program
Diagnostic Distribution Margin/Profit minus Program Diagnostic Commercialization
Expenses. In no event shall Program Diagnostic Standard Cost of Goods Sold
and/or Program Diagnostic Commercialization Expenses include costs and expenses
incurred in the development of the Abbott Diagnostic Platform. Program
Diagnostic Operating Margin/Profit shall be calculated separately for (a) (i)
the U.S. Territory and (ii) the ROW Territory, and (b) (i) Program Diagnostics
automated onto an Abbott Diagnostic Platform, and (ii) Program Diagnostics not
automated onto an Abbott Diagnostic Platform.

"NET UNITS OF PROGRAM DIAGNOSTIC SOLD" shall mean the total number of units of a
Program Diagnostic which are sold by a Party and its Affiliates to Third Parties
during the given calendar quarter or year, less any returned, recalled, damaged
or any other such units of Program Diagnostic for which the customer has been
credited the original sales price. For any given period, the Net Units of
Program Diagnostic Sold shall equal that number of units of Program Diagnostics
included in the calculation of Program Diagnostic Net Sales for the same period.
The Net Units of Program Diagnostic Sold shall be calculated separately for (a)
(i) the U.S. Territory and (ii) the ROW Territory, and (b) (i) Program
Diagnostics automated onto an Abbott Diagnostic Platform, and (ii) Program
Diagnostics not automated onto an Abbott Diagnostic Platform.

         The calculation of Program Diagnostic U.S. Territory Operating
Margin/Profit is illustrated by the example set forth on Schedule 1 to this
EXHIBIT H. The calculation of Program Diagnostic ROW Territory Operating
Margin/Profit is illustrated by the example set forth on Schedule 2 to this
EXHIBIT H.

<PAGE>

Millennium Confidential Information

                                    EXHIBIT I

                      ALTERNATIVE DISPUTE RESOLUTION RULES

         1. To begin an ADR proceeding, a Party shall provide written notice to
the other Party identifying the issues to be resolved by ADR ("ADR Notice").
Within fourteen (14) days after receipt of such ADR Notice, the other Party may,
by written notice to the Party initiating the ADR, add additional issues to be
resolved within the same ADR.

         2. Within twenty-one (21) days following receipt of the original ADR
Notice, the Parties shall select a mutually acceptable neutral party ("Neutral")
to preside in the resolution of any disputes in this ADR proceeding. If the
Parties are unable to agree on a mutually acceptable Neutral within such period,
either Party may request the President of the CPR Institute for Dispute
Resolution ("CPR"), 366 Madison Avenue, 14th Floor, New York, New York 10017, to
select a Neutral pursuant to the following procedures:

              (a) The CPR shall submit to the Parties a list of not fewer than
five (5) candidates within fourteen (14) days after receipt of the request,
along with a CURRICULUM VITAE for each candidate. No candidate shall be an
employee, director or shareholder of either Party or any of their Affiliates.

              (b) Such list shall include a statement of disclosure by each
candidate of any circumstance likely to affect his or her impartiality.

              (c) Each Party shall number the candidates in order of preference
(with the number one (1) signifying the greatest preference) and shall deliver
the list to the CPR within seven (7) days following receipt of the list of
candidates. If a Party believes a conflict of interest exists regarding any of
the candidates, the Party shall provide a written explanation of the conflict to
the CPR along with its list showing its order of preference for the candidates.
Any Party failing to return a list of preferences on time shall be deemed to
have no order of preference.

              (d) If the Parties collectively have identified fewer than three
(3) candidates deemed to have conflicts, the CPR shall designate as the Neutral
the candidate for whom the Parties collectively have indicated the greatest
preference. If a tie shall result between two candidates, the CPR may designate
either candidate. If the Parties collectively have identified three (3) or more
candidates deemed to have conflicts, the CPR shall review the explanations
regarding conflicts, and, in its sole discretion, may either (i) immediately
designate as the Neutral the candidate for whom the Parties collectively have
indicated the greatest preference, or (ii) issue a new list of not fewer than
five (5) candidates, in which case the procedures set forth in subparagraphs
2(a)-(d) shall be repeated.

         3. No earlier than twenty-eight (28) days or later than fifty-six (56)
days after the selection, the Neutral shall hold a hearing to resolve each of
the issues identified by the Parties. The ADR proceeding shall take place at a
location agreed upon by the Parties. If the Parties cannot agree, the Neutral
shall designate a location other than the principal place of business of either
Party or any of their Affiliates.

<PAGE>
Millennium Confidential Information

         4. At least seven (7) days prior to the hearing, each Party shall
submit the following to the other Party and the Neutral:

              (a) a copy of all exhibits on which such Party intends to rely in
any oral or written presentation to the Neutral;

              (b) a list of any witnesses such Party intends to call at the
hearing, and a short summary of the anticipated testimony of each witness;

              (c) a proposed ruling on each issue to be resolved, together with
a request for a specific damage award or other remedy for each issue. The
proposed rulings and remedies shall not contain any recitation of the facts or
any legal arguments and shall not exceed one (1) page per issue.

              (d) a brief in support of each Party's proposed rulings and
remedies PROVIDED THAT the brief shall not exceed twenty (20) pages. This page
limitation shall apply regardless of the number of issues raised in the ADR
proceeding.

         Except as expressly set forth in subparagraphs 4(a)-(d), no discovery
shall be required or permitted by any means, including depositions,
interrogatories, requests for admissions, or production of documents.

         5. The hearing shall be conducted on two (2) consecutive days and shall
be governed by the following rules:

              (a) Each Party shall be entitled to five (5) hours of hearing time
to present its case. The Neutral shall determine whether each Party has had the
five (5) hours to which it is entitled.

              (b) Each Party shall be entitled, but not required, to make an
opening statement, to present regular and rebuttal testimony, documents or other
evidence, to cross-examine witnesses, and to make a closing argument.
Cross-examination of witnesses shall occur immediately after their direct
testimony, and cross-examination shall be charged against the Party conducting
the cross-examination.

              (c) The Party initiating the ADR shall begin the hearing and, if
it chooses to make an opening statement, shall address not only issues it raised
but also any issues raised by the responding Party. The responding Party, if it
chooses to make an opening statement, also shall address all issues raised in
the ADR. Thereafter, the presentation of regular and rebuttal testimony and
documents, other evidence, and closing arguments shall proceed in the same
sequence.

              (d) Except when testifying, witnesses shall be excluded from the
hearing until closing arguments.

              (e) Settlement negotiations, including any statements made
therein, shall not be admissible under any circumstances. Affidavits prepared
for purposes of the ADR hearing

<PAGE>
Millennium Confidential Information

also shall not be admissible. As to all other matters, the Neutral shall have
sole discretion regarding the admissibility of any evidence.

         6. Within seven (7) days following completion of the hearing, each
Party may submit to the other Party and the Neutral a post-hearing brief in
support of its proposed rulings and remedies, PROVIDED THAT such brief shall not
contain or discuss any new evidence and shall not exceed ten (10) pages. This
page limitation shall apply regardless of the number of issues raised in the ADR
proceeding.

         7. The Neutral shall rule on each disputed issue within fourteen (14)
days following completion of the hearing. Such ruling shall adopt in its
entirety the proposed ruling and remedy of one of the Parties on each disputed
issue but may adopt one Party's proposed rulings and remedies on some issues and
the other Party's proposed rulings and remedies on other issues. The Neutral
shall not issue any written opinion or otherwise explain the basis of the
ruling.

         8. The Neutral shall be paid a reasonable fee plus expenses. These fees
and expenses, along with the reasonable legal fees and expenses of the
prevailing Party (including all expert witness fees and expenses), the fees and
expenses of a court recorder, and any expenses for a hearing room, shall be paid
as follows:

              (a) If the Neutral rules in favor of one Party on all disputed
issues in the ADR, the losing Party shall pay 100% of such fees and expenses.

              (b) If the Neutral rules in favor of one Party on some issues, and
the other Party on other issues, the Neutral shall issue with the rulings a
written determination as to how such fees and expenses shall be allocated
between the Parties. The Neutral shall allocate the fees and expenses in a way
that bears a reasonable relationship to the outcome of the ADR, with the Party
prevailing on more issues, or on issues of greater value or gravity, recovering
a relatively larger share of its legal fees and expenses.

         9. The rulings of the Neutral and the allocation of fees and expenses
shall be binding, non-reviewable, and non-appealable, and may be entered as a
final judgment in any court having jurisdiction.

         10. Except as provided in paragraph 9 of this EXHIBIT I or as required
by law, the existence of the dispute, any settlement negotiations, the ADR
hearing, any submissions (including exhibits, testimony, proposed rulings and
briefs), and the rulings shall be deemed Confidential Information. The Neutral
shall have the authority to impose sanctions for unauthorized disclosure of
Confidential Information.

<PAGE>
Millennium Confidential Information

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT J

ABBOTT [**]